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Abstract
Inadequate selenium intake is a risk factor for prostate cancer (PC). The cancer-protective 
effect of selenium is partly attributable to its incorporation into selenoproteins. 
Selenoprotein gene polymorphisms are associated with PC risk and epigenetic silencing of 
the selenoprotein glutathione peroxidase 3 (GPx3) by DNA méthylation is common in PC. 
In this thesis, five SNPs, GPxl;Prol98Leu, GPx4:718C/T, selenoprotein-15:811C/T, 
selenoprotein-P (SEPP1 ) : Ala 134Thr, mitochondrial superoxide dismutase
(SOD2):Vall6Ala, were genotyped in the CAPS (Cancer of the Prostate in Sweden) study, 
a case-control study of 2915 PC cases and 1764 controls in a low selenium population. 
S0D2-Ala was associated with increased PC risk (OR 1.19, 95%CI 1.03-1.37) vs S0D2- 
Val homozygotes. Interaction between S0D2 and SEPPl polymorphisms was observed, 
with SEPP1-Ala234 homozygotes having higher risk of PC (OR 1.43, 95%CI 1.17-1.76) 
and aggressive PC (OR 1.60, 95%CI 1.22-2.09) if they were also SOD2-Alal6+ 
(interaction, PC P=0.05, aggressive PC P=0.01), an interaction that was even stronger for 
PC in ever-smokers (OR 1.97, 95%CI 1.33-2.91; interaction P=0.001).
Genes methylated in PC were identified through re-expression of silenced genes after 
treatment of cell-lines with the demethylating agent 5-aza-2 -deoxycytidine, and by 
methylated DNA immunoprécipitation (MeDIP), followed by whole-genome micro-array 
analysis. GPx2 was methylated in PC cell-lines and tissues but not in normal prostate. The 
potential tumour suppressor genes ADAMTS12 and ID4 were shown to be 
hypermethylated in PC for the first time. RNF152 and LAYN were hypermethylated in the 
metastasis-derived PC cell lines, but not in primary tumour or normal tissue, implicating
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RNF152 and LAYN in metastatic disease. Pathway analysis identified several PC-relevant 
processes as both disrupted by DNA méthylation and affected by selenium- 
supplementation, particularly pathways involving cell-adhesion. The evidence presented in 
this thesis further elucidates potential mechanisms by which selenium may exert a cancer 
protective effect and has identified several novel genes that may have potential as 
prognostic and/or diagnostic markers of PC.
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Introduction
1.1 Prostate cancer
Prostate cancer is the most commonly diagnosed cancer in men in the United Kingdom, 
accounting for 24% of all newly diagnosed male cancer (Cancer Research UK 2008). 
Mortality rates are second only to those of lung cancer and prostate cancer was responsible 
for the deaths of over 10,000 British men in 2005 (Cancer Research UK 2007). Research 
has increasingly refocused on reducing cancer incidence through dietary measures as a 
cheap and effective form of cancer prevention. Accumulating evidence appears to support 
a role for selenium in cancer chemoprevention and in reducing disease progression, 
however the mechanism by which selenium can exert its anticancer properties remain 
largely undefined. Increasing knowledge of the pathways though which selenium exerts its 
aiiti-tumoufogenic effect can only help in the fight against this disease.
1.2. The genetics of prostate cancer -  Evidence for an inherited aspect
Evidence supporting genetic susceptibility to prostate cancer was first presented over 50 
years ago. Morganti et al (1956) observed a higher frequency of prostate cancer in close 
relatives of prostate cancer patients than in the control group. Woolf et al. (1960) reported 
that mortality from prostate cancer in the relatives of men dying from prostate cancer was 
three-fold greater that in relatives of men dying from other causes.
15
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By comparing cancer concordance rates between monozygotic and dizygotic twins, a good 
insight into the degree of genetic and environmental influence is provided. In the combined 
analysis of cohorts from Sweden, Denmark and Finland, it was concluded that as many as 
42% of prostate cancer cases may result from an inheritable genetic factor (Lichtenstein et 
al 2000).
1.2.1 Genome-wide linkage and association studies
Numerous research groups have attempted to identify prostate cancer susceptibility loci 
through genome-wide linkage and association studies. A brief overview of these studies 
can be seen in Figure 1.1 and Tables 1.1 and 1.2. The results, however, failed to identify 
common loci between studies. Susceptibility loci are rarely replicated between studies and 
are distributed widely across the genome. Several reasons could explain the lack of 
concordance between genome-wide linkage and association studies, and the failure to 
identify a single prostate cancer susceptibility gene. Multiple rare variants are believed to 
have an important role in cancer aetiology. Such genetic variants would be detected using 
linkage studies, which identify cancer susceptibility regions. Multiple rare variants 
however, as the name implies, are not common enough to be covered and indentified using 
SNP-based association studies. In addition, common low penetrance variants, which 
increase susceptibility to cancer, may be located in genomic regions detected by linkage 
studies. Association studies comprised of large case numbers are needed to enable the 
statistical power required for the identification of low penetrance variants (Simafd et al
2003) and subsequent confirmation of linkage studies. However, it is widely regarded that 
the most likely explanation for a lack of replication between genome-wide studies is due to
16
University of Surrey Chapter 1
the heterogeneity of prostate cancer per se and advanced prostate cancer (Ostrander et al
2004). This suggests that in all probability, multiple susceptibility genes are involved in 
prostate cancer development and progression.
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Table 1.1 An overview of prostate cancer susceptibility loci published from 
genome-wide linkage studies to date.
Author and date Disease (Trait) Region Possible genes
Smith eta/. 1996 Prostate cancer lq24-25 HPCl
Berthon«/a/. 1997 Prostate cancer (early onset) lq42.2-43 PCAP
XuetaL  1998 Prostate cœicer Xq27.28 HPCX
Gibbs er ail 1999 Prostate cancer lp36 CAPB
Berry e/a/. 2000 Prostate cancer 20ql3 HPC20
Suarez et al. 2000 Prostate cancer 16q23.2 Non Identified
Tavitipan «r a/. 2001 Prostate cancer 17pll HPC2 (ELAC2)
Xu et a l  2003 Prostate cancer (non MPC) 8p22-23 MSRl
Schieutker et al. 2003 Prostate cancer llq l4
3p25-26
Non Identified
Witte et al. 2000 Aggressive prostate cancer 5q31-33
7q32
Non Identified
19ql2
Goddard er aü 2001 Aggressive Prostate cancer 4q Non Identified
lq24-25
lq42.2-43
Xql2-13
Slager et a l  2003 Aggiessive prostate cancer 4q
19ql3
Non Identified
Paiss et al. 2003 Aggressive prostate cancer 7q31-33 Non Identified
Slager et al 2006 Aggressive prostate cancer 6q23
Ipl3-q21
5pl3-qll
Non Identified
Stanford er a/. 2006 Aggressive prostate cancer 2 2 q ll.l Non Identified
Lange et a l  2006 Aggressive prostate cancer 15ql2 Non Identified
Chang et al. 2003 Aggressive prostate cancer Xq27-28
22ql3
Non Identified
Schaid et al. 2007 Aggressive prostate cancer 19q and 5q 
3q, 7q 16q
Non Identified
19
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Table 1.2 An overview of prostate cancer susceptibility loci published from 
genome-wide association studies to date.
Author and date Disease Initial sample 
size
Replication 
Sample size
Region Possible
genes
Eeles a/. 2008 Prostate cancer 1,854 cases, 
1,894 controls
3,268 cases, 
3y366 controls
lOqll.23
19ql3.33
llq l3 .2
6q25.3
7q21.3
MSMB
KLK3
Intergenic
SLC22A3
LMTK2
Gudmundsson et al. 2008 Prostate cancer 1,854 cases, 
21,372 controls
8,239 cases, 
7,590 controls
X pll.22
2pl5
NUDTl.
NUDTII
LOC340602
GSPT2
MAGEDl
EHBPl
Duggan et al. 2007 Prostate cancer 1,235 cases, 
1,599 controls
1,242 cases, 917 
controls
None found None found
Murabito et al. 2007 Prostate cancer 1,345
individuals
Not replicated 3p22.2
13q33.1
6pl2.2
5ql4.3
3q24
CTDSPL
Intergenic
PKHDl
HAPLNl
Intergenic
Gudmundsson et aL 2007 Prostate cmcer I,501 cases,
II,290 controls
1,992 cases, 
3,058 controls
17ql2
17q24.3
TCF2
Intergenic
Gudmundsson et al. 2007 Prostate cancer 1,435 cases, 
3,064 controls
1,583 cases, 
2,817 controls
8q24.21 Intergenic
Yeager et al. 2007 Prostate Cancer 1,172 cases, 
1,157 controls
3,124 cases, 
3,142 controls
8q24.21 Intergenic
Thomas et al. 2008 Advanced prostate cancer 1,172 cases, 
1,157 controls
3,941 cases, 
3,964 controls
lOqll.23
10q26.13
llq l3 .2
7pl5.2
MSMB
CTBP2
Intergenic
JAZFl
20
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1.3 The epigenetics of prostate cancer
In recent years, attention has been predominantly focused on the role of epigenetics in 
cancer. Epigenetics is the inheritable modification of DNA without a change in 
sequence and literally means above or outside DNA.
DNA méthylation is central to the understanding of epigenetics in cancers. DNA 
méthylation in mammalian cells occurs through the covalent binding of a methyl group 
(CH3) at die 5-C position of cytosine in CpG dinucleotides.
DNA méthylation is catalysed by the so-called DNA methyltransferase (DNMT) family 
of enzymes. There are three DNMT families in eukaryotes; DNMT 1, 2 and 3. Members 
of the DNMT 3 family, DNMT 3a and 3b, are generally regarded as de novo 
methyltransferase enzymes, however, in conjunction with DNMT 1, DNMT 3a and 3b 
may also have a role in maintenance, copying existing méthylation profiles during DNA 
replication (Liang et a l 2002). The exact function of DNMT 2 still remains undefined.
Two forms of DNA méthylation exist: promoter-specific and global méthylation.
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1.3.1 Promoter DNA méthylation
In normal cells, promoter méthylation controls the regulation of long term gene 
regulatory mechanisms, such as tissue specific gene silencing and X-chromosome 
inactivation of imprinted genes, vital in maintaining normal cell function. Whilst CpG 
dinucleotides are under-represented throughout the genome, regions of densely packed 
CpGs, termed CpG islands, are present in approximately 50% of gene promoters 
(loshikhes and Zhang 2000). CpG islands are defined as regions of the genome greater 
than 500bp in length with a G C content equal or greater than 55% and with an 
observed CpG/expected CpG of 0.65 (Takai and Jones 2002). CpG islands remain 
largely unmethylated; however, in cancer, méthylation of CpG island is a common 
phenomenon resulting in gene silencing (Klose and Bird 2006). This transcriptional 
repression occurs through the recruitment of methyl-binding proteins and subsequent 
alterations to chromatin structure (Klose and Bird 2006)(Figure 1.2).
According to Knudson’s ‘2 hit’ theory of cancer initiation, a single mutation is unlikely 
to result in the loss of function of a tumour-suppressor gene; following many cycles of 
cell growth and divisions, a secondary mutation in the other allele is required to reduce 
tumour suppressor function, resulting in cancer (Knudson 1971). Consistent with this 
theory, méthylation of a tumour suppressor promoter may provide this ‘second hit’ or 
indeed provide both the first and the second hits, resulting in the loss of gene function.
The 7c class glutathione S transferase (GSTPl) was the first gene shown to be silenced 
by promoter méthylation in prostate cancer samples (Berthon et al. 1998). The 
promoter of GSPTl was methylated and silenced in all of the twenty prostate
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carcinomas analysed but not in normal prostate tissue or benign prostatic hyperplasia 
(Lee et a l 1994). Since this initial discovery, numerous studies have confirmed and 
built upon these findings; multiple hypermethylated genes have now been identified in 
prostate cancer (Figure 1.3).
The silencing of the GSTPl gene remains the best characterised epigenetic alteration in 
prostate cancer to date. Numerous studies have consistently shown GSTPl to be 
methylated in over 80% of prostatic carcinomas. In addition to silencing in prostate 
carcinoma, GSTPl promoter hypermethylation of 43% to 70% has also been observed 
in PIN (pre intra-epithelial neoplasia) lesions (Brooks et a l 1998; Jeronimo et al 2001; 
Jeronimo et a l 2002; Kang et al 2004; Henrique et a l 2006), widely accepted to be the 
precursor lession to prostate cancer. Unsurprisingly, GSPTl hypermethylation has 
remained the focus of continual efforts to develop novel therapeutics and biomarkers for 
prostate cancer.
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Figure 1.2. Méthylation in a normal cell and a cancerous cell In normal cells (A), 
the CpGs in the promoter are unmethylated enabling transcription; CpGs throughout the 
gene body and genome remain methylated. In cancer (B), the opposite is true; aberrant 
méthylation of the promoter and global déméthylation occurs. Méthylation of the 
promoter results in gene silencing. Exons and introns are represented by filled boxes 
and lines respectively. White circles represent unmethylated CpG; Black circles 
represent methylated CpG. Transcription is represented by the arrow; Inhibition of 
transcription is shown by X. Figure adapted from Baylin 2005
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Figure 1.3. The frequency of méthylation in genes in normal prostate, benign 
prostatic hyperplasia (BPH), pre intra-epithelial neoplasia (PIN) and prostate 
cancer (PCA). The frequency was determined by dividing the total number of cases in 
the literature (at date of publication) by the number of cases positive for méthylation at 
the specified locus. Distinct variations in méthylation patterns can clearly be observed 
from this graph, highlighting the potential use of promoter méthylation as a diagnostic 
and prognostic marker of prostate cancer. Taken from Bastian et al 2004 .
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1.3.2 Global méthylation
In addition to CpG islands, CpGs are also distributed throughout non-coding DNA in 
the genome. In contrast to CpG islands, approximately 80% of these widely dislribulcd 
CpGs remain methylated in normal tissue and have an important role in the 
transcriptional silencing of non-coding regions (Wilson et al. 2007). Maintenance of 
transcription silencing in non-coding regions is essential. Repeat sequences, 
transposons and viral sequences are often located in this area of the genome, re­
expression of which might be detrimental to normal cell function leading to genetic 
instability, chromosomal abnormalities and gene disruption. Global méthylation is 
comprehensively reviewed by Wilson et al. (2007).
Whilst global hypomethylation in cancer has been eclipsed by research into promoter 
hypermethylation in recent years, many interesting and highly important results have 
emerged. In a study of 30 radicd prostatectomies, Brothman et al observed a reduction 
of total méthylation in 96.7% of cancerous samples in coniparison to benign prostate 
tissue (Brothman et al. 2005). In the same study, global méthylation was shown to be 
higher in recurrent disease, compared to nonrecurring disease (Brothman et al. 2005). 
Further studies have demonstrated the potential use of global hypomethylation as a 
marker in disease progression. For example, a decrease in the méthylation of Alu and 
Line 1 repeats were shown to correlate with markers of prostate cancer and stage of 
disease such as prostate specific antigen (PSA), Gleason score and tumour stage (Florl 
et al. 2004; Cho et al. 2007). In addition, aberrant promoter hypermethylation was 
shown to occur in almost all tissues exhibiting global déméthylation (Santourlidis et al. 
1999; Florl et al. 2004).
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1.3.3 Promoter méthylation: a target for cancer therapeutics
Unlike DNA mutations, chromosomal rearrangements and translocations, DNA 
méthylation is reversible. Reversing the méthylation of tumour repressor genes 
provides a novel platform from which the battle against cancer can be fought. In 
addition, the identification of methylated promoters in high-grade PEN, which suggests 
that promoter hypennethylation occurs early in cancer development, could lead to the 
development of preventive therapies.
Several DNA de-methylating agents are available including the nucleotide analogs, 5- 
azacytidine and 5-aza-2'-deoxycytidine. These compounds are incorporated into 
replicating DNA and irreversibly bind DNA methyltransferases, targeting those cells 
undergoing rapid replication. However, several caveats arise from their use in cancer 
therapy; primarily cytotoxictiy, poor stability, the requirement of intravenous 
administration and the potential to induce cancers at other sites. A novel and perhaps 
most-promising addition to the nucleotide analogue family is Zebularine which is more 
stable than its counterparts, thus enabling oral administration. Zebularine, however, has 
its own problems; the requirement of high concentration doses and low bioavailability 
detract from its more promising properties (Holleran et al. 2005). Observed synergy 
between 5-azacytidine and Zebularine may make the therapeutic use of nucleotide 
analogues more feasible (L^maire et al. 2008).
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1.3.4 Promoter méthylation: Diagnostic and prognostic Markers
The use of promoter méthylation as a diagnostie tool shows great promise, with 
potential to be used as a marker of prostate eancer. Using a eombination of different 
promoters commonly known to be methylated in a prostate cancer but not normal tissue, 
>97% of tumours could be detected with 100% specificity (Tokumaru et a l 2004; 
Yegnasubramanian et a l 2004). The méthylation pattern of multiple promoters has 
been shown not only to correlate with prostate cancer per se but also with markers of 
disease progression such as disease stage and Gleason score (Bastian et a l 2005). The 
analysis of promoter méthylation not only has potential for tumour diagnosis but also 
prognosis (Bastian gt a/. 2005).
Hypermethylation of DNA in bodily fluids may provide a feasible non-invasive 
alternative diagnostic marker of prostate cancer. Méthylation patterns of promoters, in 
particular GSTPl, have been determined in plasma, serum, urine, and ejaculate fi'om 
prostate cancer patients (Goessl et a l 2000; Suh et a l 2000; Caims et a l 2001; 
Jeronimo et a l 2002; Gonzalgo et a l 2003; Crocitto et a l 2004; Gonzalgo et a l 2004; 
Hoque et a l 2005; Bastian et a l 2008). Interestingly, in urine samples fi'om 52 prostate 
cancer patients and 91 matched controls, Hoque et al used a panel of four 
hypermethylated gene promoters, {pi6, ARF, MGMT and GSTPl) to identify 87% of 
prostate cancers with 100% specificity (Hoque et a l 2005). Assays based on 
hypermethylation of gene promoters could ultimately be used in conjunction with, or as 
a replacement for serum PSA testing, which has a sensitivity and specificity of <75% 
(Neal and Donovan 2000).
28
University of Surrey _____________________ Chapter 1
1.3.5 Histone and chromatin modifications
Chromatin is comprised of DNA and its associated proteins in its condensed form. The 
nucleosome is the structural unit of chromatin; each nucleosome consist of -146 bp of 
DNA wrapped around an octomer of basic proteins called histones; each containing two 
of the H2A, H2b, H3 and H4 subunits (Komberg and Thomas 1974). This 
configuration forms the ‘beads on a string’ structure which, in turn, is tightly coiled and 
compacted. The nucleosome is subject to many forms of modification. To enable 
transcription to occur this tightly wound structure must be relaxed, and maintained in an 
open state to allow access of the larger proteins required for transcription to the DNA. 
The interaction between these histone modifications and chromatin structure is 
described as the ‘histone code’ (Jenuwein and Allis 2001). The exact nature of histone 
modifications and their interaction with chromatin structure remain poorly defined; the 
role of acétylation and deacetylation in regulating chromatin is somewhat clearer. 
Acétylation and deacetylation of histones are proving to be of particular importance in 
cancer. Several comprehensive reviews are available describing both histone 
modifications and the ‘histone code’ (Jenuwein and Allis 2001; Kouzarides 2007).
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1.3.6 Histone acétylation and deacetylation in cancer
A strong association between histone acétylation and gene expression was observed as 
early as 1964 (Allfrey et al. 1964). Histone deacetylation, regulated by the histone 
deacetylase (HDAGs), is associated with transcriptional repression; histone acétylation, 
regulated by histone acetyl transferase (HAT) enzyme, is associated with transcriptional 
activation. Whilst the effects of histone de-acetylation on the silencing of specific gene 
are not as well defined as méthylation, numerous genes silenced by deacetylation in a 
cancer specific manner, have been identified, including DAB2IP (Chen et al. 2003), 
TALSl (Stimson et al. 2002), and MATIA (Torres et al. 2000). Interestingly, acétylation 
appears to occur in conjunction with promoter hypermethylation suggesting an 
interaction between the two epigenetic mechanisms (Torres et al. 2000; Stimson et al. 
2002; Chen et al. 2003). However, it remains to be determined which event occurs 
first; méthylation or deacetylation (Santos-Rosa and Caldas 2005). It seems likely that 
future therapeutic agents utilising epigenetics as a potential therapeutic target in the 
fight against cancer will require the involvement of both histone acétylation and DNA 
de-methylation.
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1.4 A role for selenium in prostate cancer prevention: The evidence
1.4.1 Geographical and ecological studies
The association of a possible role of selenium in cancer chemoprevention was first 
identified in 1969 by Shamburger and Frost who observed that regional cancer mortality 
in the USA was correlated to the selenium concentration of forage crops (Shamberger 
and Frost 1969). Further correlative studies subsequently highlighted the relationship 
between selenium status or dietary intake and cancer incidence both within the United 
States (Shamberger and Willis 1971), within other countries (Yu et al. 1985; Burguera 
et al. 1990; Chen et al. 1992) and on a global scale (Schrauzer et al. 1977). These 
studies all showed an overall negative correlation with dietary selenium intake and, risk 
of cancer, prompting further investigation into the use of selenium as a preventative 
agent in the fight against cancer.
1.4.2 Prospective nested case control studies of selenium in prostate cancer
A total of nine large prospective or nested case-control studies of selenium status and 
prostate cancer have been published involving 195,676 men in whom 2,714 cases of 
prostate cancer developed (Knekt et al. 1990; Yoshizawa et al. 1998; Helzlsouer et al. 
2000; Nomura et al. 2000; Brooks et al. 2001; Goodman et al. 2001; van den Brandt et 
al. 2003; Li et al. 2004; Peters et al. 2007) (Table 3). Eight of these studies showed a 
reduced risk o f prosLale cancer in the highest compared to tlie lowest category of 
selenium status, the risk being significantly reduced in five. Nomura et al. (2000) and 
Helzlsouer et al. (2000) reported an adjusted odds ratio of 0.5 (95% Cl 0.3 to 0.9) and
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0.38 (95% Cl 0.17 to 0.85) respectively, when comparing the cases and controls in the 
highest quartile of selenium status against the lowest. This represents a significant 
decrease in the risk of developing prostate cancer in individuals of high selenium status. 
Interestingly, this relationship is strengthened when comparing cases o f advanced 
disease to matched controls, thus suggesting selenium is not only important for reducing 
prostate cancer but also the progression of disease (Yoshizawa et al. 1998; van den 
Brandt et al. 2003; Li et al. 2004). However, reports are inconsistent and several show 
no association. In order to overcome the limitations of individual studies a large scale 
meta analysis totalling 16 studies reported a pooled relative risk of 0.72 (95% C.I 0.61- 
0.84) concluding that results fi’om a large scale randomised control trial was required to 
further validate the findings (Etminan et al. 2005). Brinkman et al (2006) confirmed 
these findings in a meta analysis consisting of twenty separate studies in which 
selenium status had been determined in either serum, plasma or toenail samples 
(Brinkman et al. 2006). Overall, the mean selenium status was 23% (-0.40 to -0.05, P 
= 0.01) lower in individuals that subsequently developed prostate cancer in comparison 
to the cohort or controls, further supporting the evidence for a role of selenium in cancer 
prevention.
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Table 13. Large prospective studies of prostate cancer/advanced prostate cancer 
using tissue indicators of exposure
Study Population No. of
cases
Indicator
of
exposure
Comparison 
High vs. low
RR* 95%
confidence
interval
P for 
trend
Knekt et al. Finland 51 Serum Quintile 1.15 0.71
1990 General population
Yoshizawa et USA Health 181 Toenails Quintile 0.35^ 0.16-0.78* 0.03
al. 1998 professionals
Nomura et al. USA Hawaii 249 Serum Quartile 0.5 0.3-0.9* 0.02
2000 Japanese ancestry
Non smoker 87 0.8 0.4-1.9 0.93
Ex-smoker 86 0.5 0.2-1.1 0.03
Current smoker 76 0.2 0.1-0.8 0.02
Localised disease 120 0.8 0.4-1.8 0.76
Advanced disease 64 0.3^ 0.1-0.8 0.01
Helzlsouer et USA
al 2000 Washington County 117 Toenails Quintile 0.58 0.29-1.18 0.27
0.38^ 0.17-0.85* 0.12
Goodman et USA CARET Trial 235 Serum Quartile 1.02 0.7-1.6 0.69
al 2001 asbestos workers/
current/ex-smokers
retinol/p-carotene arm 111 0.75 0.41-1.36 0.40
placebo arm 124 1.52 0.78-2.79 0.12
Brooks et a l USA 52 Plasma Quartile 0.24 0.08-0.77* 0.01
2001 Baltimore
van den Netherlands 540 Toenails Quintile 0.69 0.48-0.99* 0.008
Brandt et al. Cohort Study
2003 Never smoker 72 1.19 0.48-2.92
Ex-smoker 300 0.46 0.27-0.79*
Current smoker 168 0.97 0.42-2.22
Localised disease 189 0.72 0.42-1.24 0.043
Advanced disease 183 0.62^ 0.37-1.05 0.020
Li et al USA Physicians' Health 586 Plasma Quintile 0.78 0.54-1.13 0.16
2004 Study
Baseline PSA>4 228 0.49 0.28-0.86* 0.002
Baseline PSA<4 293 0.77 0.48-1.22 0.59
Localised disease 348 0.97 0.64-1.49 0.91
Advanced disease 171 0.52^ 0.28-0.98* <0.05
Peters et al. USA PLCO Trial High 724 Serum Quartile 084 0.62-1.14 0.70
2007 vitamin E intake Ç> 28 363 0.58 0.37-0.90* 0.05
lU/d)
Multi-vitamin use
_? f"__ _____ . I m
302 0.61 0.36-1.04 0.06
^Advanced disease
3Adjusted for BMI at age 21, education and hours since last meal (Rayman 2008).
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1.43 Prostate cancer intervention studies
The Nutritional Prevention of Cancer study (NPC) (Clark et a l 1996), arguably the 
most important study to date, involved a double blind, randomised placebo controlled 
cancer prevention trial composed of 1312 subjects. The study was originally designed 
to evaluate the use of selenium in preventing the recurrence of non-melanoma skin 
cancer through supplementation with selenium at 200 pg a day. Although the incidence 
of non-melanoma skin cancer was not significantly reduced between the placebo and 
supplemented groups, an overall reduction of cancer mortality was observed (RR, 0.50, 
95% Cl 0.31 to 0.80). Of all the cancers, the reduction of prostate cancer incidence, at 
63%, was the most significant, After the inclusion of data obtained during a further 25 
months follow up, the effect of selenium supplementation upon prostate cancer 
reniained significant, but overall magnitude was reduced (RR 0.48, 95% C.I 0.28 to
0.80) (Duffield-Lillico et a l 2003).
1.4.4 In vitro models of prostate cancer
Selenium has been shown to have a significant effect on prostate cancer cells in-vitro. 
Supplementation of growth media with various selenium metabolites, methylseleninic 
acid (MSA), methyl selenite and selenomethionine, has been shown to reduce cell 
proliferation and induce apoptosis in a dose dependent manner (Redman et a l 1998; 
Menter et a l 2000; Jiang et a l 2002). Furthermore, anti-proliferative effects and 
increased apoptosis are only observed on cancerous, but not normal primary prostate 
cells. Interestingly, the different low molecular weight compounds appear to activate 
apoptosis through distinct pathways. For example, in the prostate cancer cell line
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DU 145, MSA induces apoptosis through the activation of multiple caspases; selenite 
however, activates .apoptosis through the phosphorylation of the apoptosis kinases, 
JNKl/2 and p38MAPK (Jiang et a l 2002).
A subset of 154 genes has been identified as being differentially expressed between 
various human and rat prostate cancer cell lines, identifying potential genes and 
pathways through which selenium can exert its anti-carcinogenic effects (Schlicht et a l 
2004).
1.4.5 Animal studies
Over 100 studies have investigated the effect of selenium supplementation in animal 
models of cancer. Although a few of these studies have associated selenium 
supplementation with an increased risk of cancer, the evidence overwhelmingly 
suggests the notion that selenium significantly reduces the risk of cancer; over two 
thirds of animal studies have reported a significant decrease in the incidence of tumours 
or preneoplastic markers following administration of animals with additional selenium 
(Reviewed by Combs and Grey 1998).
It is hypothesised that selenium may at least in part exert its chemopreventative 
properties through the prevention of DNA damage by oxidative stress. Supplementing 
elderly beagle dogs, which readily develop prostate cancer, with either high selenium 
yeast or selenomethionine reduced DNÀ damage by 21.9% in comparison to the control 
group. Interestingly, not only was DNA damage reduced in the selenium supplemented 
group, but apoptosis also increased two fold. This suggests that selenium not only 
reduces DNA damage but also sensitises epithelial cells with extensive damage to
35
University of Surrey_______________ '  Chapter 1
apoptosis; both these factors are likely to reduce the progression to prostate cancer 
(Waters et al. 2003).
1.5 Selenoproteins
Selenium is co-translationally incorporated into a unique class of proteins called 
selenoproteins, as the amino acid selenocysteine (Sec). Sec, named the 2U  ^amino acid, 
differs from cysteine by having a selenium atom in place of sulphur (Figure 1.4). Sec 
has the advantage of being fully ionisable and thus more reactive at physiological pH 
than cysteine, in which the thiol group remains protonated (Stadtman 1996) (Figure
1.4). Due to this high reactivity. Sec forms the active centre of many selenoenzymes. 
Enzyme activity is dramatically reduced when selenoproteins are engineered to contain 
Cys, instead of Sec (Axley et al. 1991; Rocher et al. 1992; Zhong et al. 2000). Sec 
incorporation, despite its complex regulation and necessary recoding machinery, clearly 
confers an evolutionary advantage to selenoproteins over their cysteine containing 
counterparts.
To date the mammalian selenoproteome is composed of 25 known proteins (Kryukov et 
al. 2003). Whilst some of these proteins have an antioxidant role the functions of others 
remain to be determined (Table 1.4).
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Figure 1.4a. The difference between cysteine and selenocysteine; the sulphur atom 
of cysteine is replaced with selenium in selenocysteine. 1.4b. Selenocysteine becomes 
protonated at physiological pH, whilst in cysteine the hydrogen ion is retained.
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Table 1.4 A summary of selenoproteins and known functions.
. • Selenoprotein ■ Locus . Proposed Function.
. Selenocysteine 
position (length AA)
. . GPxl . 3p21.31 • Cytoplasmic detoxification of HjOj . 
and organic hydroperoxides
47(201)
GPx2 14q32.3 Detoxification o f HjOî and organic 
hydroperoxides.
40(190) '
GPx3 .. 5q33,l , Detoxification ofHzOz, fatty acid : 
hydroperoxides, and
73(226)
phospholipid hydroperoxides in 
plasma
•G P x 4  ■ ■ 19pi3.3 Detoxification of phospholipid- and 
cholesterol-hydroperoxides.
Sperm structural and antioxidant 
selenoprotein
73(197) . ■
: GPx6 ; 6p22.1 Olfeictory ^ c t io n  : 73(221)
SEP15. . 1p22.3 Putative quality control of 93(162)
glycoprotein fialding in ER
DIOl lp32.3 Metabolism o f thyroid hormones. 126 (249)
■ . , 0102 ; . 14q31.1 / Metabolism of thyroid hormones 133 (265) . ;
0103 . • 14q32 . Metabolism of thyroid hormones 144(278)
H I l q l 2 1 44(122)
I 2p23.3 : ■ ? ■ ■ ■ , , 387(397) .
K 3p21.31 Cardiac antioxidant 92(94)
■ M 22ql2.2 : ? • 48(145).
N lp36 .ll Unclear function in muscle tissue 428 (556) :
0 22ql3.33 ? 667 (669).
. P 
R
5pl2
16pl3.3 ..
Se transport 
Se homeostasis
Reduction of oxidised methionin
59,300,318,330.345. 
352,367,369,376,37 
8(381) .
95(116)
. .  . . S . , ' 15q26.3 Anti inflainmatory 188(189)
SPS2 16pll.2 Selenocysteine synthesis ,60(448)
• ; T ■; 3q24 ? . 36(182)
: TXRI. . 12.23.3 Redox Regulation 498(499)
TXR2 3q21.2 Redox ReguWon 655 (656
. TXR3; 22qil.21 Redox Regulation ^ 522(523)
V .■ I9ql3.13 1 . .  • : . . 273 (346)
w 19ql3.32; Antioxidant function? 13 (87)
EM
For a corhprehénsivé review of selenoprotein function see Gromer et a l (2005).
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1.5.1 Selenoproteins and diet
In order for the full expression of selenoproteins an adequate nutritional intake of 
selenium is required. Plasma glutathione peroxidase (GPx3) is the most commonly 
used biomarker of selenoprotein expression; this is primarily because plasma is easily 
obtained from subjects and both the activity and concentration of GPx are easily 
measured. It is estimated that a total daily intake of 60-80 pg of selenium is required 
for optimal activity of plasma GPx (Thonison et a l 1993; Duffreld et a l 1999); far 
higher than the average intake currently achieved throughout most of Europe (Figure
1.5). Furthermore, whilst the supplementation of a low selenium population in China 
with 37 pg/d of selenium in the form of selenomethionine, (In addition to selenium 
obtained through normal diet) attained full GPx3 activity, supplementation as high as 61 
pg/d of selenium failed to reach maximal expression of selenoprotein P. These results 
suggest that full expression of the plasma protein selenoprotein P requires a daily intake 
of selenium in excess of GPx3 (Xia et a l 2005). With the exception of individuals 
taking selenium supplements, current selenium intakes across Europe and much of the 
world fail to satisfy the requirement for full expression and activity of GPx3, and are far 
below intakes required to optimise expression of selenoprotein P.
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Figure 1.5 Mean selenium intake levels by country. The light blue vertical bar 
represents the range of daily selenium intake required for optimal activity of plasma 
glutathione peroxidise (Rayman 2005).
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1.5.2 Selenoproteins and cancer
Evidence is accumulating to suggest an important role of this group of proteins in 
cancer. Firstly selenocysteine transfer RNA (Sec-tRNA) knockouts are early embryonic 
lethal and highlight the importance of this class of protein (Bosl et a l 1997). 
Furthermore, allelic variations of functional polymorphisms within selenoproteins have 
been associated with an increased risk of developing many different types of cancer 
(Rayman 2005).
Irons et al (2006) provided evidence to suggest both selenoproteins and low molecular 
weight selenium compounds have a role in cancer (Irons et a l 2006). Sec-tRNA I^A 
mutant mice, which exhibit reduced selenoprotein synthesis, show increased 
azomethane-induced aberrant crypt formation in the colon when compared to the wild 
type mice. On supplementation with sodium selenite, aberrant crypt formation in both 
the mutant (low selenoprotein) and wild type mice was significantly reduced (Irons et 
al 2006).
Furthermore, when C3(l)/Tag mice, in which oncogenes are placed under regulatory 
control of the SV40 large T antigen and which readily develop prostate cancer, were 
crossed with I^A mutant mice, the resultant I^AVTag mice exhibit an increase in PIN 
lesions and presented the earlier development of microinvasive carcinoma than the 
WT/Tag group (Diwadkar-Navsariwala et a l 2006). These results suggest an important 
role for selenoproteins in the prevention of cancer.
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1.5.2.1 Glutathione peroxidase 1
Cytosolic glutathione peroxidase (GPxl), was the first selenoprotein identified (Flohe et 
al. 1 9 7 3 )^ d  is the best characterised of all the selenoproteins. GPxl catalyses the 
removal of hydrogen peroxide and lipid hydroperoxides in presence of reduced 
glutathione. Any reduced expression or functionality of full length GPxl will reduce 
the ability of a cell to defend itself against oxidative stress.
The substitution of proline (Pro) by leucine (Leu) occurs at codon 198 in GPxl 
(Forsberg et a l 1999). Pro is known to cause a ‘kink’ in the alpha helix of 
polypeptides. Recombinant human GPxl, differing by only Pro or Leu at codon 198, 
has shown that the Leu allele is associated with reduced functionality or translational 
efficiency (Hu et a l 2003). The Leu allele has been shown to be associated with an 
increase in both lung (OR 2.3, 95% Cl 1.3 to 1.8) (Ratnasinghe et al 2000) and bladder 
cancer (OR 2.6, 95% Cl 1.5 to 4.8) (Ichimura et a l 2004). Furthermore, in bladder 
cancer patients, the Leu allele was significantly associated with advanced tumour stage: 
OR 2.58 (95% Cl 1.07 to 6.18, p = 0.034). Knight et al, however, failed to find any 
significant relationship between GPxl Prol98Leu polymorphism and breast cancer, but 
did report a significant association with a polymorphic alanine repeat in GPxl. 
Premenopausal women possessing at least one copy of the Ala4 repeat had a greater risk 
of breast cancer than those without (OR 1.55, 95% Cl 1.04 to 2.30) (Knight et a l 2004). 
Fewer GPxl heterozygotes have also been observed in breast tumour tissue indicating 
loss of heterozygosity at that locus (Hu et a l 2003). Loss of heterozygosity occurring 
on the short arm of chromosome 3, where GPxl is located, has been associated with
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poorer prognosis (Mitsudomi et a l 1996) and advanced tumour stage in lung cancer 
(Yokoyama et a l 1992), implicating a possible function of GPxl in disease progression.
In prostate cancer, however, tlie evidence is somewhat less conclusive. Contrary to 
other cancers, the Leu allele was protective; carriers of the Leu allele had a 55% lower 
risk of prostate cancer than Pro homozygotes (OR 0.45, 95% Cl 0.25 to 0.80; P = 0.006) 
(Arsova-Sarafînovska et a l 2008). Choi et al (2007) however, failed to observe an 
overall association with either allele in similar case control study consisting of smokers 
or men with a history of asbestos exposure. In addition, Kote-jarai et al (2002) failed to 
find an association with the GPxl Ala repeat and early onset prostate cancer, although 
GPxl Ala6 (in complete linkage disequilibrium with the GPxl 198 Leu allele) had a 
borderline significant association when compared to Alas (OR L67, 95% Cl, 0.97 to 
2.87). However, all of these the studies investigating the effect of polymorphisms in 
GPxl in prostate cancer have been completed in relatively small studies. There is a 
clear requirement for more-comprehensive large-scale prostate cancer case control 
studies to further enhance our understanding of how GPxl may affect prostate cancer.
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1.5.2.2 Manganese superoxide dismutase and Glutathione peroxidise 1
Although S0D2 is not a selenoprotein, the product of its activity, H2O2, is a substrate 
for GPxl. S0D2 is the major detoxifying enzyme of the mitochondria, tlie primary 
source of oxidative stress with a cell. S0D2 dismutates the superoxide anion, readily 
produced by the mitochondrial respiratory chain, into H2O2. which is subsequently 
detoxified to H2O by GPxl.
The SNP, V ail6Ala, has been shown to alter the secondary structure of the 
mitochondrial import sequence of the S0D2 protein. S0D2 16Ala allows more 
efficient import into the mitochondrial matrix and generates more active S0D2 than the 
Val variant (Sutton et a l 2003). This polymorphism has been shown to modify the 
effect described above of GPxl Prol98Leu on bladder cancer risk (Ichimura et a l 
2004): men with one or two Ala alleles at codon 16 of S0D2  have a further increase in 
OR from 2.6 (95% Cl 1.5 to 4.8) to 6.3 (95% Cl 1.3 to 31.2). Furthermore, the effect of 
the SOD2 Val 16Ala polymorphism on the risk of prostate cancer is modified in a 
selenium-dependant manner (Li et a l 2005). It has been proposed that under conditions 
of limited selenium availability, GPxl expression is reduced, resulting in the 
accumulation of H2O2 and thus oxidative stress. The Ala allele results in greater 
importation of S0D2 into mitochondria, more H2O2 is produced than with the Val 
variant (Sutton et al 2003). As GPxs are required to remove H2O2, the effect of this 
genotype is dependent on selenium status as sufficient GPx is required to remove the 
extra H2O2 formed (Li et a l 2005).
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1.5.2.3 Glutathione Peroxidase 3
GPx3 is an extracellular antioxidant enzyme found in plasma; it is primarily expressed 
in the kidney but is also expressed in other tissues including the prostate. GPx3 was 
found to be down-regulated in 67% of advanced prostate tumours compared to normal 
tissue (Yu et a l 2007). Down-regulation was shown to be a result of deletion of the 
GPx2 locus 5q33 (39%), and méthylation of the GPx3 promoter (90%). GPx3 over­
expression in prostate cancer cell lines, reduced colony formation 2-2.5 fold and 
invasiveness 2.7 fold: nude mice injected with the same cell lines had a reduced 
mortality and >4.8 fold smaller tumours compared to control mice (Yu et a l  2007). 
This suggests that GPx3 functions as a tumour suppressor as well as defending against 
oxidative stress.
1.5.2.4 Glutathione peroxidase 4
The primary function of GPx4 is to detoxify phospholipid hydroperoxides, lipid 
hydroperoxides and hydrogen peroxide. Genetic studies have shown linkage of 
chromosome 19pl3.3 to prostate cancer; this region does not include, but is directly 
adjacent to GPx4 (Hsieh et a l 2001; Eeles et a l 2008). A polymorphism (GPx4 718 
C/T) has been identified in the 3 'UTR of GPx4. This polymorphism affects the affinity 
of RNA binding proteins to the 3’UTR, essential for the incorporation of selenium in 
GPx4 and has been shown to affect both the amount and activity of GPx4 (Meplan et al 
2008). Possession of one or more copies of the 718T allele was shown to be protective 
over the 718C allele in colon cancer (OR 0.60, 95% Cl 0.37 to 0.96, p = 0.033) 
(Bermano et a l 2007). Evidence suggests that this polymorphism may affect prostate
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cancer; however, to date no study has investigated the association of this polymorphism 
in any cancer other than colon cancer.
1.5.2.5 Selenoprotein 15 kDa
The 15kDa selenoprotein, SEP15, lies on chromosome lp31, a genetic locus commonly 
deleted in cancer (Hu et a l 2001). Located on the endoplasmic reticulum, SEP 15 is 
believed to be involved in the quality control of protein folding (Korotkov et a l 2001). 
SEP 15 is highly expressed in the normal prostate but down-regulated in prostate cancer 
cells (Behne et a l 1997). The SNP 811 C/T is in complete linkage disequilibrium with 
the 1125 G/A SNP which is located in the selenocysteine insertion sequence (SECTS) 
element. The 81 IT 1125A haplotype was found to reduce selenocysteine incorporation 
into SEP 15 in vitro, in a Se-dependent manner (Kumaraswamy et a l 2000). 
Furthermore, the 1125A variant has been shown to be less responsive to the growth- 
inhibitory and apoptotic effects of selenium than the 1125G variant, suggesting a role of 
this protein in cancer (Apostolou et a l 2004). A recent study investigating the 1125 
A/G polymorphism in lung cancer showed no effect of the polymorphism per se. 
However, selenium status appeared to modify the association of this polymorphism with 
prostate cancer risk, suggesting that 1125 AA individuals would particularly benefit 
from additional selenium (Jablonska et a l 2008).
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1.5.2.6 Selenoprotein P
SEPPl is the only known selenoprotein to contain more than one Sec residue and 
contains over 40% of total plasma selenium (Moschos 2000). Deletion of SEPPl in 
mouse models alters the distribution of selenium around the body, suggesting that 
selenium transport is a major function of SEPPl (Hill et a l 2003; Schomburg et a l
2003). In addition to a postulated role as selenium transport protein, SEPPl may also 
protect against oxidative stress. SEPPl is a strong scavenger of peroxynitrite and 
protects against peroxynitrite mediated oxidation and nitration (Arteel et a l 1998). 
Furthermore, SEPPl has a strong affinity to heparin (Hondal et a l 2001); this enables 
the binding of SEPPl to proteoglycans on the membranes of vascular endothelium and 
may protect against extracellular oxidation and nitration (Burk et a l 1997).
Expression of SEPPl is dramatically reduced in cancer (Calvo et a l 2002; Al-Taie et a l
2004) suggesting a tumour repressor function. Crossing SEPPl knockout mice vyith the 
APCvcÀsï mouse model of colon cancer increases the both the frequency and size of 
high-grade tumour tissue in the colon (Michaelis et a l 2006). Interestingly SEPPl 
maps to 5q31 (Hill et a l 1996), this is near to the colon cancer tumour suppressor gene 
APC, which has been shown to be commonly hypermethylated and silenced in prostate 
cancer (Maruyama et a l 2002; Kang et a l 2004; Yegnasubramanian et a l 2004).
A polymorphism at codon 234 results in the substitution of alanine (Ala) with threonine
(Thr) in exon 4 of SEPPl. It is believed that this polymorphism may alter the stability
of SEPPl (Meplan et a l 2007). Homozygosity for the Ala234 allele of the SEPPl
Ala234Thr SNP (rs3877899) is associated with a lower concentration of plasma
selenoprotein P in men, affecting the concentration and/or activity of other
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selenoproteins, notably of thioredoxin reductase 1 (TRl) and some of the antioxidant 
glutathione peroxidases (GPx) (Meplan et al. 2007). To date, no association has been 
observed with Ala234Thr and cancer (Al-Taie et al. 2004), however, variants at four 
loci within SEPPl have been recently significantly associated with colorectal adenoma 
(Peters et al. 2008).
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1.5.3 Selenoprotein synthesis and regulation
Selenium is incorporated into proteins in the form of both the amino acids, seleno­
methionine (SeMet) and sclenocysteine (See); however, only the latter are considered 
selenoproteins. The Sec-tRNA recognises the codon UGA, previously thought to 
function only as a ‘stop’ codon (Chambers et al. 1986). This highly complex process, 
termed ‘recoding’ requires numerous cis and trans acting factors to enable the UGA to 
be read as a Sec, rather than ‘stop’ codon (Figure 1.6).
Sec tRNA synthesis is central to selenoprotein synthesis, forming the point at which 
selenium is co-translationally inserted in proteins. The Sec tRNA is unique amongst 
tRNA, as it is the only amino acid that, across all groups of life synthesised directly 
onto its tRNA. Sec tRNA synthesis utilises serine as an intermediate and is thus termed 
Sec-tRNA[Ser]Sec. Interestingly, Sec-tRNA[Ser]Sec synthesis itself requires the 
selenoprotein, SPS2 (sclenophosphate synthetase); this suggests both an auto-regulatory 
function for SPS2 and a pathway through which selenoprotein synthesis can in general 
be moderated.
Central to Sec insertion is a widely conserved domain located in the 3' UTR of all 
selenoprotein mRNA, termed the SelenoCvsteine Insertion Sequence (SECIS) (Berry et 
al 1991). The SECIS secondary structure is well characterised consisting of two 
helices parted by a variable loop (Figure 1.7). At the bottom of the second helix, are 
four non Watson-Crick base pairs, termed the SECIS core, which are central to the 
function of the SECIS element (Walczak et a l 1996). This quartet forms a Kink turn 
(K-tum) like motif that binds SECIS bind protein 2. The SECIS element and SBP2 
complex then binds the selenocysteyl-tRNA specific elongation factor (EFsec),
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resulting in the delivery of sec-tRNA to the ribosome and enabling the read though of 
UGA Codon. EFsec requires the prior binding of See-tRNA to enable it to bind with 
the SBP2-SECIS complex thus enabling the formation of the sclenocysteine insertion 
complex (Zavacki et a l 2003). Point mutations within the SECIS core ameliorate all 
function of the SECIS element, highlighting the importance of this highly conserved 
motif.
Figure 1.6. The incorporation of Sec into a selenoprotein in eukaryotes. The SBP2 
(green) is shown bound to the hairpin loop, SECIS element (black) in complex with the 
Efsec (blue) and Sec-tRNA (orange, Sec in yellow). The Sec is incorporated into the 
growing polypeptide (alternate yellow/blue beads) allowing the read through of the 
UGA codon, and showing unacylated tRNA departing the ribosomal subunit to the left 
(Hatfield and Gladyshev 2002).
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Apical loop 
7-17 nt
Helix II 
13-15 bp
Internal loop 
3-14 nt
Helix I 
7 bp
Helix
A*G  
A" G
Non Watson-Crick quartet
A" G
A/g
5 ’ 3*
U- N.
Form 1 Form 2
: Apical loop 3-5 nt
Figure 1.7. SECIS elements form 1 and form b. The two SECIS elements differ by 
the presence of an additional helix and stem loop on form B. The non-Watson crick 
quartet (SECIS core), the conserved A or G directly beneath the SECIS core, and the 
conserved AA dinucleptide in the apical loop are all essential for SECIS function. 
Adapted from Papp et al (2007)
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1.5.3.1 Nonsense mediated decay
Nonsense mediated decay (NMD) is the selective degradation of mRNAs that have 
premature, in-framc stop codons. This degradation prevents the expression of any 
potentially deleterious, truncated proteins (for a comprehensive review of the 
mechanism see Chang et a l 2007). However, NMD is proposed to have an important 
role in the regulation of expression of certain selenoprotein RNAs, degrading mRNA in 
times of limiting selenium availability (Squires et a l 2007). Importantly, it has been 
predicted that different selenoproteins are susceptible to NMD to differing extents 
(Squires et a l 2007); this suggests that NMD is important in the hierarchical regulation 
of selenoprotein expression.
Studies have shown that the transcription rate of GPxl remains unchanged under 
differing levels of selenium supplementation (Christensen and Burgener 1992; Moscow 
et a l 1992). Although tlie tianscriplion rate remains constant, mRNA levels decrease 
by 90% under conditions of limited selenium availability in the rat liver, suggesting 
susceptibility to NMD. Furthermore, other selenoprotein mRNA such as GPx4 remain 
resistant to NMD and do not alter with varying selenium availability (Weiss Sachdev 
and Sunde 2001).
Work, pioneered by Roger Sunde showed how vitally important both the presence of a 
SECIS element and the position of the UGA within the GPxl transcript are in 
maintaining the selenium responsiveness of the mRNA (Weiss and Sunde 1998). 
Remarkably, even fi-globin mRNA can be made responsive to selenium simply by the 
addition of the GPxl SECIS element and an in-frame UGA codon in positions that fulfil
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the requirements for NMD (Weiss and Sunde 1998), The importance of the Sec 
incorporation machinery in selenoprotein transcript regulation can clearly be observed 
from this set of experiments.
1.6 Summary
If the importance of a pathway, protein, or molecule was determined by the complexity 
of is regulation, selenoproteins would appear high on that list. The conservation of 
selenoproteins and their synthesis, across many species, brings to our attention the 
evolutionary pressure to maintain highly complex incorporation and regulatory 
mechanisms. This conservation and the accumulating body of evidence for 
chemoprevention by selenium further highlight the importance of this class of proteins 
upon life and cancer prevention.
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1.7 Hypothesis
In a low selenium environment, such as Sweden and the UK, men who have SNP alleles 
in selenoprotein genes or genes in die same metabolic pathways as selenoproteins, that 
reduce their ability to make functional proteins, would have a greater risk of prostate 
cancer than men who do not have these alleles. It is hypothesised that novel genes of 
importance to prostate cancer, in particular selenoproteins, are silenced as a result of 
DNA méthylation in prostate cancer and that the silencing of these genes affects cellular 
processes of importance to cancer.
1.8 Aims
1. To investigate whether DNA isolated from men with prostate cancer exhibits a 
different pattern of selenoprotein SNP genotypes from healthy male controls, 
matched for age and geographical location in a population of low selenium 
status. This will ascertain the association between risk of disease, selenoprotein 
genotypes and selenium-intake requirement.
2. To identify genes whose expression is altered by the treatment of human 
prostate cells with selenium.
3. To identify novel genes, in particular selenoprotein genes, hypermethylated in 
prostate cancer.
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4. To identify cellular processes affected by DNA promoter hypermethylation and 
whose expression is altered by the treatment of human prostate cancer cells with 
selenium.
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Materials and Methods 
2.1 The Cancer of the Prostate in Sweden study (CAPS study)
2.1.1 Study participants.
The CAPS study is a large-scale, population-based, prostate cancer case-control study, 
which has been extensively described in previous work (Lindmark et a l 2004; Olsson et 
a l 2008). The inclusion criterion for cases was à newly diagnosed, pathologically or 
cytological verified adenocarcinoma of the prostate. The current study is composed of 
CAPS 1 (1427 Cases and 801 Controls) and CAPS 2 (1488 cases and 963 controls). 
The study incorporated a stopping for futility design; all polymorphisms of interest were 
genotyped in CAPS 1 ; only those polymorphisms that provided results of interest were 
genotyped in the additional CAPS 2 population. In total, 3,648 prostate cancer patients 
were invited to participate in the study and 3,161 (87%) agreed. DNA samples were 
obtained from a total of 2,915 cases, for which the corresponding clinical data and 
completed demographic questionnaires were available. Cases were classified as either 
non-aggressive (tumour stage 1 and 2, Gleason score < 8, Differentiation G1-G2, 
NO/NX, MO/MX, PSA <100 pg/L) or aggressive (tumour stage 3-4, Gleason score > 8, 
Differentiation G3-G4, N+, M+, PSA >100  pg/L) (Lindmark et a l 2004). Controls 
matching the case distribution for age (within 5 year bands) and geographical region 
were randomly selected from the Swedish Population Registry. A total of 3,153 
controls were invited to participate of whom 2,149 agreed. DNA samples and 
completed questionnaires were obtained from a total of 1,764 controls. Written 
informed consent was obtained from all participants and the study was approved by the
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research ethics committees at the Karolinska Institutet and Umeâ University Hospital. 
The University of Surrey Research Ethics Committee also approved this genetics study.
2.1.2 Genotyping
DNA was extracted from leukocytes using a Puregene kit (Centra Systems, Minneapolis 
MN) by our Swedish collaborators. All genotyping was performed using allele-specific 
oligonucleotide probes labelled with either VIC or FAM (TaqMan® Applied 
Biosystems Inc. CA) (Table 2.1). All genotyping was completed blind to case/control 
status. Controls of known genotype for each of the polymorphisms investigated were 
included in the assay. Non-template controls and duplicate samples were incorporated 
for quality control purposes. Primer and probe details are presented in Table 2.1. 
SEPPl Ala234Thr (rs3877899) and SEP 15 (rs5845) were genotyped using a pre­
designed assay (TaqMan® Assay number C_2841533_10 and C_876937_l, 
respectively) so primer and probe details are not available.
Each reaction (12.50 pi) contained 2-10 ng of DNA, 1 x PCR master mix (ABgene, 
Epsom, UK), 1 X TaqMan® assay mix (working concentration of dual labelled probes 
100 nM each and PCR primer 900 nM). Reactions were incubated as specified by the 
manufacturer: 95°C for 15 min, 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
Fluorescence was measured and genotypes assigned using the ABI prism 7500 and 
associated software (Applied Biosystems Inc.).
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Table 2.1 Details of primers and probes for the Taqman genotyping assays
Gene SNP Forward Primer 5' -3' Reverse primer 5 ' -3 ' Probes 5' -3'
GPx4 718CT CCCACTATTTCTAGCTCCACAAGT GCAGGCAGGCCGTCAT CACGCCCT[C/T]GGAGC
GPxl Prol98Leu TTGACATCGAGCCTGACATC GAGACAGCAGCACTGCAAC CTGTCTCAAGGGC[T/C]CAGCTGTGCCT
S0D2 Alal6Val GCTGTGCTTTCTCGTCTTCAG CTGCCTGGAGCCCAGATAC CCCAAA[A/G]CCGGAGCC
2.1.3 Plasma selenium measurement
Plasma selenium measurements were performed by Dr Christine Sieniawska at the 
Trace Elements Unit, Southampton General Hospital, Southampton, United Kingdom. 
EDTA plasma samples from 169 controls were stored at -80°C prior to determination of 
selenium by dynamic reaction cell inductively coupled plasma mass spectrometry (DRC 
ICP-MS) using an Elan 6100 DRC plus (SCIEX Perkin-Elmer). ^^Selenium was 
measured, employing methane (at 0.5 ml/min) as the DRC gas to remove the argon 
dimer background (Sloth and Larsen 2000) and butanol to increase the sensitivity of the 
signal (Sieniawska et a l 1999). Within the plasma selenium concentrations used in this 
study, the within-run coefficient of variation (CV) was 2.1-2.6% while the between-run 
CV was 3.1-5.6% (n=10). Accuracy was assured by analysis of four internal quality 
control serum samples (TEQAS, University of Surrey, Guildford) and certified 
reference materials: Seronorm Serum (Nycomed, Norway) JL4409, mean value (5 
determinations) 0.90, SD 0.04 pmolL'^ (certified 0.92, range 0.84 -  1.00) pmolL'\ and 
NO0371 mean value (5 determinations) 1.76, SD 0.04 (certified 1.72, range 1.61-1.83) 
pmolL'\ The detection limit was less than 0.01 pmolL"\
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2.1.4 Data analysis
All data were analyzed using SPSS vl3. Continuous variables were shown to be 
normally distributed. The Pearson Chi squared test was used to compare observed SNP 
genotype frequencies with those expected under conditions of Hardy-Weinberg 
equilibrium. Logistic regression models were used to assess the association between 
SNP genotypes and prostate cancer risk, with genotypes coded either as number of rare 
alleles (0, 1, 2) or as minus allele/plus allele (0, 1) as appropriate, with adjustment for 
the possible confounding factors, age and geographical location. Genotype-specific 
risks were estimated as adjusted odds ratios (OR) with associated 95% confidence 
intervals (Cl) by logistic regression. The interaction between the two SNPs in 
determining prostate cancer risk was assessed using a general linear model, again 
adjusting for age and geographical region, with genotypes coded as minus allele/plus 
allele (0, 1). Data analysis was performed separately in cases with non aggressive or 
aggressive disease, and in ever- and never-smokers. A two-tailed P value of less than 
0.05 was considered statistically significant.
2.2 Tissue culture
2.2.1 Prostate Cell Lines
The human prostate cancer cell lines, DU 145, PC3, and LnCAP were purchased from 
the American Tissue Type Collection (ATCC). RWPEl was a kind gift from Moray 
Campbell (University of Birmingham, UK). The characteristics and growth medium 
can be seen in Table 2.2.
59
s
.9
2a
I
'S
Ia
I
nas
f
108
■g
o
H
H
s
Ü
I
i
.1
u
9
•3)
o  u ) M
f
I
1
1
?■
S
im
«o9
ü,
2
f
I
S
I
(S
om
f
-âII
1 1
1 1
% I
o?
i
1
D. cmU
I
I
!
%
I
University of Surrey      Chapter 2
2.2.2 Passaging of tumour cell lines
All cells were routinely cultured at 37°C in a humidified atmosphere containing 5% 
CO2. Adherent cell monolayers approaching confluency were washed three times with 
PBS (37°C) prior to incubation with 0.25% trypsin/ethylenediaminetetraacetic acid 
(EDTA) (Sigma-Aldrich Company Ltd., St Louis, MO) at 37°C until the cells were 
detached. The trypsin was inactivated with an equal volume of growth medium and the 
cell suspension was centrifuged at 400 x g for 3 minutes. The cell pellet was re­
suspended in pre-warmed growth medium and cells were seeded in new tissue culture 
flasks at the required density.
2.2.3 The treatment of cell with selenium and 5-aza-2 -deoxycytidine
The treatment of cancer cell lines with the demethylating agent 5-aza-2'-deoxycytidine 
has been commonly used to identify candidate hypermethylated genes in cancer. 5- 
Aza-2'-deoxycytidine reduces DNA méthylation and increases gene expression of 
hypermethylated genes which can be identified using microarray based detection. 
Therefore to identify hypermethylated gene promoters prostate cells were grown in the 
presence of 10 pM 5-aza-2'-deoxycytidine (Fisher Scientific UK Ltd, Loughborough, 
UK). In addition the response of gene expression to selenium was also investigated by 
the supplementation of cells with 100 nM sodium selenite (Fisher scientific UK Ltd, 
Loughborough, UK). To enable the identification of genes, both hypermetliylated and 
selenium-responsive, prostate cell lines were also cultured in the presence of both 
sodium selenite and 5-aza-2'-deoxycytidine.
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The prostate cancer cell lines, PC3, LnCAP and DU 145 and the immortalised normal 
prostate cell line, RWPEl, were seeded at low density in ventilated T75 flasks. The 
combinations of cell treatments are defined in Table 2.3. As the 5-aza-2'-deoxycytidine 
was diluted in dimethyl sulfoxide (DMSO, Sigma-Aldrich Company Ltd.) to a final 
concentration of 0.5%, cells cultured in the absence of 5-aza-2'-deoxycytidine were 
supplemented with 0.5% DMSO to ensure the observed effects were specific for 5-aza- 
2 '-deoxycytidine and not DMSO. Cells were given 24 hours to attach apart from 
LnCAP cells which were given 48 hours. 5-aza-2 -deoxycytidine treatment lasted for 4 
days and sodium selenite treatment lasted 48 hours before harvesting. Each condition 
was completed in quadruplicate.
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Table 2.3. The treatment of cell lines with S-aza-2 -deoxycytidine and sodium 
selenite and the density at which cells were seeded.
Cell line 5-Aza-2'-deoxycytidine (|iiM) Sodium selenite (nM) Cell density (1000/cm^)
RWPEl 0 0 5.0
0 100 5.0
10 0 7.5
10 100 7.5
LnCAP 0 ; 0 5.0
0 100 5.0
10 0 7.5
10 100 7.5
PCS 0 0 5.0
0 100 5.0
10 0 7.5
10 100 7.5
DU145 0 0 5.0
0 100 5.0
10 0 7.5
10 100 7.5
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2.2.4 The extraction of DNA and RNA from cultured prostate cells.
DNA and RNA were simultaneously extracted from the prostate cell lines using thé 
Qiagcn DNA/RNA allprep kit (Qiagen GmbH, Hilden, Germany). Cells were washed 
three times with PBS before the addition of 0.25% trypsin/EDTA (Sigma-Aldrich 
Company Ltd.). The trypsin was inactivated in an equal volume of cell medium before 
the cell suspension was centrifuged for (400 g) for 3 minutes. All medium was 
aspirated from the cells before the addition of 350 pi of Qiagen RLT buffer containing 
10 pl/ml B-mercaptoethanol. Cells were then disrupted by the QIAshredder 
homogeniser (Qiagen GmbH) and centrifuged at 20 000 x g for 30 seconds. The cell 
lysate was then pipetted into a DNA allprep column and the DNA bound to the 
membrane by centrifugation at 20 000 x g. The flow-through was collected and added 
to an RNA allprep column, and 350 pi of 70% ethanol added before being mixed and 
centrifuged at 20 000 x g to bind the RNA. The subsequent wash steps were completed 
according to the manufaclurcrs’ instructions. DNA was eluted in 100 pi o f Tris-EDTA 
buffer (10 mM Tris-Cl and 1 mM EDTA, sigma Aldrich Ltd.) and stored at -20 °C until 
subsequent analysis. RNA was eluted in RNase free water and stored at -80°C.
64
University of Surrey   Chanter 2
2.3 Clinical prostate cancer samples.
RNA from three aggressive prostate cancer samples and DNA and RNA from two 
normal prostate tissues was a kind gift from Dr Giuseppe Caruba (Palermo hospital, 
Italy). The normal prostate tissues were obtained from patients undergoing 
cystoprostatectomy. The advanced prostate cancer samples were obtained via radical 
prostatectomy from bladder cancer patients. Biopsy samples were histologically graded 
by a pathologist; each prostate cancer sample had a Gleason score >8 confirming the 
aggressive nature o f the tumours. The two normd prostate cancer samples were 
classified as histologically normal. The Palermo hospital ethical committee approved 
this study.
DNA obtained from five prostate cancer tumours was a kind gift from Professor Collin 
Cooper (Cancer research UK, Sutton, UK). Samples were obtained via radical 
prostatectomy. Histological analysis confirmed that the samples were cancerous; Each 
sample had a Gleason score of 6-7. In addition gene expression data were supplied for a 
number of genes of interest from the five prostate cancer samples and three additional 
normal prostate samples. Unfortunately DNA was not available for the normal prostate 
samples for which gene expression data was supplied. Ethical approval was obtained 
from the Multicentre Research Ediics Committee (MREC) and the NHS Research 
Ethics Committee,
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2.4 Whole genome expression analysis
2.4.1 Microarray design
The Agilent whole genome, human gene expression chip was used to analysis the gene 
expression patterns in the cell lines (after treatment with 5-aza-2'-deoxycytidine and 
selenium) and two normal prostate cancer samples and three cancerous prostate 
samples. The array is composed of 44 000 probes spread across 41 000 transcripts. 'The 
array uses Agilent’s Sureprint technology to directly print 60mer probes onto the slide 
surface, creating superior quality arrays (G2514F Agilent Technologies, Inc, Santa 
Clara, CA).
2.4.2 The universal reference RNA
To enable the comparison of microarray gene expression data between all samples a 
common reference RNA sample was compared to the experimental RNA on each array. 
A commercially available collection of RNA compiled fi*om ten different cell lines 
(Stratagene, La Jolla, CA) was used to enable the comparison with other microarray 
data using this same reference sample. In addition, the use of a universal reference 
sample will enable additional samples to be included in the data analysis at a future 
date.
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2.4.3 RNA quality control
To the assess the quality of the RNA prior to labelling, all samples were analysed on the 
Agilent Bioanalyser 2100 using the RNA 6000 assay (Agilent Technologies, Inc, Santa 
Clara, CA). The RNA 6000 assay assesses the quality of the 18s and 28s RNA subunits 
in each sample and expresses the integrity of the RNA as a RIN (RNA integrity 
number). RINs greater the 7 are recommended for the optimal labelling of RNA to 
ensure the success of the microarray. 20 ng of each sample was loaded onto the RNA 
6000 chip, together with 1 pi of denatured RNA ladder. All samples had a RIN greater 
than 8 out of 10 with the vast majority of samples having a RIN greater than 9 out of 10.
2.4.4 Labelling of RNA
RNA was labelled using the Agilent low RNA input linear amplification kit (Agilent 
Technologies Inc.). All components are supplied in the Agilent low RNA input linear 
amplification kit unless otherwise stated. Firstly, cDNA was synthesised from sample 
RNA. In a total volume of 11.5 pi, 250 ng of total RNA, 1.2 pi of T7 promoter primer, 
and 2.5 pi of spike in, control RNA (5188-5279, Agilent Technologies Inc.), was 
denatured for 10 minutes at 65°C before being immediately cooled on ice for a further 5 
minutes. 8.5 pi of cDNA mastermix (Table 2.3) was added to each sample and gently 
mixed by pipetting. Samples were incubated at 40°C for 2 hours before the inactivation 
of the reverse traiiscriptase, by heating to 65®C for 15 mhiutes. Samples were then 
immediately cooled on ice. 60 pi of transcription mastermix (Table 2.4) were added to 
the samples, gently mixed and incubated at 40°C for 2 hours in a rotating incubator.
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The universal reference RNA (Stratagene, Cedar Creek, TX) was labelled with Cyanine 
5 (Cy5) and the prostate cell RNA was labelled with Cyanine 3 (Cy3). Labelled cRNA 
was purified using RNA easy mini spin columns (Qiagen GmbH) in accordance vrith 
the manufacturer’s mstructiuns and stored at -80”C until use.
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Table 2.4 cDNA mastermix
Component Volume (pi)
5x First strand buffer 4.0
0.1 NiDTT (Dithiothreitoi; 2.0
10 mM dNTP mix 1.0
MMLV-RT (Moloney Murine Leukemia Virus Reverse Transcriptase) 1.0
RNaseOUT 0.5
Total volume 8.5
Table 2.5 Transcription master mix.
Component
Reference RNA 
Volume (pi)
Prostate sample RNA 
Volume (pi)
Nuclease-free water 15.3 15.3
Transcription buffer 20 20
0.1 MDTT 6.0 6.0
NTP mix 8.0 8.0
50% PEG 6.4 6.4
RNaseOUT 0.5 0.5
Inorganic pyrophosphatase 0.6 0.6
T7 RNA polymerase 0.8 0.8
Cyanine 3-CTP 2.4
cyanine 5-CTP 2.4
Total volume 60 60
69
University of Surrey _____   :_________________  Chapter 2
2.4.5 Quality control of labelled cRNA
The incorporation of Cy3 and Cy5 into the cRNA was assessed using the Nanodrop 
spectrophotometer (Agilent Technologies Inc.). The following formula was utilised to 
determine the specific activity of cyanine incorporation:
Specific activity Cyanine 3 cRNA = Pmol Cyanine 3/ul
Cone. cRNA (pg/pl)
Specific activity Cyanine 5 cRNA = Pmol Cvanine 5/ul
Cone. cRNA (pg/pl)
A specific activity greater than 8 pmol/pg, is required to enable the successful 
hybridisation of microarrays. All samples labelled in this study had a specific activity 
greater than 10 pmol/pg.
2.4.6 Hybridisation of cRNA to microarrays
For each microarray, components were combined to make a ‘fragmentation mix’ as 
outlined in Table 2.6. The fragmentation mix was gently vortexed, spun down and 
incubated at 60°C for exactly 30 minutes. 30 pi of 2x GE Hybridization Buffer HI- 
RPM (Agilent Technologies Inc) was added to the fragmentation mix and centrifuged at 
20 000 X g to remove bubbles. The mixture was then placed on ice before being 
dispensed onto the arrays, sealed with the corresponding gasket and firmly clamped 
using the Agilent SureHyb chamber. The SureHyb chamber was then placed in the 
hybridisation oven and rotated for 40 hours at 65°C (20 RPM). After hybridisation, the 
slides were removed from the SureHyb chamber and separated from the gasket whilst 
submerged in Agilent wash buffer one (Agilent Technologies Inc). Slides were washed
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for 1 min in wash buffer one at room temperature before being washed in wash buffer 
two (Agilent Technologies Inc.) for 1 min at 37°C. Slides were then slowly dipped into 
drying solution (Agilent Technologies Inc) to remove any trace of previous wash 
buffers.
Slides were scanned using the Agilent DNA microarray scanner (Agilent Technologies 
Inc.) and the data extracted using the feature extraction software. (Agilent Technologies 
Inc.).
Table 2.6 Fragmentation mix
Component Amount
Cyanine 3-labeled, linearly amplified cRNA 
(prostate sample)
825 ng
Cyanine 5-labeled, linearly amplified cRNA 
(universal reference RNA)
825 ng
1 Ox Blocking Agent 6 pi
25x Fragmentation Buffer 1.2 pi
Nuclease-ft-ee water To total volume of 30 pi
Total Volume 30 pi
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2.4.7 Normalisation and processing of microarrays
Array data were imported into R (version 2.5.0) (http://www.R-project.org, R 
Development Core Team) and global median normalised using the LIMMA package 
(Gentleman et al, 2004; Smyth and Speed, 2003). The data distribution across all arrays 
was checked and across array normalisation was performed such that the Median 
Absolute Deviation (MAD) was the same for each array [scale method in the LIMMA 
package (Smyth and Speed, 2003)].
Within the output of Feature Extraction (Agilent Technologies Inc.) there are four 
binary (1 for bad, 0 for good) variables (gIsFeatNonUnifOL/rlsFeatNonUnifOL, 
glsBGNonUnifOL/rlsBGNonUnifOL, gIsFeatPopnOL/rlsFeatPopnOL and 
gIsBGPopnOL/rlsBGPopnOL) that describe outliers in each channel on an array. Spots 
(probes) on each array were flagged as poor quality if at least one of the four Feature 
extraction variables for each channel on the array had the value 1 (bad); thus if a spot 
did not have a good signal (as determined by Feature extraction software) in both 
channels (Universal Human RNA reference and sample) then that spot was assigned 
NA.
The value assigned to each gene under a particular condition/replicate (single array) for 
downstream analysis (e.g. differential expression) was the average log] cDNA/human 
reference RNA across all probes that target that gene; where a gene did not have at least 
one good probe (not assigned NA, discussed previously) the gene was assigned NA. 
Genes that did not have an average log] cDNA/human reference RNA in at least two 
biological replicates for each condition (e.g. LnCAP medium, PC3 selenium) were
72
University of Surrey_____________  •  Chapter 2
filtered out of the data set such that only good quality data, with which we have 
assurance was used for analysis. A total of 23,117 genes remained after filtering.
2.5 The immunoprécipitation of methylated DNA
The immunoprécipitation of methylated DNA (MeDIP) allows the highly efficient, 
unbiased identification of methylated DNA from both cell culture and primary tissue 
samples (Weber et a l 2005). This technique enables the capture of methylated DNA 
using a highly specific monoclonal antibody to methylated CpG dinucleotides coupled 
with detection using existing DNA microarray technology. MeDIP was performed on 
10 samples of DNA from the prostate cell lines DU 145, LnCAP, PC3, RWPEl and 
normal prostate tissue fi-om two biological replicates. DNA extracted ft-om four 
biological replicates was combined to create two samples for each cell line. For 
example DU 145 replicate one and two were pooled to create a single sample, as were 
DU 145 replicate three and four. This maintains the use of biological replicates whilst 
minimising cost. Only two biological replicates were available for the normal prostate 
cancer tissue and were therefore not pooled.
Our protocol for the Immunoprécipitation of Methylated DNA (MeDIP) was based on a 
previously published protocol (Weber et a l 2005). 4.5 pg of DNA was sonicated to 
produce random ft-agments of DNA between 300 and 1000 bp in length. 2 pg of DNA 
was diluted in a final volume of 450 pi Tris-EDTA buffer (TE buffer) before being 
denatured for 10 minutes at 100°C. Samples were then immediately cooled on ice for a 
further 10 minutes. DNA was precipitated using 10 pi of monoclonal antibody against 
5-methylcytidine (Eurogentec, Seraing, Belgium) for 2 hours at 4°C in
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immunoprécipitation buffer (IP buffer, final concentrations: lOOmM Na-phosphate pH
7.0, 1.4M NaCl, 0.5% Triton X-100). 40 pi of magnetic Dynabeads M-280 sheep anti­
mouse IgG (Invitrogen), prewashed twice in 0.1% BSA-PBS (Sigma-Aldrich Company 
Ltd.), were incubated for 2 hrs at 4°C with the DNA/5-methyl cytidine antibody 
mixture. The beads were then collected using a magnetic rack and washed three times 
in 700 pi IP buffer, resuspended in 250pl proteinase K digestion buffer (50 mM Tris pH
8.0, 10 mM EDTA, 0.5% SDS) and incubated for 3 hours at 50°C with 7pi proteinase K 
(10 mg/ml stock) (Promega, Madison WI). The beads were collected, and the enriched 
DNA purified from the supernatant using Qiagen Mini elute (Qiagen GmbH) in 
accordance with the manufactures instructions. The DNA concentration was measured 
using the Nanodrop spectrophotometer (Agilent Technologies Inc.) and the enriched 
DNA stored at -20°C until required.
2.5.1 ChlP-oii-chip microarray design
The detection of enriched methylated DNA was completed using the Agilent human 
promoter ChlP-on-chip microarray set (G4489A Agilent Technologies Inc). This 
microarray is composed of 488,000 60mer probes spread -5.5kb upstream and 2.5 kb 
downstream of the transcriptional start site of 17,000 human transcripts. This enabled 
the méthylation analysis of gene promoters across the whole human genome.
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2.5.2 DNA labelling
DNA enriched by MeDIP was labelled with Cy3 and the input DNA labelled with Cy5 
for the first biological replicate of each sample. For the second replicate the opposite 
was true. This enabled a dye swap approach to the microarrays allowing for differences 
between the labelling efficiencies of Cy3 and Cy5 to be normalised over both biological 
replicates.
DNA was labelled using the BioPrime kit (Invitrogen). The BioPrime kit utilises the 
Klenow reaction to incorporate either Cy3 or Cy5 into the replicated DNA strand. 20 pi 
of 2.5x random primers were added to 20 pi of DNA. The sample was subsequently 
denatured at 94°C for 3 minutes before the addition of 5 pi of dNTP mix, 3.75 pi of Cy 
dye and 1.5 pi of Klenow enzyme. The reaction was incubated for 12 hours at 37°C 
before purification using the MinElute PGR purification kit (Qiagen GmbH). The 
samples were eluted in 2 x 10 pi TE buffer and stored at -80°C.
2.5.3 ChlP-on-chip hybridisation
Cy3 and Cy5 labelled samples were combined in equal volumes in a 1.5 pi micro­
centrifuge tube for each biological replicate. 50 pi of 1.0 mg/ml human cot 1 DNA 
(Invitrogen), 52 pi of lOx Agilent blocking buffer and 260 pi of 2x Agilent 
hybridisation buffer were added to the labelled DNA and gently mixed. Samples were 
then heated to 95°C for 3 minutes and incubated at 37®C for 30 minutes. Samples were 
subsequently centrifuged at 20 000 x g to remove any air bubbles before being 
dispensed onto the array. Slides were sealed with an Agilent gasket and clamped into
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the Agilent SureHyb chamber. Samples were then hybridised to the array for 60 hours 
at65°C(20 RPM).
After hybridisation, slides were removed from the SureHyb gasket and separated in 
Agilent CGH wash buffer one. The slides were washed at room temperature in Agilent 
CGH wash buffer one for 5 minutes before a second wash in Agilent comparative 
genomic hybridisation (CGH) wash buffer two warmed to 31°C, for a further 5 minutes. 
To ensure the removal of potential smears and traces of previous wash buffers, slides 
were gently dipped into Agilent stabilisation and drying solution. Slides were loaded 
into the Agilent scanner and scanned immediately. Data was extracted using Agilent 
Feature Extraction software.
2.5.4 Normalisation and processing of MeDIP arrays
Normalisation methods make the assumption that the bulk of probes on the array should 
have a signal in both channels. As the méthylation status of all promoters represented 
on the array is unknown (and therefore signals of the probes targeting those promoters 
are also unknown), normalisation was not applied to the MeDIP arrays. The outlier 
parameters of feature extraction, as described in the expression methods (section 2.4.7) 
were once again used to check spot quality. Probes that had a T i n  any of the outlier 
descriptors for the reference channel were assigned NA. Probes that did not have at 
least 2 good values in each of the conditions tested were filtered out; 457,951 probes 
that target the upstream regions of genes (700 nt upstream of annotated start and 300 nt 
downstream of annotated start) passed filtering/quality checks and were used for further 
analysis.
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2.5.5 Gene ontology analysis
The disruption of specific pathways by the potential silencing by méthylation of 
otherwise selenium responsive genes was analysed using the gene ontology program 
MetaCore. MetaCore is a web-based program for the analysis of high-throughput data 
derived from gene expression, chromatin immunoprécipitation and comparative 
genomic hybridisation microarrays (Ekins et al. 2007). It is claimed that MetaCore is 
the most comprehensive database in the bioinformatics field, consisting of over 4.5 
million findings published in recent years (Ekins et a l 2007). MetaCore is a powerful 
gene ontology program determining the pathways most significantly represented by the 
data, before combing significant pathways to form networks of cellular processes
2.6 Méthylation analysis of individual gene promoters
2.6.1 Bisulfite conversion of DNA
DNA from the cell lines and prostate cancer samples was subjected to bisulphite 
conversion. In the presence of sodium bisulfite, un-methylated cytosines are 
deaminated to uracil, and replaced by thyimidine during PCR amplification. 
Methylated cytosines, however, are insensitive to deamination and remain as cystosine. 
Thus all cytosines in the genome are converted to uracil unless they are methylated. 
This enables the downstream quantitative analysis of méthylation through PCR based 
techniques (Figure 2.1).
For each sample, DNA was sonicated to an approximate size of ~800 bp. 500 ng of 
sonicated DNA was then bisulpliiic-converted using the EZ DNA Methylation-Gold™ 
Kit (Zymo Research, Orange, CA) according to the manufacturer’s instructions.
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Figure 2.1. The modification of DNA by treatment with sodium bisulfite. Step 1. 
All unmethylated cytosines are deaminated to Uracil. Methylated cytosines remain 
unmodified. Step 2. PCR of modified DNA results in the incorporation of thymidine, 
replacing uracil. Using the unmodified sequence as a reference, it is possible to 
quantitatively determine the méthylation status of specific CpGs.
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2.6.2 Pyrosequencing primer design
PCR primers were designed using the PSQ assay design software (Biotage AB, 
Uppsala, Sweden). Due to the bisulfite conversion of DNÀ required for méthylation 
analysis, all C in CpG were first changed to Y (the degenerated code for a C/T 
polymorphism), and then all remaining C were changed to T. All primers were 
designed using this process except for GSTPl, for which the primers were already 
published (Tost et a l 2003) (Table 2.7).
Bisulphite converted DNA (2 pi) was amplified in a total reaction volume of 50 pi. The 
reaction conditions were as follows: 5 pi of PCR buffer, 200 pM dNTPs, 2 pmol of each 
primer (Table 2.7) and 1.25 units of HotStarTaq® (Qiagen GmbH). The PCR of 
GSTPl required an additional 1.5mM MgCL. Reactions were denatured at 95°C for 5 
minutes before 50 cycles of 30 seconds at 95°C, 45 seconds at the appropriate annealing 
temperature (Table 2.7), and 30 seconds at 72 °C, before a final extension at 72 °C for 5 
minutes. All thermal cycling was completed on an MJ dyad PCR block (Bio-Rad® 
Hercules CA), with a heated lid set at 100 °C.
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2.6.3 Pyrosequencing setup.
Single-stranded DNA was prepared from 40 pi of PCR template using 3 pi streptavidin 
Scpharose® IIP beads (Sigma Aldrich) in PSQ annealing buffer (Biotage AB). After 
annealing, the beads were captured using the Pyrosequencing vacuum prep tool 
(Biotage AB), subsequently washed in 70% ethanol, denatured in a NaOH, and then 
washed for 5 seconds in lOmM Tris-acetate, pH 7.6 (Fisher scientific UK Ltd, 
Loughborough, UK). The beads were then released into 45 pi of annealing buffer 
(Biotage AB) and 10 pM sequencing primer (Table 2.8). Samples were denatured for 2 
min at 80°C before being allowed to cool to room temperature. Sequencing was 
performed on the PSQ 96 MA (Biotage AB), using the PSQ Pyrogold genotyping kit 
(Biotage AB) in accordance with the manufacturer instructions.
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2.7 Quantitative reverse transcriptase polymerase chain reaction
RNA_ concentration was measured using the Nanodrop spectrophotometer (Agilent 
Technologies Inc.). Samples were diluted in autoclaved DEPC-treated water to a final 
concentration of 10 ng/pl. Samples were stored at -80°C.
Relative quantitative real-time PCR (RT-QPCR) was performed using a one step 
QuantiTect SYBR green RT-PCR kit (Qiagen GmbH). A QuantiTect primer assay was 
used to detect genes of interest (Table 2.9). Each 12.5 pi reaction contained 30 ng of 
total RNA, 6.25 pi 2x QuantiTect Sybr Green, 0.625 pi 20x Quantitect RT Mix, and 
1.25 pi of the specific QuantiTect primer assay (Table 2.9). All reactions were 
completed in triplicate and cycled on the ABI prism 7700 (Applied Biosystems Inc.) 
(Table 2.10). After the RT-QPCR reaction, Ct (cycle threshold) values were 
automatically determined by the ABI prism 7700. Melt curve analysis of PCR products 
were performed over a temperature range of 65 °C to 95 °C to confirm the specificity of 
the products.
Table 2.9. Details of Quantitect gene expression primer assays
Gene Quantitect primer assay number
SOD2 QT01008693
GPxl QT00203392
SEPPl QT01008175
GPx4 QT00067165
SEP15 QT00057316
GPx3 QT00062279
GSTPl QT00086401
ISsRNA QT00199367
chromosome 19 open reading frame 53 QT00035616
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Seri2il dilutions of Universal reference RNA (Stratagene) ranging from 10 ng to 10 pg 
were used to create standard curves for each gene. The Ct values for each dilution were 
plotted against their corresponding log amounts of RNA to create a standard curve. 
Only standard curves that had a correlation of >0.99 were considered viable.
The amount of RNA for each test sample was calculated from the standard curve using 
the following equation: ng = 10^ ^^ * * a ) + b ) ^  jg  gradient and B is the intercept 
of the corresponding standard curve. The relative amounts of both the target and 
reference gene were determined from the corresponding standard curve. The 
normalised amount of the target gene was determined by dividing the target gene by the 
reference gene. The reference gene used for analysis of gene expression in PC3, 
RWPEl and DU 145 was 18s in LnCAP, the reference gene was C19orf53.
Table 2.10. Cycling parameters for RT-QPCR
Step Time Temperature
Reverse transcription 30 minutes 50°C
Dénaturation and DNA 15 minutes 95 °C
polymerase activation
2 step thermalcycling (x40)
Dénaturation 15 seconds 95°C
Annealing, extension 60 seconds 60 T
and data collection
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2.8 Quantitative polymerase chain reaction of immunoprecipitated DNA
DNA concentration was measured using the Nanodrop spectrophotometer (Agilent 
Technologies Inc.). Samples were diluted to 10 ng/pl, in autoclaved nuclease free 
water. Samples were then stored at -20°C until required.
Relative quantitative PCR was performed using QuantiTect SYBR green QPCR kit 
(Qiagen GmbH). QPCR Primers were as follows: SelS_QPCR_F
GTCATGGAACGCCAAGAGG, SelS_QPCR_Rl GGACGACCCACCCATCAT, 
GSTP1_QPCR_F AGGCCTTCGCTGGAGTTTC and GSTP1_QPCR_R 
GAGCTCTGAGCCCCATCC. Each 12.5 pi reaction contained 30 ng of DNA, 6.25 pi 
2x QuantiTect Sybr Green, and 0.25 pi of each primer. All reactions were completed in 
triplicate and cycled on the ABI prism 7700 (Applied Biosystems Inc.) (Table 2.11). 
After the QPCR reaction, Ct (cycle threshold) values were automatically determined by 
the ABI prism 7700. Melt curve analysis of PCR products were performed over a 
temperature range of 65°C to 95°C, to confirm the specificity of the products.
Serial dilutions of human leukocyte DNA ranging from 10 ng to 10 pg were used to 
create standard curves for each gene. The Ct values for each dilution were plotted 
against their corresponding log amounts of DNA to create a standard curve. Only 
standard curves that had a correlation of >0.99 were considered viable.
As with RNA, tlie amount of DNA for each test sample was calculated from the 
standard curve using the following equation: ng = 10^ ^^ * x a ) + b ) ^  ig  the gradient 
and B is the intercept of the corresponding standard curve. The relative amounts of
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GSTPl and SelS mRNÀ were determined from the corresponding standard curve. The
normalised amount of GSTPl was determined by dividing GSTPl by SelS.
Table 2.11. Cycling parameters for QPCR
Step Time Temperatures Temperature
(GSTPl) (SelS)
Dénaturation and DNA 15 minutes 95 °C 95°C
polymerase activation
3 step thermal cycling x40
Dénaturation 30 seconds 95°C 95°C
Annealing 30 Seconds 56 "C 60 T
Extension and data 31 Seconds . 72 °C 72 °C
collection
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The CAncer of the Prostate Sweden study (CAPS)
3.1 Introduction
The association of polymorphism in selenoprotein genes with cancer provides some of 
the strongest evidence that selenium, in particular selenoproteins, has a role in cancer 
prevention. This evidence has been extensively reviewed in the previous chapter, but 
will be briefly described below, in context of the current study.
In order to further investigate the association of selenoproteins and prostate cancer, 
candidate polymorphisms were chosen to be genotyped in the CAncer of the Prostate 
Sweden (CAPS) study. Polymorphisms were identified in 5 genes; either selenoprotein 
genes or genes involved in the same metabolic pathways as selenoproteins. The 
polymorphisms investigated and evidence to support a role in prostate cancer are 
outlined below.
3.11 Glutathione peroxidise 1 Prol98Leu {GPxl rsl050450)
GPxl detoxifies hydrogen peroxide and its organic hydroperoxides, reducing oxidative 
stress which is, widely accepted as being important in carcinogenesis. A polymorphism 
results in the incorporation of either proline or leucine at codon 198 of GPxl (Forsberg 
et a l 1999). The Leu allele is associated with reduced translational efficiency and or 
functionality in recombinant human GPxl (Hu and Diamond 2003). The Leu allele has 
been associated with an increase risk of both lung (OR 2.3, 95% Cl 1.3 to 3.8, P = 
<0.001) (Ratnasinghe et a l 2000) and bladder cancers (OR 2.63, 95% Cl 1.45 to 4.75, P 
= 0.001) (Ichimura et a l 2004). The effect of the Prol98Leu polymorphism upon
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prostate cancer, however, remains unclear; the Leu allele was reportedly protective in 
one study (Arsova-Sarafmovska et al. 2008) whilst in another, no overall association 
was observed (Choi et al. 2007).
3.1.2 Manganese superoxide dismutase ValI6Ala {SOD2 rs4880)
The product of S0D2 activity, H2O2, is a substrate for the selenoprotein GPxl. A SNP 
in exon 2 of SOD2 results in a Val for Ala substitution; this polymorphism alters the 
secondary structure of the mitochondrial import sequence. Import of the Ala variant into 
the mitochondrial matrix is more efficient and generates more active S0D2 than the Val 
variant (Sutton et al. 2003). This polymorphism has been shown to modify the risk of 
breast and bladder cancer (Ichimura et al. 2004; Cox et al. 2006). Furthermore, the 
association of this polymorphism with prostate cancer is modified in a selenium- 
dependant manner (Li et al. 2005).
3.1.3 Glutathione peroxidise 4 718 C/T {GPx4 rs713041)
GPx4 functions to protect cells against oxidative stress by reducing phospholipid 
hydroperoxides, lipid hydroperoxides and hydrogen peroxide in the presence of reduced 
glutathione. The genomic locus of GPx4, 19pl3.3, is both commonly deleted in cancer 
and lies adjacent to a region that has shown linkage to prostate cancer (Hsieh et al. 
2001; Eeles et al. 2008). A polymorphism {GPx4 718 C/T) located in the 3'UTR of 
GPx4, which lies in close proximity to the putative selenocystëine insertion sequence 
(SECIS element), vital for selenium incorporation into GPx4 (Figure 3.1) (Villette et al.
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2002). This polymorphism alters the ability of RNA binding proteins to associate with 
the 3' UTR, and is believed to be the mechanism by which this SNP effects both the 
amount and activity of GPx4 (Meplan et a l 2008). To date, no studies have investigated 
the association of GPx4 with prostate cancer; in colon cancer however, possession of 
one or more copies of the 718T allele was shown to be protective over the 718C allele 
(OR 0.60 95% Cl 0.37 to 0.96, p = 0.033) (Bermano et a l 2007).
The 718C allele leads to increased levels of 5 '-lipoxygenase products (Villette et a l 
2002) and may influence the production of 5-HETE, which stimulates proliferation of 
prostate cancer cells and inhibits apoptosis (Ghosh and Myers 1998). Thus, the GPx4 
718 C/T polymorphism could be of great importance in prostate cancer progression.
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Figure 3.1. Positions of polymorphisms in SEP15 and GPx4: SEP 15 811 C/U in
SECIS-like structure of SEP 15 (a), SEP 15 1125 G/A in SEP 15 functional SECIS 
element (c), GPx4 718 C/U (b).
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3.1.4 Selenoprotein 15 kDa 811 C/T (SEP15 rs5845)
SEP 15 is thought to be involved in the quality control of protein folding (Korotkov et 
al. 2001). The genetic locus of SEP15, lp31, is commonly deleted in cancer (Hu et al. 
2001). The SNP 811 C/T is in complete linkage disequilibrium with the 1125 G/A 
SNP. Whilst the 811 C/T polymorphism is located within an RNA structure similar to a 
SECIS element, studies have shown it to be non-functional (Figure 3.1)(Hu et al. 
2001). The 1125 G/A SNP however, is located in a fully functioning SECIS element 
and thus functional differences between haplotypes are attributed to the 1125 G/A 
polymorphism. Functional analysis suggests the 8I1C/1125G haplotype is more 
responsive to selenium supplementation than is 811T/1125A (Kumaraswamy et al. 
2000). Furthermore cells homozygous for SEP 15 1125G were more sensitive to growth 
inhibition and apoptosis by selenium than 1125A homozygous cells (Apostolou et al. 
2004). Although no direct association with SEP 15 811 C/T has been observed in 
cancer, selenium status may modify the association of this polymorphism with lung 
cancer (Jablonska et al. 2008). However, to date, no study has investigated the 
association of this polymorphism in a large prostate-cancer case-control study.
3.1.5 Selenoprotein P AIa234Thr (SEPPl rs3877899)
The exact function of SEPPl remains undetermined; however, both animal models and 
its high selenium content suggests an important role in selenium transport and 
homeostasis (Hill et al. 2003; Schomburg et al. 2003). Four polymorphisms within 
SEPPl have been associated with colon cancer risk, further supporting a potential role 
for SEPPl in cancer prevention (Peters et al. 2008). A polymorphism in SEPPl results 
in the substitution of alanine for threonine at codon 234 (rs3877899). Homozygosity
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for the SEPPl Ala234 allele is associated with a lower concentration of plasma 
selenoprotein P in men, affecting the concentration and/or activity of other 
selenoproteins, notably of thioredoxin reductase 1 (TRl) and some of the antioxidant 
glutathione peroxidises (Meplan el a l 2007). Thus it is conceivable that SEPPl 
Ala234Thr genotype may affect prostate cancer risk.
3.2 Study Population
For the initial part of the study, stage 1, only CAPS 1 samples were available. CAPS 2 
samples subsequently became available; together with CAPS 1, CAPS 2 samples from 
stage 2 of the study. This enabled a ‘stopping for futility’ approach to the project. After 
the analysis of results from CAPS 1, the results were assessed to determine the benefit 
of additional genotyping in the CAPS 2 population. This approach enhances the 
statistical power of results whilst minimising cost and waste of precious and limited 
samples. Thus, only those polymorphisms that provided interesting results from CAPS 
1 would be genotyped in the additional CAPS 2 population. The characteristics of the 
study participants are described in Table 3.1; participant recruitment and study design is 
describe in materials and methods.
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Table 3.1 Demographic data for Stage 1 (CAPS 1) and stage 2 (CAPS 1 and 2 
combined).
Characteristic Control group Case group
Stage 1: CAPS P
Participants (n) 801 36.0% 1427 64.0%
Mean age at diagnosis ± SD (yr) 68.0 ±7.2 66.6 ±7.4
Mean BMI at diagnosis ± SD 26.18 ±3.37 26.31 ±3.40
Smoking status
Ever smoked 474 62.0% 799 60.0%
Never smoked 290 38.0% 532 40.0%
Total 764 100% 1331 100%
Stage 2: CAPS 1 and CAPS 2
Participants (n) 1764 37.7% 2915 62.3%
Mean age at diagnosis ± SD (yr) 67.1 ±7.4 66.4 ±7.1
Mean BMI at diagnosis ± SD 25.0 ±6.69 25.3 ±6.31
Smoking status
Ever smoked 504 60.9% 811 60.1%
Never smoked 323 39.1% 538 39.9%
Total 827 100% 1349 100%
Selenium status (pg/L) n = 169 76.0 ± 17.2
The initial Cancer of the Prostate study was composed of CAPS 1 only (stage 1); the study was enlarged 
to include both CAPS 1 and CAPS 2 (stage 2). Only polymorphisms that provided interesting results in 
CAPS 1 were genotyped in the additional CAPS 2 population.
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3.3 Results
3.3.1 Selenium status
The mean (±SD) plasma selenium was 76.0 ± 17.2 pg/L in 169 CAPS control samples 
confirming the expected relatively-low selenium status of this group of Swedish men. 
Mean plasma selenium was not significantly different between ever-smokers and never- 
smokers.
3.3.2 The CAPS study: Stage 1
3.3.2.1 SNP genotyping
Genotyping error rates, determined by genotyping duplicated samples, were less than 
1.5%. All polymorphisms investigated were shown to be in Hardy Weinberg 
equilibrium and the allele fi*equencies within the control population (Table 2) were 
comparable to those in other published data (Ratnasinghe et al. 2000; Li et al. 2005; 
Bermano et al. 2007; Meplan et al. 2007; Jablonska et al. 2008).
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Table 3.2 Allele frequencies of polymorphisms in cases and controls from stage 1 
of the CAPS study.
Polymorphism Allele Controls • Cases
GPxl Codon 198 C(Pro) 0.680 0.684
T (Leu) 0.320 0.316
GPx4 718 C 0.579 0.565
T 0.421 0.435
SEP15%\\ C 0.794 0.786
T 0.206 0.214
S0D2  Codon 16 T(Val) 0.498 0.483
C (Ala) 0.502 0.517
SEPPl Codon 234 G (Ala) 0.752 0.770
A(Thr) 0.248 0.230
3.3.2.2 Genotype and prostate cancer risk
No association between genotype and prostate cancer risk was observed in any of the 
SNPs investigated in stage 1 of the CAPS study (Table 33a  and 3.3b).
3.3.2.3 Effect of selenoprotein genotype on markers of aggressive disease
To investigate if there was an association with aggressive disease, cases were classified 
as either non-aggressive or aggressive for each individual clinical marker.
Cases determined as aggressive (or non-aggressive) were compared to the control group 
for each clinical marker (T stage, N stage, M stage, Gleason score, differentiation and 
PSA), adjusting for age and geographical location using logistic regression.
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Possession of at least one copy of the SEP 15 81 IT allele was associated with an almost 
50% increased risk of having prostate cancer in men whose serum PSA level was 100 
ng/ml Or higher (OR 1.48, 95% Cl 1.05 to 2.10, P = 0.025) (Table 3.4). No further 
associations between genotype and individual markers of disease severity were 
observed (data not shown).
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Table 3.4. SEP15 811 C/T genotype odds ratios in prostate cancer cases with a 
PSA >100ng/ml versus controls.
Genotype
SEP 15 811 Genotype
Controls
n
Cases PSA >100 
n OR (95% CD P
. n=781 n=159
CC 493 85 1 (ReD
C T andJT 288 74 1.48(1.05-2.10) .025
Not all the techniques available to assess the stage and aggressiveness of prostate cancer 
are routinely undertaken during the diagnosis. Thus, for some clinical markers, the 
information available was inevitably incomplete. In order to overcome this, cases were 
designated ‘aggressive’ if they were classified as ‘aggressive’ according to one or more 
of the clinical markers (see above), and compared to controls using logistic regression, 
adjusting for age and geographical location as before. There was no association 
between genotype of any of the genes investigated and either non-aggressive or 
aggressive disease (Table 3.3a and 3.3b).
3.3.2.4 Gene-environment interactions
Because of potential gene-nutrient interactions, we investigated the effect of lifestyle 
and environmental factors, i.e. including smoking, BMI, age and geographical location, 
and selenoprotein genotype on risk and progression of prostate cancer. There was no 
evidence for gene-environment interactions (data not shown).
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3.3.2.S Gene - gene interactions in stage 1 of the CAPS study
Because of reported interactions between genes involving selenium and risk of prostate 
cancer, gene x gene interactions were investigated. In contrast to other cancer studies, 
no interaction between S0D2 and GPxl was observed in prostate cancer per se, non- 
aggressive prostate cancer or clinically aggressive disease (data not shown). 
Interestingly however, an interaction was observed between SEPPl Ala234Thr and 
S0D2 V all6Ala and prostate cancer risk (Table 3.5). In men homozygous for the 
SEPPl 234 Ala allele, possession of at least one S0D2  16 Ala gave a 66% increased risk 
of prostate cancer in comparison to SOD2 Val homozygotes (OR 1.66, 95% Cl 1.23 to 
2.24, P = < 0.001). Conversely, in men possessing at least one SEPPl 234Thr allele, 
possession of the S0D2  16Ala allele did not increase prostate cancer risk, when 
compared to SOD2 16Val homozygotes (OR 0.86, 95% Cl 0.60 to 1.23, P = 0.41). The 
interaction between the polymorphisms in determining risk of prostate cancer was 
highly significant (P = 0.006).
In non-aggressive prostate cancer the magnitude of the interaction was of similar size to 
prostate cancer per se, however the interaction between the polymorphisms was no 
longer significant (P = 0.69) In aggressive prostate cancer, however, the association 
was even greater and more significant than in prostate cancer per se ÇP = 0.002). In 
SEPPl 234 Ala homozygotes, men in possession of at least one SOD2 16Ala had a 
71% increase in aggressive prostate cancer compared to S0D2 Val homozygotes (OR 
1.71, 95% Cl 1.15 to 2.53, P = 0.008); by contrast no increase in risk was associated 
with the S0D2 16Ala Allele in SEPPl 234 Thrf men (OR 0.70, 95% Cl 0.46 to 1.063, 
P = 0.09). No gene-gene interaction was observed between any of the other genes 
investigated (data not shown).
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3.3.3 The CAPS study: Stage 2
In order to increase the statistical power and importance of the significant findings in 
stage^l of the CAPS study, S0D2  V all6Ala and SEPPl Ala234 I hr where genotyped in 
an additional 1488 cases and 963 controls. This effectively doubled the size of the 
study fi'Om 2228 participants in CAPS 1 to 4679 in CAPS 1 and 2 combined (Table 
3.1).
In contrast to stage 1 of the CAPS study, the SOD2 Alai 6 allele was associated with an 
increased risk of prostate cancer in stage 2. Individuals with at least one S0D2  Alai 6 
allele (SOD2 Alai 6+) had an almost 20% increased risk of prostate cancer compared to 
V all6 homozygotes (OR 1.19, 95% Cl 1.03 to 1.37, P = 0.02; Table 3.6). The 
association between the S0D2  polymorphism and either non-aggressive or aggressive 
disease was of similar magnitude to that with total prostate cancer (non-aggressive plus 
aggressive) (Table 3.6).
As observed in Stage 1, SEPPl ala was not associated with increased risk of total 
prostate cancer per se, non-aggressive prostate cancer or clinically-aggressive prostate 
cancer (Table 3.6).
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3.3.3.1 Gene - gene interactions: the interaction of SEPPl and SOD2 with prostate 
cancer risk.
Men homozygous for the SEPPl Ala234 allele, who were also S0D2 Alai 6+, were at 
43% greater risk of prostate cancer than SOD2 V all6 homozygotes (OR 1.43, 95% Cl 
1.17 to 1.76, P = 0.0005; Table 3.7, Figure 3.2). By contrast, there was no association 
between SOD2 genotype and cancer risk in SEPPl Thr234+ men. This interaction 
between the two SNPs in determining risk of prostate cancer had a borderline 
statistically significant P value of 0.05.
In aggressive prostate cancer, the interaction between the SNPs was stronger (P = 0.01) 
SEPPl Ala234 homozygotes who were also SOD2 Alai 6+ having a 60% increased 
risk of aggressive disease compared to S0D2  Val 16 homozygotes (OR 1.60, 95% Cl 
1.22 to 2.09, P = 0.0007; Table 3.7, Figure 3.2), whereas there was no association wiüi 
S0D2  genotype in the SEPPl Thr234+ men. Although the association with SNP 
genotypes in non-aggressive disease might appear significant, the interaction between 
the two SNPs was far fi’om statistical significance as demonstrated by the broad overlap 
between the odds ratio confidence intervals in the two SEPPl genotype groups 
(P=0.278, Table 3.7).
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33.3.2 Gene -  gene -  environment interactions: The impact of smoking on the 
SOD2 and SEPPl associations with prostate cancer risk
Neither S0D2 nor SEPPl genotype taken separately significantly affected the risk of 
prostate cancer in either never- or ever-smokers; however, the interaction between 
SEPPl and S0D2  SNPs in determining prostate cancer risk was modified by smoking 
status (Table 3.8, Figure 3.2). Ever-smokers homozygous for SEPPl Ala234 had a 
highly-significant two-fold increase in prostate cancer risk if they were also S0D2 
A lai6+ (OR 1.97, 95% Cl 1.33 to 2.91, P = 0.0007). The association between SOD2 
genotype and cancer risk in ever-smokers was not observed in SEPPl Thr234+ men 
(OR 0.75, 95% Cl 0.47 to 1.18, P = 0.21). This interaction between SEPPl and S0D2 
SNPs in determining prostate cancer risk in ever-smokers was highly significant (P = 
0.0014) contrasting with the lack of interaction found in never-smokers (P = 0.43).
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3.4 Discussion
The mean plasma selenium of 76.0 ± ,17.2 pg/L in control samples confirms the 
relatively low selenium intake and status in the Swedish population (cf mean US value 
of 125 pg/L determined in the Third National Health and Nutrition Examination Survey 
(Niskar et al. 2003)). This value is less than the 92 pg/L required for maximal plasma 
GPx activity (Duffield et al. 1999) and considerably less than the plasma concentration 
required for full expression of SEPPl (Moschos 2000; Xia et al. 2005); demonstrating 
that the study population has a selenium intake inadequate for optimal selenoprotein 
synthesis and/or activity. This may be relevant to prostate cancer risk since low 
selenoprotein production led to higher-grade lesions and aggressive disease in a 
transgenic mouse model of prostate cancer (Diwadkar-Navsariwala et al. 2006).
In the present study it is hypothesised, that in a population with relatively-low selenium 
status, inter-individual variation in selenium requirement, as determined by 
selenoprotein genotype, might have a greater effect on the risk of prostate cancer than in 
a selenium-replete population. Despite the study rationale, no effect of selenoprotein 
genotype per se was observed on prostate cancer risk. Though previous studies have 
found a significant association between GPxJ Prol98Leu and the risk of lung and 
bladder cancer (Ratnasinghe et al. 2000; Ichimura et al. 2004), no such association vdfii 
prostate cancer or disease severity was found in this study. However, the studies in 
which significant associations were found were notably of selenium-replete populations 
(USA and Japan), calling into question the validity of the initial hypothesis, i.e. that 
GPxl genotype-determined differences in risk might be more pronounced in 
populations of low-selenium status. It may be that populations need to be selenium
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replete to express their selenoproteins fully in order to manifest the associations 
between certain functional selenoprotein SNPs and prostate cancer. Alternatively, these 
results may suggest that the role of GPxl in the prostate is not as important as in the 
lung and bladder. Both studies that associated the GPxl Leu 198 polymorphism with 
cancer risk concerned tissues exposed to high levels of oxidative stress, viz. the lungs of 
smokers (Ratnasinghe et al. 2000) and the bladder (Ichimura et al. 2004) which is 
subject to high exposure to H2O2 present in urine (Halliwell et al. 2000). A reduction in 
GPxl function associated with the Leu allele would be more noticeable in oxidatively 
stressed tissue. Findings from GPxl knockout models reinforce this theory, as the 
difference in phenotype between wild-type and knockout mice was only observed under 
conditions of high oxidative stress (Lei 2001).
Arsova-Sarafinovska et al (2008) reported the 198Leu allele to be protective in prostate 
cancer. The mechanism by which the Leu allele may protect against cancer is not 
understood and appears to contradict previous findings; nutrition and the co segregation 
of GPxl with other potentially functional SNPS are cited as potential reasons for this 
finding. However, the study was particularly small, consisting of only 82 prostate 
cancer cases; the results presented here in conjunction with recent findings in a study of 
equal size, suggest there is no association with either allele of the Prol98Leu 
polymorphism and prostate cancer (Choi et al. 2007).
It has to be remembered that to date, we have only tested one SNP in the GPxl gene, 
albeit a putatively functional one, so it will be important to examine other SNPs. For 
instance, in a small case-control study investigating the effect of GPxl genotype on risk 
of young-onset prostate cancer, an allele of a polymorphic alanine repeat containing six
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alanines (Ala^ allele) was found to be associated with a border-line significant increased 
risk of prostate cancer (Kote-Jarai et a l 2002). The Ala^ allele is in linkage 
disequilibrium (LD) with 198Leu, whereas the Alas and Ala? alleles are in LD with the 
198Pro (Moscow et a l 1994; Kote-Jarai et a l 2002).
The GPx4 718 C allele has previously been shown to increase the products of 5' 
lipoxygenase (Villette et a l 2002); one of these products, 5-HETE has been shown to 
inhibit apoptosis and stimulate the proliferation of prostate cancer cells in vitro (Ghosh 
and Myers 1998). Thus, in the present study it was hypothesised that the GPx4 718C 
allele may be associated with an increase risk of prostate cancer or aggressive disease. 
However, GPx4 718 T/C genotype was not associated with risk of prostate cancer, 
whether non-aggressive or aggressive. These results suggest that whilst the production 
of 5-HETE may be a strong stimulant of prostate cancer cells in vitro, this may not 
necessarily be the case in vivo. Whilst no association with the GPx4 718 T/C genotype 
was observed in this study, possession of the GPx4 718 T allele was shown to be 
protective in colon cancer; individuals with at least one T allele had 40% less risk of 
colon cancer compared to C homozygotes ( OR 0.60, 95% Cl 0.37 to 0.96, P = 0.033) 
(Bermano et a l 2007). The effect of polymorphisms within GPx4 may have a stronger 
phenotype in the colon due to the high exposure of colon tissue to dietary fats, and 
could at least in part explain a tissue specific association of this polymorphism with 
cancer. However, that study was small consisting of only 252 cases of colon cancer and 
187 controls. In order to validate these findings the study would require replication in 
a larger population complete with dietary markers of fat intake.
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Changes in the hierarchy of selenoprotein synthesis have been cited as a possible 
mechanism by which GPx4 718 genotype may affect cancer risk (Bermano et al. 2007). 
The GPx4 718 C allele, resulting in increased synthesis of GPx4, could reduce the 
availability of selenium for the synthesis of other selenoproteins such as GPxl, which is 
more sensitive to selenium depletion than GPx4 (Weiss Sachdev and Sunde 2001). 
Interestingly, both plasma selenium status and erythrocyte GPxl activity was reduced in 
CC individuals in a subset of colon cancer patients, further supporting this theory 
(Bermano et al. 2007). Tissue specific regulation of the selenoprotein synthesis 
hierarchy may help provide an explanation to contradictory findings observed between 
colon and prostate cancer. Further investigation into the tissue specific regulation of 
selenoproteins will be needed to support this hypothesis.
SEP 15 811 C/T genotype had no effect on risk of prostate cancer per se (Table 3.3). A 
recent study investigating the association of this polymorphism with lung cancer also 
reported no overall association (Jablonska et al. 2008). Interestingly however, selenium 
status appeared to modify the effect of genotype upon risk of lung cancer (Jablonska et 
al. 2008). Whilst genotype did not affect the risk of lung cancer in low plasma 
selenium individuals, in high selenium individuals (>80 pg/1), lung cancer risk 
increased with possession of the C allele. Conversely, risk did not increase on raising 
plasma selenium concentration in SEP 15 811 T homozygotes. Of particular relevance, 
no effect of genotype was observed on lung cancer risk in study participants with 
plasma selenium concentrations similar to that reported in this study (76.0 ± 17.2 pg/L). 
These findings could help explain the results observed in prostate cancer. These results 
(as with GPxl) suggest that the association of the SEP 15 811 C/T SNP with prostate 
cancer risk may be diminished in a low selenium population; a population with high
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selenium status may be required to observe an association of SEP 15 811 C/T with 
prostate cancer risk.
Selenoprotein genotype did have an effect on one marker of disease progression; PSA. 
In men with a plasma PSA of 100 ng/ml or higher, possession of a SEP 15 81 IT allele 
was associated with a 50% increased risk of having prostate cancer (Table 3.4). 
Though the significance of this finding is unclear, we considered whether a PSA >100 
might reflect progression of cancer beyond the prostate but found no further 
associations between genotype and individual or combined markers of disease severity.
Interestingly, however, an effect of genotype in a pathway associated with selenoprotein 
function was observed: although S0D2 is not a selenoprotein, the product of its activity, 
H2O2, is a substrate for GPx. The Val 16Ala SNP in SOD2 has been shown to alter the 
secondary structure of the mitochondrial import sequence of the superoxide dismutase 
protein such that the Ala 16 variant is imported more efficiently into the mitochondrial 
matrix, resulting in h i^ e r  enzyme activity (Sutton et a l 2003). Individuals with at 
least one S0D2 Alai 6 allele (Ala 16+) therefore generate more active superoxide 
dismutase (and therefore more H2O2) than those homozygous for the Val 16 variant. In 
this study, SOD2 Alai 6+ men were at a 19% increased risk of prostate cancer compared 
to Val 16 homozygotes (Table 3.6). The mitochondrion contains little or no catalase 
and so is entirely dependent on the activity of GPx to remove H2O2 (Chance et a l 
1979), though of course H2O2 is sufficiently long-lived to diffuse out of the 
mitochondrion.
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H2O2 promotes prostate cancer cell proliferation and migration (Lim et al. 2005; 
Polytarchou et al. 2005), and induces matrix metalloproteinases required for tumour 
invasion (Zhang et al. 2002; Kinnula and Crapo 2004). For instance, H2O2 levels rose 
in cell-lines of the LnCAP series as tumorigenic and metastatic potential increased (Lim 
et al. 2005). Furthermore, addition of ebselen, a GPx mimetic, to the assay completely 
abolished the chemiluminescence attributable to H2O2 (Lim et al. 2005). At low 
selenium concentration where there is insufficient GPx activity to remove H2O2, the 
S0D2 16Ala allele would therefore be expected to have a deleterious effect owing to 
the higher H2O2 production associated with that allelic variant. This population has a 
mean plasma selenium concentration well below the level required to fully optimise 
GPx (as plasma GPx) (Duffield et al. 1999) making these observation consistent with 
predictions.
Furthermore, the mean selenium concentration in this study was below the bottom of 
the range of plasma selenium (84-131 pg/L) in the study in which Li et al (2005) 
reported an association between S0D2  Alai 6Val genotype and prostate cancer risk 
when subjects were divided according to quartile of selenium status. In that study, high 
selenium status was advantageous for S0D2  Alai 6 homozygotes as the combination of 
high S0D2  activity in the mitochondrion, together with high selenium/GPx, enabled 
efficient removal of both reactive oxygen species, superoxide and H^O?. By contrast, 
Alai 6 homozygotes were at increased risk, particularly of aggressive prostate cancer, 
when their selenium status was in the bottom quartile (Li et al. 2005). While we saw an 
overall effect of S0D2 A lal6Val genotype in this low-selenium population, Li et al 
observed no overall effect, perhaps because the range of selenium status in their 
population encompassed both positive and negative effects of genotype on prostate
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cancer risk leading to a null effect overall. The findings presented here might help 
explain why the S0D2  Val 16Ala risk allele appears to vary from study to study in a 
number of cancers and illustrates a gene-nutrient interaction where the effect of 
genotype on risk reverses with change in nutrient status of the population.
Results from the ATBC study may further illustrate this point. Finnish smokers who 
were SOD2 Alai 6 homozygotes had a 70% increased risk of prostate cancer when 
compared to Val homozygotes (Woodson et a l 2003). This is consistent with the 
findings of Li et al in their lowest selenium quartile where the S0D2  Alai 6 
homozygotes had an increased risk of prostate cancer (Li et a l 2005) and suggests that 
men from the ATBC cohort must have had a similar selenium status to the bottom 
quartile of US men. Although at first sight this might seem surprising since the cohort 
was recruited after the introduction of selenium-enriched fertilizers in Finland, in fact 
there are data to show that the ATBC study did indeed include men with very low 
selenium status (Hartman et a l 2002). When the use of selenised fertilisers was 
implemented in 1984, mean plasma selenium in Finland was 70 pg/L. However, 
selenium status did not peak until 1990, reaching a maximum of 120 pg/L (cf mean US 
value 125 pg/L (Niskar et a l 2003)), before declining to 90 pg/L in 1999 (Eurola and 
Hietaniemi 2000). Thus the mean selenium status of this Finnish cohort, recruited from 
1985-88 and followed up until death or 1993, would have been considerably lower than 
that of the US men and would certainly have been lower during the time this slow- 
growing cancer was developing, prior to the initiation of the selenised fertilizer 
program.
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Previous studies have identified an interaction between GPxl and S0D2 in both breast 
cancer and bladder cancer (Ichimura et a l 2004; Cox et a l 2006). However, in the 
current study no interaction was observed between GPxl Prol98Leu and S0D2 
Val 16Ala though such an interaction might have been expected. Under conditions of 
limited selenium availability, however, as observed in this population, GPxl expression 
may be significantly reduced, so the effect of any polymorphism in GPxl is unlikely to 
further increase oxidative stress to any significant extent.
Because of evidence suggesting the SEPPl Ala234Thr polymorphism altered the 
concentration and activity of other selenoproteins (Meplan et a l 2007), the interaction 
between SEPPl Ala234Thr and the other SNPs was investigated. Whilst no interaction 
between SEPPl Ala234Thr and other selenoproteins was observed, this study does 
provide evidence for a gene-gene interaction between the SEPPl Ala234Thr 
polymorphism and the SOD2 Val 16Ala polymorphism. Individuals homozygous for 
SEPPl Ala234 and S0D2 A lai6+ were 43% more likely to have prostate cancer 
compared to Val 16 homozygotes (Table 3.7); this interaction was stronger in 
aggressive disease resulting in a 60% increased risk. Interestingly, prospective cohort 
studies have shown a stronger association between selenium status and risk of 
aggressive than localized disease (Yoshizawa et a l 1998; Helzlsouer et a l 2000; 
Nomura et a l 2000; van den Brandt et a l 2003; Li et a l 2004).
Of relevance to these findings, Méplan et al (2007) recently found that male SEPPl 
Ala234 homozygotes had lower plasma selenoprotein P than heterozygotes, with an 
associated trend for reduced activity or protein concentration of GPxl (cytosolic GPx) 
and GPx4 (phospholipid GPx). The authors suggest that the Ala234Thr polymorphism
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affects the stability of selenoprotein P, possibly through a post-translational 
modification, affecting protein levels only when selenium intake is suboptimal. Thus 
genotype-dependent differences in plasma selenoprotein P concentration were only 
observed under relatively low selenium conditions and disappeared after 
supplementation with selenium (Meplan et al. 2007). The observations presented here, 
in a population of relatively-low selenium status are consistent with those findings.
Because there is strong evidence that selenoprotein P plays a critical role in delivery of 
hepatic selenium to other tissues (Hill et al. 2003; Schomburg et al. 2003; Renko et al. 
2008), it is hypothesised that men homozygous for the SEPPl Ala234 allele have 
reduced availability of selenium for the production of GPx in the prostate. This would 
impede the ability of the prostate to remove H2O2 and protect against prostate cancer 
(Lim et al. 2005; Polytarchou et al. 2005) (Figure 3.3). In this study, the SEPPl 234 
polymorphism only affected prostate cancer risk in conjunction with the SOD2 Alai 6 
allele, which, by allowing more efficient transport of superoxide dismutase into the 
mitochondrion, caused increased production of H2O2 that became detrimental in the face 
of low selenium.
The gene-gene interaction between the SEPPl Ala234Thr and S0D2  V all6Ala 
polymorphisms was also apparent in current or ex-smokers who had a two-fold 
increased risk of prostate cancer compared with S0D2  Val 16 homozygotes (Table 3.8). 
It is postulated that the mechanism by which these polymorphisms have their combined 
effect is oxidative-stress related, the greater strength of the interaction in smokers than 
in the study as a whole, despite smaller numbers, might be explained by an exacerbation 
of oxidative stress in ever-smokers though it may equally well be related to the lower
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selenium status seen in smokers (Bates et al. 2002; Northrop-Clewes and Thumham 
2007). In this study, no difference in plasma selenium status was observed between 
ever-smokers and never-smokers in the 169 control samples measured; this however, 
may result from the relatively small number of samples analysed.
0 ,"  + S 0 D 2 t
SOD2 16Ala 
homo/heterozygotes
O , + HgOgt
X  G P x i
cell proliferation ^ ^  prostate ^ 
and migration cancer risk
selenoprotein P i
HgO
detoxification
SEPP1 234Ala/Ala
Figure 3.3: Postulated mitochondrial mechanism for the interaction between 
SEPPl and SÔD2 polymorphisms and the risk of prostate cancer. Possession of a 
S0D2 Alai 6 allele promotes higher import of mitochondrial superoxide dismutase to 
the mitochondrion resulting in higher activity and greater production of H2O2 than with 
the S0D2  Val 16 variant. The availability of selenium for the production of GPx in the 
prostate, already low in the Swedish population, is further reduced in men homozygous 
for the SEPPl Ala 234 allele, reducing die ability o f the prostate to protect against 
excess hydrogen peroxide (promoter of cell proliferation and migrationfLim et al. 2005; 
Polytarchou et al. 2005)) and cancer.
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This study has limitations in that HapMap (www.hapmap.org) shows considerable 
linkage disequilibrium (LD) at both the SEPPl and S0D2  loci so it is remains unclear 
whether these polymorphisms are the only functional SNPs affecting risk of prostate 
cancer in the SOD2 and SEPPl genes. However, given the published studies implying 
functional consequences of the amino-acid changes, it would seem plausible that they 
have some function in this context. Both of these SNPs were included in the recent 
genome-wide screen of a subset of this case-control study (498 aggressive cases and 
494 controls) and results are consistent with the present data on a larger sample 
(Duggan et a l 2007). Other recent genome-wide SNP screens in prostate cancer have 
not implicated either of these genes (Eeles et a l 2008; Gudmundsson et a l 2008; 
Thomas et a l 2008), but the UK study did find an associated SNP (rs9364554) in the 
SLC22A3 genQ (Eeles et a l 2008) on chromosome 6, jiist over 700kb telomeric of 
SOD2. Analysis of HapMap CEPH data reveals no LD between this SNP and S0D2 
V all6Ala, suggesting that the S0D2 SNP is independently associated with prostate 
cancer risk and is not acting as a marker for SLC22A3 association.
If confirmed, the evidence presented here would allow identification of individuals who 
would particularly benefit fi*om selenium supplementation to prevent prostate cancer. 
Among the Swedish men in this study, 41% had the high risk genotype combination 
(homozygosity for SEPPl Ala 234 and possession of an S0D2  Alai 6 allele). Similar 
allele fi*equencies have been identified in other populations of European descent (NCBI 
SNP database www.ncbi.nlm.nih.gov/SNP/ and for example (Li et a l 2005; Meplan et
al 2007)). Within this study we have observed the combined effect of the S0D2
.
V ail6Ala and SEPPl Ala234Thr SNPs under conditions of limited selenium 
availability. Such an effect can probably not be observed in areas of higher selenium
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status such as North America where plentiful selenium supply can probably obviate the 
disadvantage of homozygosity for SEPPl 234 Ala except for those with the lowest 
intakes (Li et a l 2005). Optimising the selenium intake of individuals homozygous for 
SEPPl Ala234 will improve their ability to supply selenium via selenoprotein P for 
GPx synthesis and H2O2 removal (Meplan et a l 2007). Confirmation of these findings 
in other populations with low selenium intake should be a high priority,
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The identification of bypermethylated genes using 5-aza-2 -deoiycytidine and
selenium
4.1 Introduction
The aberrant hypermethylation of gene promoters is a commonly occurring event in 
cancer. Hypermethylation of promoters results in the silencing of genes, many of which 
have tumour suppressor functions (Bastian et al. 2004). The treatment of cancer cell 
lines with the demethylating agent, 5-aza-2'-deoxycytidine, has been commonly used to 
identify candidate hypermethylated genes in cancer. 5-aza-2 -deoxycytidine reduces 
DNA méthylation and increases expression of hypermethylated genes which can be 
identified using microarrays and QPCR. The selenium content of cell culture media is 
generally considered to be insufficient for the full expression of selenium responsive 
genes, in particular for many selenoprotein genes (Baker et al. 1998; Rebsch et al. 
2006). Therefore genes which are both hypermethylated and selenium responsive may 
not increase expression after treatment solely with 5-aza-2 -deoxycytidine sufficiently 
to enable detection.
Many selenoproteins have been shown to be down-regulated in cancer, including 
SEP 15, GPxl and SEPPl in prostate cancer (Behne et al. 1997; Gladyshev et al. 1998; 
Calvo et al. 2002; Zachara et al. 2005). Whilst loss of heterozygosity may, at least in 
part, account for the down-regulation of some of these selenoproteins, the 
hypermethylation o f selenoprotein promoters may also play a significant role in the 
silencing of these genes. To date, the down-regulation of only one selenoprotein in 
cancer has been attributed to promoter méthylation. The aberrant hypermethylation of 
the GPx3 promoter has been shown to silence this selenoprotein in prostate cancer
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(Lodygin et a l 2005; Yu et a l 2007). It is therefore hypothesised that the down- 
regulation of further selenoproteins may result from epigenetic silencing of gene 
promoters.
4.2 Results
4.2 1 The induction of GPx3 by selenium and 5-aza-2 -deoxycytidine -  a positive 
control
To confirm the re-expression of epigenetically silenced genes by 5-aza-2'- 
deoxycytidine, QPCR expression analysis after cell treatment with 5-aza-2- 
deoxycytidine, and 5-aza-2 '-deoxycytidine and selenium combined, was carried out on 
GPx3, previously shown to be hypermethylated in prostate cancer (Lodygin et a l 2005; 
Yu et al 2007). GPx3 expression was calculated relative to a control gene (18s RNA in 
DU145, PC3 and RWPEl and C19orf53 in LnCAP) that did not respond to any of the 
treatments used. The méthylation status of the GPx3 gene promoter was analysed using 
pyrosequencing to confirm hypermethylation of the promoter in the current study.
The GPx3 promoter was hypermethylated in the prostate cancer cell lines PC3 and 
LnCAP, with a mean CpG méthylation of 89% and 84% respectively. The promoter in 
RWPEl cells was partially methylated (27%) and in DU 145 was effectively 
unmethylated (5%) (Figure 4.1).
GPx3 mRNA was below the limit of detection by QPCR in the two cell lines showing 
the greatest level of GPx3 promoter méthylation, PC3 and LnCAP, when grown in 
medium not supplemented with either selenium of 5-aza-2'-deoxycytidine. Upon
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supplementation with 5-aza-2'-deoxycytidine, GPx3 gene expression was significantly 
up-regulated (P<0.001) with an even greater increase in gene expression observed with 
supplementation of both 5-aza-2'-deoxycytidine and selenium (P<0.001) (Figure 4.2). 
This suggests that the GPx3 promoter is silenced by méthylation and that the gene 
requires selenium supplementation for full expression. In the RWPEl cell line in which 
the GPx3 promoter is partially methylated, expression was much higher than in PC3 and 
LnCAP at baseline, and a significant increase in gene expression was observed on 
supplementation with 5-aza-2'-deoxycytidine. Supplementation with selenium had little 
effect, suggesting that selenium at baseline was already optimal for GPx3 expression in 
the RWPEl cell line. In the DU 145 cell line, in which the GPx3 promoter is effectively 
unmethylated (5%), expression was even higher than in RWPEl at baseline and was not 
significantly up-regulated by either selenium or 5-aza-2'-deoxycytidine treatments 
individually, again consistent with the méthylation pattern and suggestive that 
endogenous selenium was sufficient for full expression of GPx3 in DU 145 cells. 
However, the combined treatment of both selenium and 5 -aza-2 ' -deoxycytidine 
significantly increased GPx3 expression in comparison to the untreated cells, although 
the double-treatment was not different fi*om either of the single treatments, suggesting 
that it may not be biologically significant.
These results clearly suggest that treatment of these prostate cell lines with 5-aza-2 - 
deoxycytidine results in the re-expression of a gene silenced by méthylation, and that 
further supplementation with selenium can increase the gene expression in certain cell 
lines where selenium is sub-optimal at baseline. These findings suggested that the 
treatment with 5-aza-2 -deoxycytidine had indeed caused déméthylation and up- 
regulation of expression and gave us the confidence to move to whole genome
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expression mieroarrays to enable the identification of novel genes that are both 
hypermethylated and require selenium supplementation for full expression.
Méthylation profile of the GPx3 promoter
100-,
80-
DU145
PC3
LnCAP
RWPE-1
o 60-
20 -
N ' V ' b
CpG position
Figure 4.1 The méthylation of CpGs within the GPx3 promoter. GPxS promoter 
méthylation analysis in the prostate cancer cell line DU 145, PC3 and LnCAP and the 
immortalised normal prostate cell line RWPEl using pyrosequencing.
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4.2.2 The similarity between microarray and QPCR gene expression data
In order to validate the microarray data, the expression profiles of several genes, 
including the selenoproteins GPxl, GPx3, GPx4, SEP 15, SEPWl and SEPPl, were also 
analysed using QPCR. All of the genes analysed by QPCR had similar expression 
profiles to those obtained firom the microarray (Figure 4.3a, b and c) and these 
expression profiles were highly correlated, all samples having a Pearson correlation 
coefficient of at least 0.88 (Table 4.1). The absolute amounts of expression appear very 
different in some cases but this is simply because gene expression is given relative to a 
reference RNA for the microarrays and housekeeping gene RNAs for the QPCR. The 
high correlation between the QPCR and microarray expression profiles for these six 
genes in different cell lines gives us confidence to use the microarray data for the 
analysis of other genes.
Table 4.1. The correlation of gene expression data between microarray and 
quantitative PCR
Gene Cell line Correlation between microarray 
data and QPCR (Pearson r)
GPx3 DU145 0.92
GPx3 LnCAP 0.89
GPxS PC3 0.96
GPxS RWPEl 0.99
GPxl PC3 0.90
GPx4 PC3 0.88
SEP15 LnCAP 0.88
SEPWl DU145 0.96
SEPPl PC3 0.92
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Microarray
GPx3 (DU145)
1.5-M in i
QPCR
GPx3 (DU145)
I
I;
0l i i n i
GPx3 (LnCAP) GPx3 (LnCAP)
_  0.5
L u
GPx3 (PC3) GPx3 (PC3)
_  0.5-,
Î -S
s 0.3-
I °-2-
II
«  0.0 ■ini t
GPx3 (RW PEl) GPx3 (RWPEl)
_  2.0
& 1.0
Figure 4.3a The validation of microarray gene expression profiles by QPCR. Microarray data is 
normalised against the Universal reference RNA; QPCR is normalised against a house-keeping gene (18s 
RNA in DU 145, PC3 and RWPEl and C19orf53 in LnCAP). This accounts for the apparent difference in 
gene expression determined by QPCR and microarray. Medium = Blue ,10 pM 5-aza-2'-deoxycytidine 
(red), 100 nM sodium selenite (yellow), the combined treatment of 10 pM 5-aza-2'-deoxycytidine and 
100 nM sodium selenite (green).
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Microarray
SEPP1 (PC3)
Ô U.1Ü-
i - a l n l0.00- - ^ — ----------
QPCR
SEPP1 (PC3)
a  1.0-
# 1
g 2-
Ë 1-
SEPW1 (DU145)
Î
SEPW l (DU 145)
i t  1.0-
i l l  i - m m D A
SEP15 (LnCAP) SEP15 (LnCAP)
-  3
GPx4 (PC3) GPx4 (PC3)
I M I n l
Figure 4.3b. The validation of gene microarray gene expression profiles by QPCR. Microarray data 
is normalised against the Universal reference RNA; QPCR is normalised against a house-keeping gene 
(18s RNA in DU 145 and PC3, and C19orf53 in LnCAP). This accounts for the apparent difference in 
gene expression determined by QPCR and microarray. Medium = Blue ,10 pM 5-aza-2'-deoxycytidine 
(red), 100 nM sodium selenite (yellow), the combined treatment of 10 pM 5-aza-2'-deoxycytidine and 
100 nM sodium selenite (green).
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Mieroarray
Expression of GPX1 in PCS (mico-array)
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QPCR
Expression of GPX1 in PCS (QPCR)
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Figure 4.3c. The validation of gene m icroarray  gene expression profiles by QPCR. Mieroarray data 
is normalised against the Universal reference RNA; QPCR is normalised against a house-keeping gene 
(18s RNA). This accounts for the apparent difference in gene expression determined by QPCR and 
mieroarray. Medium = Blue ,10 pM 5-aza-2'-deoxycytidine (red), 100 nM sodium selenite (yellow), the 
combined treatment of 10 pM 5-aza-2'-deoxycytidine and 100 nM sodium selenite (green)
4.2.3 Clustering analysis of gene expression profiles.
The similarities and differences in gene expression profiles between tissues, cell lines 
and treatments were analysed using a Pearson correlation clustering algorithm. 
Clustering analysis produces a ‘condition tree’; those samples that are most similar 
cluster together on the same branch of the tree whilst samples that show a weaker 
correlation between gene expression profiles are found on different branches of the tree 
(Figure 4.4). Correlation analysis revealed that the prostate cancer tissue derived from 
advanced carcinoma of the prostate (Gleason >8) clustered in line with the normal 
prostate tissue as opposed to the cancer cell lines. All four of the cell lines were 
clustered together. Interestingly, the ‘normal’ immortalised prostate epithelial cell line, 
RWPEl, clustered more closely with the prostate cancer cell lines than with the normal
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prostate tissue. Furthermore, the expression profile of the RWPEl was also more 
closely associated with the profiles of DU 145 and PC3 rather than LnCAP, which was 
located on a separate branch of the condition tree, in relation to the other cell lines. 
Within each of the cell lines, treatment with both 5-aza-2'-deoxycytidine and selenium, 
and 5-aza-2' -deoxycytidine alone, clustered together, as did selenium and those cells 
grown in unsupplemented medium.
■il
I
Figure 4.4 Gene expression condition tree. The clustering of gene expression profiles 
by Pearson correlation analysis. Condition A = 10 pM 5-aza-2 '-deoxycytidine. 
Condition B = 10 pM 5-aza-2'-deoxycytidine and 100 nM sodium selenite (ie both 
treatments). Condition S = 100 nM sodium selenite. Condition M = unsupplemented 
medium (baseline). Normal prostate tissue = two samples from histologically normal 
prostates; Cancerous prostate tissue = tissue from three histologically advanced 
carcinoma of the prostate (Gleason > 8).
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4.2.4 The identification of candidate hypermethylated genes in prostate cancer
In previous studies identifying novel hypermethylated genes using mieroarray analysis, 
the threshold of up-regulation of genes by 5-aza-2 '-deoxycytidine has been determined 
by taking the 1.8-fold up-regulation of the gene GSTPl that is known to be 
hypermethylated (Lodygin et a l 2005). However, in the present study, the GSTPl 
probes failed, so there was insufficient data for downstream analysis. As a result, this 
approach could not be employed in determining the threshold for up-regulation of 
methylated genes in the current study. Therefore, a threshold of two-fold induction, 
which is commonly used in mieroarray analysis as a threshold for the identification of 
up-regulation genes, was utilised.
In total, 2291 genes showed greater than two fold up-regulation in PC3, 1454 in 
LnCAP, 2877 in DU 145 and 2833 in RWPEl cell lines after treatment with 10 pM 5- 
aza-2 -deoxycytidine. To identify genes commonly methylated in prostate cancer, 
genes were identified if they were two-fold up-regulated in all three prostate cancer cell 
lines; 307 genes fulfilled this criterion (Figure 4.5). In addition, genes were eliminated 
from this list if they were also induced by 5 -aza-2 ' -deoxycytidine in the immortalised 
normal prostate epithelial cell line RWPEl. This identified 62 potentially 
hypermethylated genes specific to prostate cancer (Table 4.2).
Of the 62 potentially hypermethylated genes, 14 were observed to be down-regulated in 
normal prostate compared to advanced prostate cancer tissue (data not shown), 
suggesting true biological relevance in prostate cancer. Whilst at first glance this list 
seems to contain genes that have no obvious role in cancer, the true function of many of
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these genes remains unknown but their potential roles will be considered in the 
discussion section.
PC 3 A>M
(n = 2291)
L nCA P A>M
(n = 1454)
993 153 748
307
838 246
1486
DU 145 A>M
(n = 2877)
A>M c o m m o n  
b e tw e e n  all cancer 
cell l in e s  (n = 307)
R W PE l A>M
(n = 2833)
245 2588
Figure 4.5. The identification of genes responsive to 5-aza-2 -deoxycytidine. Venn 
diagrams show: i. Genes responsive to 10 pM 5-aza-2'-deoxycytidine, in the cancer cell 
lines only. ii. Genes responsive to 10 pM 5-aza-2 '-deoxycytidine in the cancer cell 
lines cell only AND NOT in RWPEl. A = 10 pM 5-aza-2'-deoxycytidine, M = 
unsupplemented medium.
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Table 4.2 Candidate hypermethylated genes. Genes responsive to 10 pM 5-aza-2'- 
deoxycytidine in the cancer cell lines only but not in RW PEl.
Gene symbol Gene ID gene name
. Down-regulated 
in prostate 
cancer
ACTL8 NM 030812 actln-like 8 No
AK021866 AK021866 AK021866 No
ARTS-1 NM_001040458 type 1 tumor necrosis factor receptor shedding amlnopeptidase 
regulator
No
AW972815 AW972815 AW972815 No
BAMBI NM 012342 BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) No
BATF2 NM 138456 basic  leucine zipper transcrip tion  factor, ATF-llke 2 Yes
C14orf174 NM 001010860 chromosome 14 open reading frame 174 No
C1orf190 NM 001013615 chromosome 1 open reading frame 190 No
C0L16A1 NM 001856 collagen, type XVI, alpha 1 No
CRISP2 NM 003296 cysteine-rich secretory protein 2 No
CSRP2 NM 001321 cysteine and glycine-rich protein 2 No
CYP27B1 NM 000785 cytochrome P450, family 27, subfamily B, polypeptide 1 No
DBH NM 000787 dopamine beta-hydroxylase (dopamine beta-monooxygenase) No
DLX2 NM 004405 distal-less homeobox 2 No
D0K7 NM 173660 docking protein 7 Yes
EPS8L1 NM 133180 EPS8-like 1 No
FAM74A4
FGF18
AK127145 family with sequence similarity 74, member A4 No
NM 003862 fibroblast growth factor 18 No
FKBP1B NM 054033 FK506 binding protein IB, 12.6 kOa No
FU30851 NM 001040710 hypothetical LOC653140 No
FMOD NM 002023 fibromodulin No
FZD5 NM 003468 frizzled homolog 5 (Drosophila) No
GJB2 NM 004004 gap junction protein, beta 2, 26kDa (connexin 26) No
GLB1L NM 024506 galactosidase, beta 1-like No
HCLS1 NM 005335 hematopoietic cell-specific Lyn substrate 1 No
HIST1H3G BC012185 histone cluster 1, H3g No
HIST2H2AA4 NM 001040874 histone cluster 2, H2aa4 No
ICA1L NM 138468 islet cell autoantigen 1,69kDa-like No
ID4 NM_001546 inhibitor of DNA binding 4, dom inant negative helix-loop-helix 
protein
Yes
IFI30 NM 006332 interferon, gamma-indudble protein 30 No
KRTAP1-5 NM 031957 keratin associated protein 1-5 No
LM 02 NM 005574 LIM dom ain only 2 (rhombotin-like 1) _ Yes
LY96 NM 015364 lymphocyte antigen 96 No
LYPD5 NM 182573 LY6/PI_AUR dom ain containing 5 Yes
MAP7 NM 003980 microtubule-associated protein 7 No
MARVELD3 NM 052858 MARVEL domain containing 3 No
NEFM NM 005382 neurofilament, medium polypeptide 150kDa No
PROG NM 000312 protein C (inactivator of coagulation factors Va and Villa) No
RAI2 NM 021785 retinoic acid induced 2 No
RBMY1E NM 001006118 RNA binding motif protein, Y-linked, family 1, member E No
S100A14 NM 020672 S I 00 calcium  binding protein A14 Yes
SAMD9 NM 017654 sterile  alpha motif dom ain containing 9 Yes
SCN4B NM 174934 sodium  channel, voltage-gated, type IV, beta Yes
SLC16A6 NM 004694 solute carrier family 16, member 6 (monocarboxylic acid transporter 7) No
TDGF1 NM 003212 teratocarcinoma-derived growth factor 1 No
THBD NM 000361 throm bom odulin Yes
THC2650074 THC2650074 THC2650074 Yes
THC273ÛÔ31 THC2730631 THC273Û631 Yes
TMEM140 NM 018295 transmembrane protein 140 No
TMEM155 NM 152399 transmembrane protein 155 No
TMEM16B NM_020373 transmembrane protein 16B No
TRIM63 NM 032588 tripartite motif-containing 63 No
TSPAN8 NM 004616 tetraspanin 8 No
TTC21A NM_145755 . tetratricopeptide repeat domain 21A “ No
U2AF1 AK023589 U2 small nuclear RNA auxiliary Aretor 1 No
UTS2 NM 021995 urotensin 2 No
VIT NM 053276 vitrin Yes
VTCN1 NM 024626 V-set dom ain containing T cell activation Inhibitor 1 Yes
WNT3A NM 033131 w ingless-type MMTV integration s ite  family, m em ber 3A Yes
ZNF350 NM 021632 zinc finger protein 350 No
ZNF577 NM 032679 zinc finger protein 577 No
ZNF649 NM 023074 zinc finger protein 649 No
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4.2.3 The identification of genes both hypermethylated and selenium responsive in 
cancer
Genes which are both selenium responsive and hypermethylated were identified in the 
prostate cancer cell lines. For each cell line, such genes were selected on the basis of 
being up-regulated at least two-fold by the combined treatment with 5-aza-2 '- 
deoxycytidine and selenium, compared to both untreated control cells and cells treated 
with selenium alone. Genes which were up-regulated by treatment with 5-aza-2'- 
deoxycytidine alone were also excluded from subsequent analysis (Figure 4.6a and 
4.6b). Genes up-regulated at least two-fold by 5-aza-2'-deoxycytidine plus selenium, 
compared to selenium alone in the RWPEl cells were removed from this list in an 
attempt to ensure that the effect was specific to prostate cancer (Figure 4.6a and 4.6b). 
A large number of genes, 163 in DU145, 120 in PC3 and 69 in LnCAP, were found to 
be responsive to selenium plus 5-aza-2 -deoxycytidine. The gene expression profiles 
clearly demonstrate the up-regulation as a result of déméthylation and selenium 
supplementation (Figure 4.7). Only three genes were found to be regulated in common 
between two or more of the prostate cancer cell lines after treatment with both 5-aza-2 '- 
deoxycytidine and selenium (data not shown). These were LRRC15 (Leucine rich 
repeat containing 15), DNAH5 (dynein, axonemal heavey chain 5) and FAM83A (family 
with sequence similarity 83, member A). Because so few genes were found to be 
commonly up-regulated by the double-treatment between the cell lines, subsequent 
analysis was undertaken using each individual cell line.
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Figure 4.7 The expression profiles of genes up-regulated at least two-fold by 
selenium plus 5-aza-2'-deoxycytidine. Cell lines: D = DU145, L = LnCAP, P = PC3. 
Conditions; A = 10 pM 5-aza-2'-deoxycytidine, B = 10 pM 5-aza-2'-deoxycytidine 
plus 100 nM sodium selenite, S = 100 nM sodium selenite, M = unsupplemented 
medium (baseline).
University of Surrey________________________________________________ Chapter 4
4.2.4 The identification of pathways modulated by selenium after déméthylation in 
prostate cancer cell lines
Of relevance to prostate cancer, MetaCore pathway analysis revealed that genes 
involved in the activation of pro-apoptotic pathways were significantly over-represented 
(P=0.009) among those genes up-regulated by déméthylation plus selenium 
supplementation in PC3. In the DU 145 cell line, the main network identified was that 
of the ‘DNA dependant regulation of transcription’ (p = 3.4 x 10’^ ^; 54 of the 104 genes 
mapped onto pathways involved in this network. A further four pathways involved in 
transcription and transcriptional regulation were found within the top ten most 
significant pathways. In the LnCAP cell line, ‘actin filament capping’ was also shown 
to be significantly over-represented within the genes up-regulated by déméthylation and 
selenium supplementation. A more complex analysis of annotated networks further 
identified ‘cytoskeleton rearrangement’ (P=0.0006) as major a pathway influenced by 
genes that would be selenium responsive were they not hypermethylated in prostate 
cancer.
4.2.5 The méthylation of selenoproteins
Several selenoproteins and genes in the same metabolic pathways as selenoproteins 
have been show to possess genetic polymorphisms that alter the risk of cancer (Chapter 
3). To assess the impact of epigenetic silencing within these genes and to determine if 
the méthylation of these gene promoters may further interfere with transcription of these 
genes, the méthylation profiles of several candidate genes were determined using 
pyrosequencing (Figure 4.9a and 4.9b).
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The promoters of GPxl, GPx4, and S0D2, were not hypermethylated in any of the 
prostate cancer cell lines, in comparison to the RWPEl or normal prostate tissue. 
Interestingly, SEP 15 was partially methylated in LnCAP (29%) but did not show an 
increase in expression after the treatment of LnCAP with 5-aza-2'-deoxycytidine, or 5- 
aza-2'-deoxycytidine plus sodium selenite (Figure 4.8a). Furthermore, SEP15 was not 
methylated in DU 145, PC3, RWPEl or the normal prostate tissue samples (Figure 4.9a 
and 4.9b).
SEPPl was shown to be highly methylated in all the prostate cancer cell lines DU 145 
(90%), LnCAP (71%) and PC3 (79%) and 5 prostate cancer biopsy samples (77% to 
90%) (Figure 4.9b). However, a similar degree o f  SEPPl promoter méthylation was 
also observed in the RWPEl (69%) and the normal prostate tissues (74% and 85%); no 
significant difference was observed in the expression of SEPPl between normal and 
cancerous prostate tissue. Interesting, SEPPl was shown to be expressed to a lower 
extent in the DU 145 and PC3 than both the LnCAP, cancerous prostate tissue and 
normal prostate tissue samples (Figure 4.8a).
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4.2.6 The identification of selenium responsive pathways
Analysis of selenium responsive genes was carried out using Metacore network 
interaction and pathway analysis. Genes that showed at least a two-fold increase or 
decrease in gene expression after the supplementation of cell culture medium with 100 
nM sodium selenite, were selected for network and interaction analysis using MetaCore 
gene ontology software. In total 649 genes for DU145, 734 genes for LnCAP and 922 
genes for PC3 were included in the analysis. Pathway analysis of selenium responsive 
genes in DU 145 revealed that selenium supplementation alters the expression of 21 out 
of 360 genes within the ‘cell adhesion’ pathway (P=0.00008). Network analysis 
revealed that ‘proteolysis of connective tissue degradation’ was also altered upon 
selenium supplementation (P=0.0004). Of particular relevance to prostate cancer, 
pathway analysis of selenium responsive genes in LnCAP revealed that selenite 
treatment alters the regulation of 33 out of the 438 genes mapped to the cell migration 
pathway and 19 of the 185 genes in the ‘chemotaxis’ pathway. ‘Chemotaxis’ was the 
most significantly affected network (P=4.09 x 10" )^, closely followed by networks 
involving blood vessel morphogenesis (P=2.97 x 10"^ and cell adhesion (P=0.0002). 
This suggests selenium may exert its cancer protective effects by altering pathways 
effecting metastasis and angiogenesis in prostate cancer.
In the PC3 cell line, ‘cell-cell signalling’ (P=1.39 x 10 and ‘cell motility’ pathways 
(P=7.94 X 10"^ were significantly modified upon selenite supplementation. Subsequent 
network analysis revealed the ‘blood vessel morphogenesis’ network to be significantly 
altered by selenium supplementation (P = 0.002), as for the LnCAP cell line.
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These results identify possible pathways and networks through which selenium may be 
protective in prostate cancer. However, whilst gene ontology programs, such as 
MetaCore, which can handle large data sets, are useful tools for the identification of 
candidate pathways responsive to a stimulus, certain limitations exist, for example it 
remains unclear exactly how these pathways are modified although our data suggest that 
hypermethylation in prostate cancer may be one mechanism. Any pathways and 
networks identified as containing multiple genes modified by selenium supplementation 
would require validation and demand further investigation. Unfortunately this is 
beyond the scope of this project but provides interesting opportunities for future work.
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4.3 Discussion
An increasingly large body of evidence is accumulating to suggest an important role of 
both selenium and selenoproteins in cancer. Many selenoproteins are down-regulated in 
cancer; however the mechanism for this down-regulation is poorly understood. 
Recently, the selenoprotein GPx3 was shown to by hypermethylated and silenced in 
prostate cancer (Lodygin et al. 2005; Yu et a l 2007). Thus it is not inconceivable that 
the aberrant promoter méthylation might result in the silencing of other selenoproteins 
and putative selenium responsive genes in prostate cancer. The aim of this experiment 
was to identify candidate hypermethylated genes, selenium regulated genes and 
hypermethylated genes that would otherwise be regulated by selenium in prostate 
cancer cell lines using a mieroarray approach.
Several studies have used mieroarray analysis to identify both methylated genes 
(Lodygin et a l 2005) and selenium responsive genes (Calvo et a l 2002; Schlicht et a l 
2004; Pagmantidis et a l 2008); however the present study is unique in that it is the only 
study to identify genes that would be selenium responsive were they not 
hypermethylated as a result of cancer.
In total, 62 genes were shown to be up-regulated by déméthylation in all three cancer 
cell lines, but not in the ‘normal’ immortalised prostate epithelial cell line RWPEl. Of 
these genes, 14 were shown to be down-regulated in prostate cancer compared to the 
normal tissue (Table 4.2), suggesting that these in particular may be biologically 
relevant in prostate cancer.
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One of these genes was the SlOO calcium binding protein A14 (S100A14). Whilst its 
function is currently unknown, this gene has been consistently identified as 
dysregulated in cancers of many different origins. S100A14 has been shown to be 
down-regulated in kidney, rectum and colon cancers (Pietas et al. 2002), oesophageal 
squamous cell carcinoma (Ji et al. 2004) and circulating tumour cells from multiple 
locations (Smirnov et al. 2005). Whilst the mechanism behind the down-regulation of 
S100A14 remains unclear, these results strongly suggest a role of epigenetic silencing 
by DNA méthylation. Further investigation will be required to elucidate both the 
functions of this protein, its role in cancer and the precise mechanism of the epigenetic 
silencing of this gene.
Another of these 14 genes is a member of the inhibitor of DNA binding protein family, 
ID4. This protein reportedly inhibits the binding of basic helix-loop-helix transcription 
factors (Umetani et al. 2005). The hypermethylation and associated down-regulation of 
ID4 has been observed in gastric adenocarcinoma (Chan et al. 2003) and malignant 
lymphoma (Hagiwara et al. 2007). Furthermore, ID4 hypermethylation has been 
associated with unfavourable prognosis of colorectal cancer (Umetani et al. 2004) and 
an increased risk of lymph-node metastasis and tumour recurrence in breast cancer 
(Umetani et al. 2005; Noetzel et al. 2008), suggesting that ID4 may be a candidate 
marker for early stage metastasis in breast cancer (Umetani et al. 2005). The down- 
regulation of ID4 has previously been reported in prostate cancer; however the 
mechanism for this silencing was not determined (Yuen et al. 2006). The present 
results strongly suggest that ID4 promoter méthylation may explain the down- 
regulation. However, in addition to these findings, nuclear expression of ID4 was show 
to be positively correlated with the likelihood of developing distant métastasés of
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prostate cancer suggesting ID4 expression increases cell metastatic potential (Yuen et 
al. 2006). This suggests that ID4 expression may serve as a marker for the metastasis of 
prostate cancer cells. Thus the function of ID4 in prostate cancer and the potential use of 
ID4 promoter méthylation as a diagnostic marker are still not clear and warrant further 
investigation.
Wnt3a (wingless-type MMTV integration site family, member 3 A) was identified as a 
candidate hypermethylated gene in prostate cancer. Wnt3a is a member of a larger 
family of Wnt secreted glycoproteins, given their name due to their homology with the 
drosophila wingless gene. Cellular proliferation and migration are amongst the process 
modulated by the Wnt family members and Wnt proteins have been implicated in the 
stimulation of bone proliferation (Emami and Corey 2007). Wnt3a has been shown not 
to be expressed in prostate cells of any kind including normal prostate epithelial cells 
(Zhu et al. 2004). However, in the current study Wnt3a was found to be down- 
regulated in the cancerous tissue compared to the normal prostate tissue, and expression 
was lower in the RWPEl than in the cancerous cell lines (data not shown). However 
the quantification of absolute RNA levels would be required to determine the true extent 
of this down-regulation. It has been previously shown that the treatment of LnCAP 
with recombinant Wnt3a significantly increases cell proliferation (Verras et al. 2004). 
This would suggest that the epigenetic silencing of Wnt3a in prostate cancer may 
actually have a protective function, however it is clear further work will be necessary to 
fully understand the role of Wnt3a méthylation in both normal and cancerous prostate 
tissue.
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Given that three of the 14 genes identified as demethylated/upregulated by 5-aza-2'- 
deoxycytidine in the prostate cancer cell lines and down-regulated in prostate cancer 
tissue are already known to be implicated in cancers, this suggests that the remaining 11 
genes are very good candidates for hypermethylation in cancer. However, remarkably 
little is known about these 11 remaining genes (Table 4.2) arid further work will be 
required to identify both their roles in prostate cancer and how they are affected by 
méthylation.
In total, 649 genes for DU145, 734 genes for LnCAP and 922 genes for 922 PC3 were 
found to be sodium selenite responsive, either increasing or decreasing expression more 
than two-fold. The identification of selenium responsive genes in prostate cancer has 
been published previously; Schlict et al (2004) identified a subset of 154 genes 
responsive to selenium in the forrri of seleno-DL-methione, using both the human PG3 
and rat PAH cell lines. IGFBP-3 (Insulin like growth factor binding protein 3) and 
RXRâ (retinoid X receptor alpha) were found to be commonly up-regulated between 
both the rat and the human cell lines, and were identified as potential genes through 
which selenium might exert its chemopreventative effect on prostate cancer (Schlicht et 
al. 2004). However, in the present study, both IGFBP-3 and RXRa failed to respond to 
selenite supplementation in any of the prostate cancer cell lines including, PC3. This 
could be explained by the supplementation of the cell lines with different selenium 
compounds. Cancer cells grown in culture, in the presence of selenomethionine, require 
the expression of fi-lyase to make selenium available. B-lyase converts 
selenomethionine to methylselenol whereas selenite is first converted to hydrogen 
selenide before being either metabolised to methylselenol or used for selenoprotein 
synthesis. In addition, Jiang et al (2002) identified two distinct pathways through which
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different selenium compounds, selenite and methylseleninic acid (MSA), induced 
apoptosis in the prostate cancer cell line DU 145. This suggests the involvement of 
different mechanisms by which selenium compounds inhibit cancer proliferation.
The comprehensive gene ontology program, MetaCore, was employed to identify 
metabolic pathways and gene networks influenced by selenium supplementation. 
Numerous pathways of relevance to cancer were significantly modulated by the 
supplementation of prostate cancer cell lines with sodium selenite. These included, cell 
adhesion, cell migration, chemotaxis, blood vessel morphogenesis and cell signalling. 
Numerous prospective or nested case control trials have shown a reduced risk of 
advanced prostate cancer in the highest compared to the lowest category of selenium 
status (Yoshizawa et al. 1998; van den Brandt et a l 2003; Li et a l 2004). The 
pathways identified here are well-known to be involved in cancer but their clear 
identification in the present genome-wide study provides new evidence to support their 
involvement in the mechanism through which selenium may prevent progression to 
advanced prostate cancer. These findings represent only the first steps in determining 
the mechanisms underlying the involvement of these selenium responsive pathways in 
prostate cancer, so require further research to fully understand their role in cancer 
chemoprevention by selenium.
For each cell line, genes responsive to selenium after déméthylation with 5-aza-2'- 
deoxycytidine, but not to either selenium or déméthylation alone, were identified. 
These genes represented a subset of genes that were hypermethylated in prostate cancer 
but which would otherwise have been selenium responsive. In other words they may be 
the targets for the chemopreyentative actions of selenium, either by preventing 
méthylation directly or by increasing the expression of the small amount of gene
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expression that may escape hypermethylation in cancer. Subsets of 163, 62 and 126 
genes were identified as potentially hypermethylated but otherwise selenium responsive 
in the DU 145, LnCAP and PC3 cell lines respectively. Of relevance to cancer, the 
network DNA dependent transcription appeared to be prominent among the genes 
modulated in DU 145. Cytoskeletal rearrangement and pro-apoptotic pathways were 
implicated in the LnCAP and PC3 cell lines, although they were somewhat less 
significant than that observed in the DU 145. Whilst further analysis is crucial in 
determining the role of both méthylation and selenium supplementation in modulating 
these pathways, these results suggest that selenium supplementation may be of benefit 
to cancer patients undergoing therapy with demethylating agents. However although 
both 5-aza-cytidine and 5-aza-2 '-deoxycytidine have been approved for the treatment of 
myelodysplasia, to date, no demethylating agents have been approved for the treatment 
of prostate cancer. Therefore, these results represent future opportunities for the use of 
selenium supplementation in conjunction with therapeutics targeting DNA méthylation.
The identification of candidate hypermethylated genes using the cytidine analogue 5- 
aza-2 -deoxycytidine has a major caveat. 5-aza-2 -deoxycytidine is highly toxic and 
may induce genes through stress response pathways that may not be methylated, or it 
may indirectly down-regulate repressors. However, those genes identified as both 
selenium responsive and hypermethylated have controlled for the toxic effect of 5-aza- 
2'-deoxycytidine by filtering out genes up-regulated by 5-aza-2'-deoxycytidine alone. 
Whilst we can be confident that the genes identified in this study are both selenium 
responsive and hypermethylated, the méthylation status of candidate gene promoters 
identified in this study will still need to be confirmed using an alternative technique.
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In addition to the genes both responsive to selenium and hypermethylated identified in 
this current work, the méthylation status of individual selenoproteins and genes in the 
same metabolic pathways a& selenoproteins, of interest to prostate cancer, were also 
investigated
SEP 15 has been previously shown to be down-regulated in prostate cancer (Behne et a l 
1997), however, in the current study SEP 15 was not shown to be down-regulated in 
prostate cancer tissue. Analysis of the méthylation profile showed that the SEP 15 
promoter was not methylated in the PC3, DU 145, RWPEl or normal prostate cancer 
tissue. SEP15 was however methylated in the LnCAP prostate cancer cell line (30%) 
with méthylation at specific CpGs reaching as high as 55%. However, SEP 15 
expression did not increase in LnCAP after treatment with either 5-aza-2'-deoxycytidine 
or 5-aza-2'-deoxycytidine and selenium. Furthermore, SEP 15 expression was similar in 
all four prostate cell lines suggesting that the méthylation of the SEP 15 promoter in 
LnCAP does not result in the down-regulation of this gene.
Selenoprotein P has previously been shown to be down-regulated in prostate cancer 
(Calvo et a l 2002). However, the results presented in this study contradict these 
findings: whilst Calvo et al demonstrated tlie down-regulation of SEPPl in prostate
cancer tumours no such observation was made in the current study. Calvo et al (2002)
«%
also reported the down-regulation of SEPPl in LnCAP and PC3, however, in the eurent 
study, the expression of SEPPl in LnCAP was similar to that of normal prostate tissue. 
Furthermore, the absolute expression o f SEPPl was not determined in either the Calvo 
et al (2002) study or in this work. It is entirely feasible to suggest that the observed
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differences in SEPPl expression between samples may be an artefact of the low 
expression of SEPPl in the prostate resulting from SEPPl promoter méthylation; this 
could account for the conflicting results presented by these two studies. However, the 
absolute expression of SEPPl in the prostate is required to confirm this hypothesis.
This study (Chapter 3) has provided evidence for a gene-gene interaction between the 
SEPPl Ala234Thr polymorphism and the S0D2 V all6Ala polymorphism in 
determining the risk of prostate cancer and advanced prostate cancer. It has been 
postulated that possession of the S0D2 Alai 6 allele promotes higher import of 
mitochondrial superoxide dismutase to the mitochondrion, resulting in higher activity 
and greater production of H2O2 than with the S0D2 V ail6 variant (Sutton et a l 2003). 
The availability of plasma selenium for the production of GPxl in the prostate is 
reduced in men homozygous for the SEPPl Ala 234 allele (Meplan et a l 2007), 
reducing the ability of the prostate to protect against excess H2O2. The méthylation of 
SEPPl in a tissue specific manner reinforces this theory. These results suggest that the 
interaction between the two polymorphisms may due to a reduction in plasma SEPPl, 
associated with the SEPPl 234 Ala allele (Meplan et a l 2007), rather than as a direct 
consequence of SEPPl expressed within the prostate cancer cells. Additionally, the 
GPxl and S0D2  promoters were unmethylated in both the cancerous and normal 
prostate tissue. This suggests that GPxl activity within the prostate can be increased by 
selenium supplementation and is not subject to gene silencing as a result of promoter 
méthylation. The potential increase in GPxl activity will enable the detoxification of 
excess H2O2 produced by the S0D2  ala allele, protecting the cell against oxidative 
stress.
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The epigenetic silencing of S0D2 has been described in breast cancer (Hitchler et al. 
2006). In contrast, SOD2 was not significantly down-regulated and was not 
hypermethylated in prostate cancer in this study. Expression of SOD2, the major 
detoxifying enzyme of the mitochondria, is required to catalyse the production of H2Ü2 
from superoxide, which is subsequently detoxified by GPxl. The silencing of S0D2  in 
breast cancer would result in the accumulation of superoxide, due to the reduced 
conversion of superoxide to H2O2 by S0D2. This would suggest that GPxl activity in 
prostate cancer is of greater importance than breast cancer and due to the ability of 
GPxl to reduce oxidative stress induced by the H2O2. Furthermore, this suggests that 
selenium supplementation would particularly benefit prostate cancer patients.
Using the whole genome expression analysis of prostate cancer cells treated with 
differing combinations of 5-aza-2 -deoxycytidine and selenium, numerous candidate 
hypermethylated genes have been identified. In addition, genes that are both 
hypermethylated and responsive to selenium supplementation have been discovered. 
MetaCore pathway analysis revealed numerous processes of interest to cancer that are 
modulated by selenium supplementation and that are also affected by the méthylation of 
selenium responsive genes. It is clear, however, that the high resolution mapping of 
promoter méthylation is required to further identify candidate genes hypermethylated in 
prostate cancer. A newly established technique, MeDIP (the immunoprécipitation of 
methylated DNA) (Weber et al. 2005) coupled with the identification of methylated 
DNA using a whole genome DNA microarray was utilised to achieve this goal; the 
results obtained from this technique are discussed in Chapter 5.
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The identification of methylated genes using the immunoprécipitation of
methylated DNA.
5.1 Introduction
The immunoprécipitation of Methylated DNA (MeDIP) allows the highly efficient, 
unbiased identification of methylated DNA from both cell culture and primary tissue 
samples (Weber et a l 2005). This technique enables the capture of methylated DNA 
using a highly specific monoclonal antibody to methylated CpG dinucleotides coupled 
with detection using existing DNA microarray technology. MeDIP offers several 
advantages over more traditional methods of detecting hypermethylated gene promoters, 
such as the treatment of cells grown in culture with demethylating agents like the 
cytidine analogue, 5-aza-2 -deoxycytidine. Importantly, only a small quantity of 
starting material (DNA) is required from each sample, enabling the detection of the 
DNA méthylation profile fi’om small tissue samples such tumour biopsies.
A number of research groups have exploited MeDIP to understand the methylome of 
several tissue types including plant tissue, human somatic cells and cancer cells (Weber 
et a l 2005; Keshet et a l 2006; Zhang et a l 2006); however this is the first study to date 
to identify the aberrant méthylation of gene promoters in prostate cancer using MeDIP.
To create a comprehensive whole genome méthylation profile for prostate cancer, 
methylated DNA fi-om prostate cancer cell lines, DU 145, LnCAP, PC3, immortalised 
normal prostate epithelial cell line RWPEl and healthy prostate tissue was enriched 
using MeDIP. DNA purified using a monoclonal antibody to methylated CpG was then 
compared to MeDIP input DNA (ie total, non-enriched DNA) on a microarray to
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identify gene promoters enriched by MeDIP i.e. methylated promoters. A comparison 
between genes enriched in the cancer cell lines and normal prostate tissue enabled the 
identification of genes hypensefiiylated in cancer,
The microarray consisted of 480,000 probes tiled across the promoters of 17,000 genes, 
distributed across the entire genome. In order to limit detection of the effects of global 
hypomethylation (not the subject of this thesis), only probes binding within 700 bp 
upstream and 200 bp downstream of the transcriptional start of a gene were included in 
the analysis. Only genes where at least two probes showed enrichment in the 
methylated DNA fi-action were considered hypermethylated, to avoid artefacts due to 
individual random ‘sticky’ probes.
5.2 Results
5.2.1 MeDIP validation
As a positive control, the relative enrichment of the gene, GSTPl, that is known to be 
methylated in prostate cancer, was determined in MeDIP samples. Pyrosequencing of 
GSTPl confirmed the hypermethylation of GSTPl in the prostate cancer cell lines 
(Figure 5.1a). As selenoprotein S {SelS) was shown not to be methylated in the 
prostate cell lines using pyrosequencing, it was chosen as a negative control gene 
(Figure 5.1b).
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To confirm enrichment of methylated promoters in the immunoprecipitated DNA, 
relative QPCR was performed on the GSTPl and SelS promoters, before and after 
immunoprécipitation. The amount of GSTPl and SelS DNA in each sample analysed 
was determined from a standard curve generated from human leukocyte DNA. 
However, due to the limited yield of DNA after MeDIP, enrichment could not be 
calculated for all cell lines and conditions; for example, insufficient DNA was 
recovered in order to evaluate the enrichment of the GSTPl promoter in the RWPEl 
cell line. The promoter region of GSTPl, which is highly methylated in the prostate 
cancer cell lines, PC3 (mean CpG méthylation 65%), DU145 (60%) and LnCAP (93%), 
(Figure 5.1a) was shown to be enriched 35, 63 and 65 fold in the three cell lines 
respectively in immuneprecipitated vs. input DNA, when normalised against the 
unmethylated promoter of SelS (Figure 5.1c). The GSTPl promoter, which remains 
unmethylated in the one normal prostate sample tested here (normal prostate 1; mean 
CpG méthylation 2%), showed a 10-fold reduction in the relative DNA concentration 
after enrichment for methylated DNA. This confirms that methylated DNA can be 
enriched using MeDIP, whilst the relative concentration of unmethylated DNA is 
reduced.
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5.2.2 The identification of candidate hypermethylated genes in prostate cancer
In total 1277, 1805, and 1165 genes had promoters with two or more probes enriched by 
MeDIP in the cancer cell lines DU 145, PC3 and LnCAP respectiyely. Of these 444 
were common to all three cancer cell lines (Figure 5.2a). To further eliminate 
promoters methylated in normal prostate tissue, genes whose promoters were 
methylated in the immortalised normal prostate epithelial cell line RWPEl were 
subtracted from the 444 genes methylated in all three prostate cancer ceU lines. In total 
170 genes were found to be methylated m all three cancer cell lines, but not in either the 
normal RWPEl prostate cancer cell line (Figure 5.2c) or the normal human prostate 
tissue samples.
The subset of genes that were found to be yery highly methylated (enriched >4-fold in 
two or more probes) were considered separately. Only 25 genes were shown to be 
hypermethylated by this definition in all three cancer cell lines, whist remaining un­
enriched in the normal tissue samples (Figure 5.2b). As aboye, one gene whose 
promoter was methylated in RWPEl but not in normal prostate tissue was also remoyed 
from further analysis, leaying a total of 24 genes hypermethylated in the cancer cell 
lines only (Figure 5.2d, Table 5.1).
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5.2.3 The confirmation of promoter méthylation by pyrosequencing candidate 
hypermethylated genes.
Genes of potential interest in cancer were selected for méthylation profile analysis using 
pyrosequencing. These genes were layilin {LAYN), ring finger protein 152 (RNF152) 
and a disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 12 
{ADAMTS12).
Méthylation analysis by pyrosequencing o f LAYN confirmed méthylation of the 
promoter across eight CpGs positions in DU 145, LnCAP and PC3, with a mean 
méthylation of 75%, 69%, and 82% respectively (Figure 5.3a). In contrast, the LAYN 
promoter was not methylated in the immortalised normal prostate cancer cell line 
RWPEl (6%) or in either of the normal prostate cancer tissue samples (4% and 3%), 
identifying méthylation of the LAYN promoter as a potential diagnostic marker for 
prostate cancer. RNFL52 and ADAMTSL2, were also methylated in the prostate cancer 
cell lines and not in either the normal prostate tissue or RWPEl cell line (Figure 5.3).
5.2.4 Méthylation and gene expression profiles of candidate hypermethylated genes
To assess the therapeutic and diagnostic potential of these candidate genes, promoter 
méthylation analysis was performed using pyrosequencing on five samples obtained 
fi*om carcinoma of the prostate. Corresponding gene expression data was also provided 
for the prostate cancer samples by Professor Collin Cooper (Cancer Research UK), who 
kindly gave us the samples fi"om the CRUK repository; gene expression analysis for 
these samples had been performed on Affymetrix exon 1.0 st microarrays (consisting of
...
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1.1 million probes) so the data were not directly comparable with the Agilent 
microarray data presented in this thesis. Gene expression data for additional normal 
prostate cancer samples (normal 3, 4 and 5) were also provided by Professor Cooper 
(Figure 5.4); however, DNA was not available so a direct comparison between the gene 
expression and méthylation profiles in these additional normal prostate samples was not 
possible.
In contrast to the méthylation data obtained from the cancer cell lines, RNF152 and 
LAYN  were not found to be hypermethylated in the prostate cancer samples. Gene 
expression data showed no difference between prostate cancer and normal prostate 
samples for both RNF152 and LAYN. This suggests that whilst, RNFL52 and LAYN are 
hypermethylated in the prostate cancer cell lines, these gene promoters are not 
methylated in clinical samples of carcinoma of the prostate.
Promoter analysis of ADAMTS12 produced the most promising results. All five prostate 
cancer samples exhibited higher mean méthylation (26% to 56 %) than that observed in 
the normal prostate tissue (16% to 19 %). However, mean méthylation was 
considerably lower than observed in the prostate cancer cell lines (86% to 94%). The 
mean méthylation of these two hypermethylated CpGs in prostate cancer tissues was 
39%, more than double that observed in the healthy prostate tissue (17%). Gene 
expression data confirmed the down regulation of ADAMTSL2 in prostate cancer 
(Figure 5.4).
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5.2.5 Méthylation of selenoproteins
In the human genome, there are thought to be twenty-five selenoproteins and five 
proteins that are directly involved in the synthesis of selenoproteins (SPS2, SBP2, 
EEFSEC, SECP43, L30 and SLA). Of these thirty genes, four were shown to be 
methylated in cancer. These genes contained two or more probes enriched by MeDIP to 
a greater extent in the cancer cell lines than in the normal prostate tissue; these genes 
were, GPx2, Gpx3 GPx6, and SEPPl (Figure 5.5). In addition SEPWl, SEEK and 
DI02  were methylated in two of the three prostate cancer cell lines, but not in the 
normal prostate tissue.
Analysis of the SEPPl promoter using MeDIP identified SEPPl as methylated in the 
cancer cell lines but not in the normal prostate tissue samples. Pyrosequencing of CpG 
directly adjacent to the differentially methylated regions of the SEPPl promoter showed 
méthylation of both normal (80%) and cancerous (84%) prostate tissue. No significant 
expression of SEPPl was observed in the prostate suggesting that those differentially 
methylated CpG may have little or no influence on the expression of SEPPl. These 
results suggest méthylation may be important for regulating the tissue specific silencing 
of SEPPl in the prostate.
The selenoprotein GPx2, which is primarily expressed in the gastrointestinal tract but 
also found in the prostate, and GPx6, exclusively expressed in the olfactory system, 
were also shown to be methylated in all three prostate cancer cell lines but not the 
normal prostate tissue. There was no significant expression of GPx6 in either cancerous 
or normal prostate samples implicating the tissue specific silencing of GPx6 irrespective
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of promoter méthylation. GPx2 however, was significantly down-regulated in 
cancerous versus normal prostate tissue (P = 0.009, unpaired T test) thus implicating 
méthylation of the GPx2 promoter in the mechanism of its down-regulation in cancer.
Analysis of the GPx3 promoter by pyrosequencing showed méthylation in all three of 
the cancer cell lines (mean méthylation 60%) but not in the normal prostate cell line 
(6%) (Figure 4.1, Chapter 4); this confirmed the cancer specific hypermethylation of 
GPx3 observed in earlier work (Lodygin et al. 2005; Yu et al. 2007). In contrast to 
other studies, however, expression of GPx3 was not significantly different in normal 
and cancerous prostate tissue. (Lodygin et al. 2005; Yu et al. 2007).
166
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LnCAP (n =6)
DI03SEPHS2
GPx2
GPx3
SEPW l \  
SELK '
SE PPl
GPx4
SELH
SELV
DU145 (n = 9)
PC3 (n = 8)
Figure 5.5 Identification of methylated selenoproteins using MeDIP. Venn 
diagrams show selenoprotein and selenoprotein synthesis genes showing méthylation at 
two or more probes by MeDIP in the prostate cancer cell lines but not normal prostate 
tissue.
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5.2.6 The identification of pathways disrupted by hypermethylation in prostate 
cancer
The disruption of specific pathways by the silencing of methylated genes was 
investigated using gene ontology and pathway analysis software. 170 genes shown to 
be enriched as a result of méthylation in the cancer cell lines alone were analysed using 
Metacore, (described in section 4.2.4, http://www.genego.com/metacore.php) (Ekins et 
al. 2007).
The ‘anatomical structure development’ pathway was the most significant pathway 
(P=2.16 X 10'^). Interestingly, processes involved with chromatin structure feature 
prominently in the list of pathways: ‘DNA packaging’ (P=9.86 x 10" )^, ‘nucleosome 
assembly’ (P=1.25 x 10'^), ‘protein-DNA-complex assembly’ (P=2.85 x 10'^) and 
‘chromatin assembly and disassembly (P=4.29 x 10'^) are all within the top eight most 
significant pathways. Multiple pathways involving cell adhesion were significant, 
which is of interest in prostate cancer as it may reflect the metastatic nature of the cell 
lines DU145, LnCAP and PC3.
Using a subset of more defined, annotated networks, MetaCore identified five well 
characterised networks disrupted through méthylation. Of the 170 genes analysed 57 
were mapped onto process networks. ‘Cadherin-based cell adhesion’ was the network 
most significantly affected (P=0.00037), with eight of the 179 pathways in this network 
affected by DNA promoter méthylation (Table 5.3). In addition, the second most 
significant process was also a cell adhesion pathway: genes involved in ‘cell adhesion 
modulated at cell junctions’ were enriched in six out of the 163 genes within that
168
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network (P=0.0055), suggesting the disruption of cell adhesion by méthylation in 
prostate cancer.
Whilst the comprehensive analysis of large data sets using gene ontology software 
identifies multiple pathways containing genes hypermethylated in prostate cancer, it 
remains unclear what effect the silencing of these genes by méthylation may have on the 
specific pathways identified. Knockdown experiments targeting specific genes within 
the identified pathways will surely be required to gain a true insight into the functional 
consequences of epigenetic silencing of these gênes.
5.2.7 The identification of hypermethylated genes using 5-aza-2 -deoxycytidine and 
MeDIP: A comparison.
In this study two different techniques for the identification of methylated genes in 
prostate cancer have been utilised: the treatment of cancer cell lines with 5-aza-2'- 
deoxycytidine to re-express epigenetically silenced genes and the capture of methylated 
DNA using an antibody against methylated CpGs coupled with microarray detection. 
To enable a comparison between the results, those genes identified as methylated in 
cancer hy each technique were compared side by side. Of the 61 genes identified as 
methylated using 5-aza-2 -deoxycytidine treatment, only one gene was also identified as 
hypermethylated in the cancer cell lines using MeDIP: ZNF577 (zinc finger protein 
577). This clearly shows that these techniques identify different subsets of genes but 
may in part be due to the stringent parameters employed by both techniques to identify 
hypermethylated genes. Each technique offers several advantages over the other: 5-aza-
169
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2 '-deoxycytidine up-regulates genes that would normally be expressed if they were not 
methylated, whilst MeDIP identifies all methylated genes in cancer regardless of 
expression. In addition, the epigenetic silencing of genes may result fi-om both histone 
acétylation and promoter méthylation. Such genes would not necessarily have been 
identified using 5-aza-2 -deoxycytidine as histone deacetylation would continue to 
repress their expression even after treatment with a demethylating agent; these genes 
however, would have been identified using MeDIP.
5.2.8 The up-regulation of methylated genes by 5-aza-2'-deoxycytidine and 
selenium
The response of gene expression to the supplementation of cell culture medium with 
selenium, 5-aza-2 ' -deoxycytidine and both together (Chapter 3) was investigated in 
genes shown to be methylated by MeDIP enrichment. Genes identified as methylated 
by the enrichment of two or more probes in cancer cell lines using MeDIP were 
included in the analysis. For each condition and cell line, enriched genes showing up- 
regulation by either selenium, 5 -aza-2 ' -deoxycytidine or both were divided by the total 
number of methylated genes. This determines the propensity of hypermethylated genes 
to be up-regulated by treatment with the different compounds (Figure 5.6).
Supplementation with ■ selenium alone showed a greater propensity to up-regulate 
methylated genes than treatment with 5-aza-2'-deoxycytidine or both, in the cell line 
DU 145. In the cell lines, LnCAP and PC3, the propensity of selenium to up-regulate 
hypermethylated genes was of similar magnitude to either 5-aza-2 -deoxycytidine alone
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or both selenium and 5-aza-2'-deoxycytidine. Thus treatment of the cancer cell lines 
with 100 nM selenium had a similar (or sliÿitly greater for DU 145) high propensity to 
5-aza-2 '-deoxycytidine to lead to increased gene expression in hypermethylated genes; 
the observation that this does not increase Anther on treatment with both agents 
suggests that they may both be acting through the same pathway that has a threshold, 
reached on treatment with either agent alone. This potentially implicates selenium 
directly in déméthylation.
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5.2.9 The identification of clusters of methylated gene promoters
The hypermethylation of gene promoters has until recently been regarded as a focal 
occurrence, silencing individual genes within a genomic location. However, recent 
evidence challenges this more traditional view of promoter hypermethylation, following 
the identification of regions of the genome containing multiple hypermethylated genes 
(Frigola et a l 2006; Novak et a l 2006; Hitchins et a l 2007) Interestingly, the silencing 
of non-methylated genes interspersed between methylated genes occurs, suggesting the 
long range inactivation of gene expression by méthylation of nearby genes (Frigola et 
al 2006; Hitchins et a l 2007).
In colon cancer, 3p22 has been shown to contain regions of hypermethylated gene 
promoters spanning several mega bases and therefore appeared to be a logical starting 
point for the identification of méthylation clusters in the prostate cancer cell lines 
(Hitchins et a l 2007). Visual inspection of the methylome of the prostate cancer cell 
lines (MeDIP data) revealed that this locus contained multiple methylated genes 
suggesting this region may also be silenced in prostate cancer (Figure 5.7a). A region 
directly adjacent, 3p21, contained a substantially larger cluster of methylated genes and 
may represent a second region of cluster highly methylated genes on 3p (Figure 5.7a).
A cluster of hypermethylated probes was observed on 5q31.3 (Figure 5.7b). This 
region contains the protocadherin gene cluster composed of 50 members of the larger 
cadherin super-family. Little data has been published regarding the expression and role 
of the protocadherin gene cluster in prostate cancer. The protocadherin genes have been 
shown to be highly expressed in the brain and in neuronal development (reviewed by
173
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Yagi et al. 2008), therefore this cluster may represent the long range epigenetic 
silencing of the protocadherin gene cluster in a tissue specific manner. However, 5q31- 
33 is a region identified as containing a potential prostate cancer susceptibility gene 
(Witte et a l 2000).
A clearly defined cluster of methylated genes was identified at 7pl5-14 (Figure 5.7c). 
This region contains the HOXA gene cluster, a region of homeotic genes shown to be 
inactivated in breast cancer (Novak et a l 2006). This result may represent the 
epigenetic silencing of this -100 kb, gene rich region in prostate cancer.
To date this is the only study to have looked at the physical clustering of methylated 
genes across the whole human genome. The clustering of methylated genes is present 
on almost every chromosome (Appendix 1, 2 and 3), suggesting that such clustering 
within the human genome is far more common than previously thought. Further 
analysis of the current data is required to fully investigate the effect of long range 
epigenetic silencing in prostate cancer.
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5.3 Discussion
Using the immunoprécipitation of methylated DNA (MeDEP) followed by genome-wide 
microarray analysis, twenty four genes were found to be highly methylated in the cancer 
cell lines DU145, LnCAP and PC3. Méthylation analysis of three particularly interesting 
genes (LAYN, RNF152 and ADAMTS12), by pyrosequencing confirmed the gene promoters 
were methylated in the prostate cancer cell lines but not the normal prostate tissue or the 
normal immortalised prostate cell line RWPEl Méthylation analysis by pyrosequencing 
was also performed in DNA collected from five prostate cancer biopsies to validate this 
finding in clinical samples. ADAMTS12 (a disintegrin and metalloproteinase with 
thrombospondin motifs) was shown to be methylated in the prostate cancer cell lines and 
prostate cancer tissue. However, LAYN (Layilin), and RNF152 (Ring finger protein 152) 
were methylated in the cancer cell lines but not in the prostate cancer tissue. Whilst the cell 
lines are derived from prostate cancer metastasis, the prostate cancer samples are obtained 
from primary tumours. Thus, it is possible that hypermethylation oi LAYN and RNF152 
may be markers of aggressive and metastatic disease. Confirming the epigenetic regulation 
of LAYN, the hypermethylation of the LAYN promoter was associated with decreased 
expression in the cancer cell lines. Unfortunately, the gene expression profiles of RNF152 
were not available from the cell lines so the association between méthylation and gene 
expression could not be established. The function of RNF152 remains to be determined 
and as a result, any potential role in prostate cancer is unclear. LAYN however, is 
postulated to function as transmembrane signalling molecule involved with cell structure 
(Bono et al. 2005) and may be of great importance in the metastasis of prostate cancer. The
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analysis of LAYN and RNF152 promoter méthylation in metastatic tumours will be required 
to evaluate the potential use of these genes as markers of aggressive disease.
The hypermethylation and down-regulation oLADAMTS12 was observed in prostate cancer 
cell lines and prostate cancer tissue. Nineteen members of the ADAMTS family have been 
identified (Flannery 2006), which have a wide range of catalytic substrates including 
aggrecan, brevican and von Willebrand factor (reviewed by Flannery 2006). To date 
however, the substrate for ADAMTS 12 remains to be identified.
The dysregulation of members of the ADAMTS family has been described previously in 
breast cancer (ADAMTS6 and ADAMTS 18) (Porter et a l 2004), colon cancer 
(ADAMTS20) (Llamazares et al 2007), osteocarcinoma (ADAMTS20) (Cal et a l 2002) 
and glioblastoma (ADAMTS4 and ADAMTS5) (Held-Feindt et a l 2006). Lower 
ADAMTS 13 activity has also been reported in advaneed prostate cancer (Oleksowicz et al 
1999; Koo et al 2002). This, however, is the first time dysregulation of ADAMTS 12 has 
been described in prostate cancer and also suggests that the mechanism is hypermethylation 
of the promoter.
A recent experiment in the Madin-Darby canine kidney (MDCK) cancer cell line may be of 
relevance (Llamazares et a l 2007). Hepatocyte growth factor stimulation of wildtype 
MDCF cells resulted in the disassembly of junction components and the loss of cell-cell 
adhesion; however clones arose that showed no loss of cell-cell adhesion or the 
disassembly of the junction components and were found to re-express ADAMTS12, usually
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not expressed in MDCK cells. The invasive capacity of the MDCK cells when grown in a 
collagen matrix, was significantly reduced by the re-expression of ADAMTS12, supporting 
_a possible role of .ADAMTS12 in preventing tumour metastasis. The same authors found 
that addition of exogenous ADAMTS 12 to the endothelial cell line, BAEl, reduced 
vascular endothelial growth factor-induced tubulogenesis from 64% to 10%, suggesting a 
potential inhibitory role of ADAMTS 12 in tumour-associated angiogenesis. Xenografts of 
the human lung adenocarcinoma cell line, A549, expressing ADAMTS 12 exhibited slowed 
tumour growth and 50% less tumour mass than wild type A549 cells after injection into 
immunosuppressed mice. These results clearly imply ADAMTS 12 has a strong tumour 
suppressor function (Llamazares et a l 2007).
ADAMTS12 is located at 5q35, identified through genome wide linkage analysis as 
containing a potential advanced prostate cancer susceptibility gene (Schaid al 2007). 
Thus, according to Knudson’s 2 hit theory of carcinogenesis (Knudson 1971) it is entirely 
feasible that méthylation of ADMTS12 may provide the second hit, resulting in the 
silencing of both alleles of the gene. Such a phenomenon has previously been reported in 
hereditary non-polyposis colorectal cancer, in which detrimental germline mutations in the 
MSH2 and MLHl genes were frequently associated with the méthylation and silencing of 
these genes (Yuen et a l 2002). Given the evidence suggesting ADAMTS12 is located in 
region containing a prostate cancer susceptibility genes it is possible that ADAMTS12 
harbours polymorphisms that increase the both the risk of prostate cancer and the likelihood 
of hypermethylation.
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Although the méthylation of ADAMTS12 was investigated in only five prostate cancer 
-samples and 2 normal prostate cancer samples, hypermethylation was observed in 100% of 
the prostate cancer and 0% of the normal prostate samples. Thus, ADAMTS12 may be a 
potentially useful clinical marker for prostate cancer. A more comprehensive analysis of 
the ADAMTS 12 promoter, in prostate cancer samples from tumours of differing clinical 
grade and métastasés will be required to assess the utility of ADAMTS12 as a potential 
clinical marker of prostate cancer progression. Another consideration is that the 
méthylation of only two CpGs within the promoter of ADAMTS12 were analysed in this 
current study. Expanding the number of CpGs analysed will further clarify the méthylation 
profile of this potentially clinically important tumour suppressor gene, newly discovered as 
implicated in prostate cancer.
As with all DNA mcthylation, the epigenetic silencing of the ADAMTS12 promoter is 
potentially reversible. In light of recent findings^ the re-expression of ADAMTS 12 may 
provide a novel therapeutic target, with the potential to reduce metastasis, angiogenesis and 
tumour size. Further studies will be required to fully evaluate the re-expression of 
ADAMTS 12 in prostate cancer.
In total 24 genes were identified as hypermethylated in the prostate cancer cell lines. 
However due to time restraints and the limited availability of clinical prostate cancer tissue 
it was only possible to analyse the méthylation patterns of three of these genes. 
Considering the results presented for LAYN, RNFL52 and most importantly ADAMTS12, it
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is highly likely that this list of 24 genes contains many novel hypermethylated genes in 
cancer. Further work will confirm these findings in prostate cancer tissue at different 
-stages of disease progression and aim to identify how the epigenetic silencing of the genes 
is of importance to cancer.
To address one of the main aims of this project, the identification of methylated 
selenoproteins in prostate cancer; the MeDIP enrichment of selenoproteins and proteins 
involved in selenoprotein synthesis was assessed. Four selenoproteins were found to be 
enriched and thus methylated in cancer: SEPPl, GPx2, GPx3 and GPx6.
GPx6 is believed to have an antioxidant role in the olfactory system and as a result is only 
expressed in olfactory epithelium (Brigelius-Flohe 2006). The MeDIP results suggest that 
méthylation of the GPx6 promoter is increased in prostate cancer. However, no significant 
expression of GPx6 was observed in either the prostate cancer or tlie normal prostate tissue, 
suggesting the tissue specific silencing of GPx6. Furthermore, this would suggest the tissue 
specific silencing of GPx6 is independent of DNA promoter méthylation and regulated in a 
tissue specific manner by transcription factors and chromatin structure.
The cancer specific enrichment of GPx2 (gastro-intestinal glutathione peroxidise) by 
MeDIP and the concomitant down regulation of GPx2 expression in prostate cancer tissue 
(P = 0.009, unpaired student’s T test) suggest that the epigenetic silencing of GPx2 by 
méthylation may be a significant event in cancer. To support this hypothesis another
182
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member of our selenoprotein research group confirmed the cancer specific 
hypermethylation of the GPx2 promoter by pyrosequencing (Bram Bekaert; personal 
communication).
GPx2 is a powerful cytoplasmic antioxidant localised in the cytoplasm of gut epithelial 
cells, protecting the colon from inflammation (Brigelius-Flohe 2008). Although termed 
‘gastrointestinal’ glutathione peroxidise, it is not exclusively expressed in the Gl-tract and 
has been shown to be expressed in prostate cells (Rebsch et al. 2006). A recent study 
investigating the expression of specific selenoproteins in the prostate observed the 
expression of GPx2 to be undetectable in the prostate cancer cell lines LnCAP and PC3; in 
contrast however, GPx2 expression was observed in the normal prostate cell line RWPEl 
(Rebsch et al. 2006). In the current study, no significant expression of GPx2 was observed 
in the prostate cancer cell lines or RWPEl; however GPx2 expression was significantly less 
in the cell lines than observed in the normal prostate tissue.
The exact role of GPx2 in cancer remains elusive. Knockout mice lacking GPx2 more 
readily develop cutaneous squamous cell carcinomas than wildtype mice when challenged 
with UV radiation (Walshe et al. 2007). Paradoxically however, GPx2 has been shown to 
inhibit apoptosis in an oxidative stress-induced manner through the inactivation of p53 
(Yan and Chen 2006), and is dysregulated in several cancers including colorectal adenomas 
(Florian et al. 2001) and lung adenocarcinoma of smokers (Woenckhaus et al. 2006). 
Whilst the expression of GPx2 may protect the cell from cancer neogenesis, subsequent 
expression in cancer may inhibit oxidative stress-induced apoptosis and enhance cell
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proliferation (Yan and Chen 2006). The significance of the méthylation and epigenetic 
silencing of GPx2 in prostate cancer remains undefined; further work is required to clarify 
the role of GPx2 in both prostate cancer initiation and progression.
In contrast to GPx2, the epigenetic silencing of GPx3 in prostate cancer has been reported 
previously (Lodygin et al. 2005; Yu et al. 2007). The results presented in this study 
confirm the hypermethylation of GPx3, suggesting an important role for GPx3 in prostate 
cancer. GPx3 has been reported to have a tumour suppressor function in prostate cancer 
cells (Lodygin et al. 2005; Yu et al. 2007). GPx3 and GPx2 both metabolise H2O2 and 
hydroperoxides. It is therefore entirely feasible to suggest that expression of GPx2 in 
prostate cancer may have similar tumour suppressor activity to that observed for GPx3. 
Silencing of both GPx2 and GPx3 may further enhance the proliferation and growth of 
tumours. However, it remains unclear whetlier tlie tumour suppressor functions of GPx3 
are attributable, at least in part, to the metabolism of phospholipid hydroperoxides, which 
are not metabolised by GPx2. It is clear however, that members of the glutathione 
peroxidise family will be the focus of continued research in defining the roles of these 
enzymes in prostate cancer, both individually and in combination.
Méthylation analysis of the SEPPl gene promoter by pyrosequencing showed no difference 
in méthylation status in cancerous (84%) or normal tissue (80%) (Figure 4.9b Chapter 4). 
However, MeDIP data suggests regions of the SEPPl promoter directly adjacent to that
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analysed by pyrosequencing are differentially methylated in the cancer cell lines compared 
to the normal tissue. Multiple assays were developed to analyse these regions of the SEPPl 
-promoter; however—bisulfite conversion of the DNA, creating sequence rich in A. and T, 
and the presence of multiple complex repeats prevented the analysis of further CpGs due to 
the poor availability of suitable PGR primer binding sites. Importantly, no significant 
expression of SEPPl was observed in either cancerous or normal prostate tissue. 
Méthylation of those CpGs detected by pyrosequencing could therefore cause tissue- 
specific silencing of SEPPl expression in the prostate. Those CpGs shown by MeDIP to 
be differentially methylated presumably have no impact on expression. This suggests that 
epigenetic silencing may be implicated in the tissue-specific regulation of SEPPl in the 
prostate.
Analysis of genes identified as hypermethylated in cancer by MeDIP and gene expression 
data revealed that many such hypermethylated genes were up-regulated by selenium. Two 
explanations are possible: selenium may function as a demethylating agent or the genes 
may be only hemizygously methylated, so that selenium can still up-regulate the 
unmethylated copy. Selenium has recently been shown to reactivate genes silenced by 
méthylation in a dose dependant manner (Xiang et a l 2008). The authors reported that 
treatment of LnCAP cells, for seven days, with 1.5 pM selenium in the form of sodium 
selenite, increased expression of the hypermethylated gene, GSTPl. Furthermore the 
treatment of LnCAP with selenite, resulted in the partial déméthylation and re-expression 
of GSTPl in a dose dependant manor. However, Ramachandran et al (2007) failed to 
observe re-expression of GSTPl in LnCAP after treatment with 10 pM selenite for 96 hrs
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(Ramachandran et al 2007), most likely resulting from the shorter treatment time. 
Although the response of GSTPl was not analysed in the current study another member of 
our selenoprotein research group investigated the response of GSTPl expression to both 
100 nM selenium and 10 pM 5-aza-2 -deoxycytidine in the prostate cell lines. GSTPl was 
significantly up-regulated by both 100 nM selenium and 10 pM 5-aza-2 '-deoxycytidine in 
the PC3 cell line but only by 10 pM 5-aza-2'-deoxycytidine in the LnCAP (Data not 
shown, Bram Bekaert; personal communication). Owing to the length of treatment and the 
concentration of selenite, it is unlikely that selenium actively demethylated gene promoters 
in the current study. However, selenium supplementation may increase the expression of 
many genes that are partially methylated in cancer, including partially methylated GSTPl 
(as observed in the PC3 cell line) and may provide a mechanism by which selenium is 
cancer protective.
It is possible, due to the pro-apoptotic effect and growth inhibitory effect of selenium 
(Redman et a l 1998; Menter et a l 2000; Jiang et a l 2002) that the relative up-regulation of 
methylated genes by selenium may result from selective apoptosis of highly methylated 
cells. However, selenite treatment of the prostate cancer cell lines in the present study did 
not reduce cell proliferation (data not shown) and only a 16% reduction in growth of PC3 
after treatment with 1.5 pM selenite was reported by Xiang et al (2008), making this 
explanation unlikely.
Several studies have reported the down regulation of both DNA methyl transferase and 
histone deacetylase by selenium (Cox and Goorha 1986; Fiala et a l 1998; Xiang et al
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2008); although this was not observed in the current study (data not shown) and is unlikely 
to account for the up-regulation of methylated genes shown here.
Several studies have reported the reduction in the risk of advanced prostate cancer on 
supplementation with selenium (Yoshizawa et al 1998; van den Brandt et a l 2003; Li et 
al 2004; Yan and Chen 2006). It is entirely plausible that selenium supplementation may 
result in the re-expression of genes involved in cell adhesion, which, in the current study, 
are hypermethylated in prostate cancer. The maintenance of cell-cell contacts (cell 
adhesion), as well as an intact matrix, is vital in preventing the metastasis of prostate 
cancer. The up-regulation of genes involved in the cell adhesion pathway may provide a 
mechanism by which selenium can reduce or slow the progression of prostate cancer to a 
stage of advanced disease. In particular, the novel finding that the tumour suppressor gene 
ADAMTS12 was down-regulated, most likely through hypcrmetliylation, in prostate cancer 
tissue and cell lines derived from prostate cancer métastasés provides strong evidence for a 
role for epigenetic silencing of genes in cell adhesion/matrix remodelling pathways in 
prostate cancer.
Although selenium appeared not to affect DNA promoter méthylation in the current study, 
the supplementation of cancer patients, with selenium at a physiological concentration over 
a long period of time may lead to the déméthylation of gene promoters in cancer. Analysis 
of promoter méthylation and DNMT expression in human cancers obtained from selenium
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supplementation trials, such as the SELECT trial (Lippman et al. 2005), will be required to 
further investigate the effects of selenium upon the epigenetic silencing of genes.
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Summary
-A  considerable body of evidence suggests that an inadequate intake of selenium is a risk 
factor for prostate cancer. Polymorphisms in some selenoprotein genes have previously 
been associated with increased cancer risk. It was hypothesised that in a low selenium 
environment, such as Sweden and the UK, men who have SNP alleles in selenoprotein 
genes or genes in the same metabolic pathways as selenoproteins, reducing their ability to 
make functional proteins, would have a greater risk of prostate cancer than men where 
these alleles are absent. In keeping with the hypothesis, this study provides evidence for a 
gene-gene interaction between the Ala234Thr polymorphism in the selenium transport 
protein, SEPPl, and the S0D2 Vall6Ala polymorphism. Individuals homozygous for 
SEPPl Ala234 who also had at least one copy of the S0D2 Alai6 allele were 43% more 
likely to develop prostate cancer compared to S0D2 Vail6 homozygotes of the same 
SEPPl genotype; there was no difference by SOD2 genotype in men who were not 
homozygous for the SEPPl Ala234 allele and the interaction was statistically significant. 
The interaction was stronger in aggressive disease resulting in a 60% increased risk. There 
are published data to show that the S0D2 Alai 6 allele of mitochondrial superoxide 
dismutase is imported more efficiently into the mitochondrion resulting in higher activity 
and greater production of H2O2 than with the S0D2 Vail6 variant (Sutton et al. 2003). For 
selenoprotein P, there are published data suggesting that SEPPl Ala234 is less stable than 
the Thr234 allele, resulting in reduced plasma SEPPl (Meplan et al. 2007). It is therefore 
postulated that the availability of selenium for the production of GPx in the prostate, 
already low in the Swedish population, is further reduced in men homozygous for the
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SEPPl Ala234 allele. This reduces the ability of the prostate to protect against excess 
hydrogen peroxide. Consistent with this postulated mechanism for the interaction between 
Jhe S0D2 and SEPPl SNPs, SEPPl was shown to be methylated in normal prostate tissue 
and prostate cancer samples and no significant expression was detectable in the prostate 
cell lines. These findings suggest that interaction between the two SNPs results from the 
impaired delivery of selenium via plasma selenoprotein P associated with the SEPPl Ala 
234 allele, rather than from SEPPl expressed within the prostate itself. GPxl was not 
methylated in the prostate, so that supplementation with selenium would help protect the 
prostate from both cancer initiation and progression to aggressive disease by increasing the 
amount of plasma SEPPl and thereby increasing the expression of GPxl in the prostate. 
The evidence presented here would allow the identification of individuals who would 
particularly benefit from selenium supplementation to prevent prostate cancer.
One potentially useful finding in this study was the novel finding of GPx2 as a gene 
hypermethylated in prostate cancer. Although GPxS has been previously identified as 
hypermethylated in prostate cancer (Lodygin et al. 2005; Yu et al. 2007), this is the first 
Study to identify the hypermethylation of and down-regulation of GPx2. GPx3 has also 
been shown to exhibit a tumour-suppressor function in prostate cancer (Yu et al. 2007) and 
considering the similarity of the GPx2 and GPx3 substrates, it is entirely feasible to suggest 
that GPx2 may also have a tumour-suppressor function in the prostate. Furthermore, 
knockout mice lacking GPx2 have been shown to more readily develop cutaneous 
squamous cell carcinomas than wildtype mice when challenged with UV radiation (Walshe 
et al. 2007), further supporting a tumour-suppressor function of GPx2. The epigenetic
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silencing of both GPx2 and GPxS simultaneously might be expected to be particularly 
detrimental because GPx2 and GPx3 may have a synergistic effect upon tumour 
proliferation and metastasis.
In addition to selenoproteins, several genes of relevance to prostate cancer were identified 
as potentially hypermethylated in prostate cancer. ADAMTS12 (a disintegrin and 
metalloproteinase with thrombospondin motifs) was identified as epigenetically silenced by 
méthylation in both the prostate cancer cell lines and prostate cancer tissue but not in the 
normal prostate. Whilst the specific substrate of ADAMFS12 is yet to be identified, 
evidence suggesting an important tumour repressor role for ADAMTS 12 in cancer. 
ADAMFS12 expression has been shown to protect against the loss of cell-cell adhesion, the 
disassembly of junction components and the invasive capacity of a canine cancer cell line 
(MDCK) (Llamazares et al. 2007). Furthermore, xenografts of human lung 
adenocarcinoma (A549) expressing ADAMTS12, exliibited botli slower tumour growth and 
tumour mass than wildtype A549 in immunosuppressed mice (Llamazares et al. 2007). 
This study is the first to identify the epigenetic silencing of this potent tumour suppressor 
gene, ADAMTS12, providing great potential as a diagnostic and prognostic marker of 
prostate cancer.
Both LAYN (Layilin) and RNF152 (Ring finger protein 152) were shown to be methylated 
in the prostate cancer cell lines. Whilst neither LAYN nor RNF152 were shown to be 
methylated in the prostate cancer tissue, the prostate cell lines were derived from tumour 
métastasés suggesting that hypermethylation of both RNF152 and LAYN may be potential
191
University of Surrey_____________________ _____________ ;___________ Chapter 6
markers of metastatic prostate cancer. Whilst the functions of these proteins remain 
unclear, LAYN has been implicated in the transmembrane signalling of cell structural 
j a t h ^ y s  (Bono et al. 2005), further highlighting its potential role in tumour metastasis.
SI00 calcium binding protein A 14 (S100A14) is regularly down-regulated in multiple 
cancer sites and in circulating cancer cells (Pietas et al. 2002; Ji et al. 2004; Smirnov et al. 
2005). The data presented in this study suggests that the down-regulation of S100A14 
results from the méthylation of its promoter in cancer. Whilst the function of this protein is 
unclear, the current evidence suggests that S100A14 may be a potential candidate marker 
for the diagnosis of prostate cancer.
A member of the inhibitor of DNA binding protein family, LD4, has been recently shown to 
be silenced by méthylation in cancer. (Chan et al. 2003; Hagiwara et al. 2007). Whilst LD4 
has been showii to be dowii-regulated in prostate cancer (Yuen et al. 2006), this is the first 
study to suggest DNA promoter méthylation is the mechanism of this down-regulation. 
Highlighting the potential importance of the epigenetic silencing of LD4 in prostate cancer, 
hypermethylation of LD4 in colon cancer has been associated with an unfavourable disease 
outcome (Umetani et al. 2005). Furthermore the epigenetic silencing of LD4 in breast 
cancer was associated with increased lymph node metastasis and disease recurrence 
(Noetzel et al. 2008). This data suggests that LD4 may be a suitable prognostic marker, 
identifying cancers with a high risk of metastasis and disease recurrence.
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Multiple other genes were identified as potentially methylated and silenced in prostate 
cancer, however it was beyond the scope of the current work to investigate the effect of 
^hypermethylation in all of these genes. The work presented here has only scratched the 
surface, and will provide many opportunities for the further identification of 
hypermethylated genes of importance to prostate cancer.
Pathway analysis of genes responsive to selenium supplementation, using gene ontology 
software, revealed several pathways significant in prostate cancer involving cell adhesion, 
cell migration, chemotaxis, blood vessel morphogenesis and cell signalling. This supports 
previously published evidence that selenium (as selenite) inhibits the growth and 
proliferation of prostate cancer cells (Menter et al. 2000; Jiang et al. 2002) and suggests 
potential pathways through which selenium may exert its anticancer effects.
Pathway analysis of genes nietliylated in prostate caiicer, identified using MeDEP, revealed 
several key processes disrupted by méthylation, including pathways involving chromatin 
structure and DNA packing as well as the cadherin cell-cell adhesion network. Since 
cadherins are implicated in metastasis, this suggests that the epigenetic silencing of genes 
may have a role in this aspect of the disease.
Interestingly, selenium was shown to up-regulate genes identified as hypermethylated (by 
MeDEP) in prostate cancer. Combined with evidence from previous studies, this suggests 
that selenium supplementation may be a useful and safe alternative to aid the re-expression 
of hypermethylated genes in cancer.
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In addition to the stated aims of this project, several clusters of hypermethylated genes were 
identified including the silencing of the HOXA homeotic gene cluster and region 3p22 
shown to be silenced in colon cancer (Hitchins et al. 2007). The presence of these clusters 
of methylated genes suggests that the long range epigenetic silencing of genes by 
méthylation may be common place in prostate as well as other cancers.
To summarise, the data presented in this thesis led to the identification of a gene-gene 
interaction that increases the risk of prostate cancer that has the potential to be ameliorated 
by simply increasing selenium intake. This study has led to the identification of novel 
hypermethylated genes, including the selenoprotein GPx2, LAYN, S100A14 ADAMFS12, 
and LL)4. Pathway analysis has provided new insights into the biological processes affected 
by DNA méthylation in prostate cancer and the processes influenced by the 
supplementation of prostate cancer cells with selenium, suggesting that selenium may in 
part exert its eaneer proteetive effeet by reversal of epigenetie sileneing.
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Future work
JThe prostate eaneer (CAPS) , study in Sweden identified an assoeiation between two 
funetional single nucleotide polymorphisms in selenoprotein P and mitochondrial 
superoxide dismutase, which determines prostate cancer risk. Therefore the priority of any 
future work should be to replicate this finding in another population of low selenium status, 
such as the UK. In addition, the examination of HapMap (www.hapmap.org) reveals that 
six SNPs are required to tag all the genetic variation within S0D2 and seven for SEPPL It 
is therefore hypothesised that these genes may contain other SNPs that are associated with 
an increased risk of prostate cancer. The present study only investigated the association of 
five SNPs with prostate cancer risk and given the current evidence, it is highly likely that 
SNPs in other selenoprotein genes and genes involved in the same metabolic pathways as 
selenoproteins may be associated with an increased risk of prostate cancer. The production 
of a selenoprotein SNP chip designed to cover all genetic variation within these genes 
would enable the identification of SNPs in other selenoprotein genes associated with an 
increased risk of prostate cancer. A SNP chip would also allow the analysis of interactions 
between SNPs in selenoprotein genes in determining the prostate cancer risk.
Unlike many SNP association studies, this study has identified a group of men who are at 
risk because of their genotype but where there is the potential to ameliorate that excess risk 
of prostate cancer by simply increasing selenium intake. The work presented here will lead 
to intervention studies testing the hypothesis that the increased risk of a particular genotype 
combination can be reduced by selenium supplementation. The long term objective of this
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would be to create a simple genetic test for men, to indicate whether they would 
specifically benefit from selenium supplementation.
There is clear evidence to suggest a role of selenoproteins in cancers other than prostate 
cancer (Rayman 2005). The design and production of a SNP chip would provide a cost 
effective, highly robust format to investigate the association of selenoprotein SNPs in other 
cancers.
The present study has identified several candidate genes methylated in cancer but not in 
normal prostate tissues, however, the limited availability of both normal and cancerous 
prostatic tissue was a major limitation of this study. To assess the potential use of the 
hypermethylated genes discovered in this study as therapeutic targets or diagnostic markers 
of disease progression, méthylation analysis using pyrosequencing will need to be 
completed in a greater number of samples. Tissues of different disease stages, including 
samples obtained from pre-intraepithlelial neôplasia (PIN), commonly regarded as the 
precursor lesion to prostate cancer, benign prostatic hyperplasia (BPH), localised prostate 
cancer and metastasis, will be required to assess the méthylation status at differing stages of 
disease progression. The long term objective of this work is to create a diagnostic test to 
identify aggressive prostate cancer or cancers that are likely to progress to an advanced i.e. 
life-threatening, stage of disease. This would enable the early detection and successful 
treatment of high risk patients. Several studies have already demonstrated that the 
hypermethylation of gene promoters can be used as diagnostic and prognostic markers of 
prostate cancer, using the non-invasive sampling of urine and ejaculate. However, the
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quality of such assays is largely determined by the correlation of gene promoter 
hypermethylation with the stage of disease. Through the utilisation of techniques such as 
MeDIP the number of hypermethylated genes identified in prostate cancer will continue, to 
increase and therefore the likelihood of genes to fulfil these criteria will also increase.
ADAMTS 12 was shown to be both hypermethylated and epigenetically silenced in prostate 
cancer. Whilst multiple studies have highlighted important tumour repressor functions of 
this gene in cancer cell lines, none of these cell lines has been derived fi'om the prostate. 
The development of a prostate cancer clone expressing ADAMTS 12 would enable the 
functional analysis of this gene in the prostate, and would determine if restoring the 
expression of ADAMTS12 reduces tumour proliferation and metastasis as observed in other 
cell lines. Furthermore, it is crucial that the substrate of this metalloproteinase is 
discovered. This could lead to the development of therapeutic agents targeting the same 
patliways aiid processes tliat are modulated by ADAMTS 12 mimicking tlie functions of this 
protein. Of particular importance exogenous ADAMTS 12 was shown to reduce vascular 
endothelial growth factor induced tubulogenesis. This suggests that purified ADAMTS 12 
itself, may have the potential to be used as a therapeutic agent. Testing this hypothesis in 
animal models of cancer will be the first step to identifying any future role of exogenous 
ADAMTS 12 as a therapeutic agent in cancer.
In the current study, the méthylation of candidate genes was identified using prostate cancer 
cell lines. The clustering analysis of microarray gene expression profiles, which classified 
prostate cancer tissue as closer to normal prostate tissue than the prostate cancer cell lines.
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clearly highlighted the differences between prostate cancer cell lines and clinical prostate 
tissue samples. These differences may be real since all of the cell lines are derived from 
métastasés, but they may also reflect mutations acquired as a result of long-term culture. 
Novel techniques, such as MeDIP, now enable whole-genome méthylation analysis of more 
clinically relevant samples than previous techniques which largely relied on the ability to 
grow cancer cells in culture. Future whole genome méthylation analysis will be able to 
exploit these techniques, which require the low input of DNA available from cancer tissues 
without the requirement to grow cells in culture. This will lead to the successful 
identification of more clinically relevant genes hypermethylated in cancer, and will 
hopefully identify genes with greater suitability as both therapeutic targets and diagnostic 
markers of disease progression.
In addition to méthylation, the use of whole genome tilling arrays will allow the binding of 
further gene regulatory components of DNA to be analysed on the same array. This can be 
achieved simply by altering the antibody used for the immunoprécipitation of chromatin 
(Chip on chip). Future work will identify not only the méthylation of promoters, but also 
patterns of histone acétylation, transcription factor binding, gene expression and 
chromosomal deletions on a single microarray platform. Coupled with data derived from 
SNP chips, this will help to create a comprehensive profile of cancer, helping to understand 
how all these factors interact.
This study has shown that selenium has the potential to up-regulate many genes that are 
partially methylated. Recent studies have observed the active déméthylation of gene
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promoters by the supplementation of cell lines with selenium. This has clear potential as a 
therapeutic mechanism by which cancer patients can potentially reactivate epigenetically 
silenced genes by simply increasing their intake of selenium. However, to date, these 
studies have been completed in vitro: in vivo studies are required to analyse the effects of 
selenium supplementation in the nutritional or supplemental range upon DNA méthylation 
within the body.
In this study, several pathways of interest to cancer have been identified as potentially 
disrupted by méthylation in prostate cancer. A greater understanding of how the epigenetic 
silencing of genes within these pathways affects the phenotype of cancer cells is required. 
Confirming hypermethylation of genes contained within these pathways in primary prostate 
samples is the first step to understanding the clinical relevance of the disruption these 
pathways in prostate cancer. The knockdown of specific genes in these pathways in other
cell lines, simulating epigenetic silencing, will provide a greater insight into how
hypermethylation disrupts these pathways. Furthermore, the over-expression and
knockdown of selenium responsive genes will clarify the mechanism by which selenium 
supplementation exerts its chemo-protective effect.
Both GPx2 and GPx3 were shown to be hypermethylated in prostate cancer tissue samples. 
Whilst GPxS has been shown to have a tumour suppressor function in prostate cancer (Yu 
et al 2007) the functional role of GPx2 in the prostate remains largely undefined. Future 
work will aim to identify the role of GPx2 in the prostate and focus on understanding how 
the epigenetic silencing of GPx2 alters the phenotype of prostate cancer cells. It will be of
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particular interest to further clarify the relationship between GPx2 and GPxS in prostate 
cancer and determine the consequences of the simultaneous hypermethylation of these 
genes.
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